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Thesis Summary 
__________________________________________________________________ 
Hepatitis C virus (HCV) is a potentially chronic illness that has been associated 
with physical and psychological co-morbidity. An expanded self-regulatory model 
of illness, which incorporates illness perceptions and coping strategies, and benefit 
finding, demonstrated utility in predicting physical and psychological adjustment 
among individuals with HCV. Further, illness perceptions related to treatment 
control, benefit finding, and depression predicted HCV treatment response after 
controlling for demographic and biomedical markers. 
 
Simon A. J. Langston (2017). 
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Abstract 
 
Objectives. Study 1.1 investigated whether illness perceptions, adaptive and 
maladaptive coping strategies, and benefit finding predicted physical and 
psychosocial adjustment in individuals diagnosed with hepatitis C virus (HCV) 
within an expanded self-regulatory model of illness (SRM). Study 1.1 also 
determined whether coping strategies and benefit finding mediated the relationship 
between illness perceptions and physical and psychosocial adjustment outcomes. 
Study 1.2 assessed whether coping strategies independently accounted for variance 
in adjustment and the role of illness perceptions in predicting adjustment after 
controlling for coping strategies. Study 2.1 investigated whether illness perceptions 
and adaptive and maladaptive coping strategies predicted Hepatitis C (HCV) 
treatment outcomes after controlling for clinical, behavioural and demographic 
markers relevant to HCV. Study 2.2 assessed whether benefit finding predicted 
HCV treatment response after controlling for treatment control, substance use and 
mental health. Study 2.3 investigated whether physical (physical health) and 
psychosocial adjustment (depression, life satisfaction, and positive affect) 
predicted HCV treatment response after controlling for substance use and mental 
health comorbidity. 
Method.  For Studies 1.1 and 1.2, a total of 126 participants with HCV completed 
an online questionnaire assessing illness perceptions, coping, benefit finding, and 
depression, physical functioning, life satisfaction and positive affect as the 
adjustment outcomes. For Studies 2.1, 2.2 and 2.3, thirty two participants with 
HCV completed two online questionnaires at Time 1 (pre-HCV treatment) and 
Time 2 (three months post commencement of HCV treatment). At time 1 clinical, 
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behavioural and demographic data were collected as were and measures of illness 
perceptions and coping. At time 2 HCV treatment adherence and HCV treatment 
response were measured. 
Results. In Study 1.1, illness perceptions (personal control, identification with 
HCV symptoms, perceptions related to illness duration, illness coherence, and 
emotional responses to HCV) predicted psychosocial and physical adjustment. The 
combined contribution of adaptive and maladaptive coping strategies also 
explained significant variance in adjustment. Greater more maladaptive coping 
strategies predicted poorer physical health, higher depression, greater life 
satisfaction, and positive affect outcomes, whereas greater engagement with 
adaptive coping strategies predicted higher positive affect. More benefit finding 
predicted positive affect, greater life satisfaction, and higher depression. Mediation 
tests revealed maladaptive coping strategies mediated the relationships between 
illness identity and depression, and emotional response and depression, and 
partially mediated the relationship between illness identity and physical health. 
Benefit finding mediated the relationships between personal control and positive 
affect, and personal control and life satisfaction. Study 1.2 demonstrated that 
maladaptive coping strategies independently accounted for variance in depression, 
physical health, and positive affect adjustment outcomes. Adaptive coping 
strategies independently predicted more life satisfaction and positive affect. After 
controlling for coping strategies, personal control accounted for variance in 
depression, physical health, life satisfaction, and positive affect. Greater 
identification with HCV illness symptoms predicted greater depression, lower 
illness identity scores predicted better physical health, shorter perceptions related 
to illness timeline predicted increased life satisfaction, and greater negative 
vi 
 
emotional responses to HCV predicted lower positive affect. In Study 2.1, 
treatment control was the only predictor of HCV treatment response. A greater 
belief in the efficacy of HCV treatment protocols predicted treatment response (i.e. 
blood test results indicating nil detection of HCV). Coping strategies failed to 
make any significant contributions to the predictive model. The only clinical 
variables that predicted response outcome were substance use and mental health 
comorbidity. Recreational drug use and mental health comorbidity predicted HCV 
treatment response. In Study 2.2, lower benefit finding predicted treatment 
response. Consistent with results reported in Study 2.1, treatment control continued 
to predict HCV treatment response. In Study 2.3 lower depression emerged as the 
sole predictor of HCV treatment response.  
Conclusions. The cross-sectional studies reported in the present thesis demonstrate 
an important role for adaptive and maladaptive coping strategies in the prediction 
of physical and psychosocial adjustment among individuals with HCV, regardless 
of their order of entry into SRM predictive models. In the longitudinal studies, the 
results demonstrate the important role of illness perceptions related to treatment 
control in predicting HCV treatment response, and provided support for including 
HCV pre-treatment psychological interventions to address maladaptive illness 
perceptions for individuals preparing for HCV treatment. Importantly, the results 
reported in Study 2.3 provided support for the assessment of depression for 
individuals preparing for HCV treatment. 
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Chapter 1 
Thesis Overview 
Hepatitis C (HCV) is a high prevalence blood borne disease (approximately 
170 million individuals worldwide currently live with the disease), often chronic in 
nature, that has been associated with a number of physical comorbidities such as 
cirrhosis of the liver, hepatocellular carcinoma, musculoskeletal pain, cognitive 
impairment (Bacon, Farahvash, Janney, & Neuschwander, 1994; Barkhuizen et al., 
1999; Bayard, Holt, & Boroughs, 2006; Benvegnu, Gios, Boccato, & Alberti, 
2004; Chapko et al., 2005; Chen & Morgan, 2006;  Forton, Taylor-Robinson, & 
Thomas, 2003; Fried et al., 2002; Friedman, 1999;  Glacken, Coates, Kernohan, & 
Hegarty, 2003; Hauser, Zimmer, Schiedermaier, & Grandt, 2004; Hoofnagle, 1997;  
Koziel, 2005; Lee & Harrison, 2005; Lehman & Cheung, 2002; Mendez et al., 
2001; Ramalho, 2003; Shiffman et al., 2004; Simmonds, 2001), and psychological 
comorbidities such as depression and anxiety (Chapko et al., 2005; Chen & 
Morgan, 2006; Fried et al., 2002; Hauser et al., 2004; Lee & Harrison, 2005; 
Shiffman et al., 2004; Simmonds, 2001). Despite the potential for individuals to 
clear HCV through anti-viral treatment regimens, there is considerable variance in 
treatment outcomes (Bianchi et al., 2000; Shiffman et al., 2004), and unlike other 
types of Hepatitis, such as Hepatitis B (HBV), there is currently no vaccine to 
protect individuals from contracting it (Choo et al., 1989; Coppola et al., 2004; 
Shiffman et al., 2004). To date much of the research in HCV has focussed on 
developing biomedical treatment models (Cheng, Bonis, Lau, Pham, & Wong, 
2001; Chen & Morgan, 2006; Lee & Abdo, 2003; Shiffman et al., 2004). There has 
been a corresponding paucity of research on the role of psychological variables in 
predicting biomedical HCV treatment outcomes. Similarly, despite the strong 
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association between chronic HCV and physical and psychological comorbidity 
(Barkhuizen et al., 1999; Bonkovsky et al., 2007; Chen & Morgan, 2006; Forton et 
al., 2003; Glacken et al., 2003; Hauser et al., 2004; Law et al., 2001; Lehman & 
Cheung, 2002; Mendez et al., 2001; Neri, Pulvirenti, & Bertino, 2006; 
Rothenhausler et al., 2009; Zickmund, Ho, Masuda, Ippolito, & LaBrecque, 2003), 
a relatively limited number of published studies had focussed on the role of 
psychological variables in predicting physical and psychosocial adjustment among 
individuals living with HCV. In addressing these gaps in HCV research, the 
primary aims of the present thesis were to test: (1) whether psychological variables 
could predict biomedical treatment response after controlling for biomedical 
markers identified in previous HCV research as having important links to treatment 
outcomes (e.g., Shiffman et al., 2004), and (2) assess how well psychological 
variables could explain variance in physical and psychosocial adjustment among 
individuals living with HCV. A supplementary aim of the present thesis was to 
determine if physical and psychosocial adjustment variables could predict HCV 
treatment response after controlling for biomedical markers identified in previous 
research as having links with HCV treatment outcomes (Lee & Abdo, 2003).  
In order to achieve the aims of the present thesis, two studies, one cross-
sectional and one longitudinal, were conducted that utilised the self-regulatory 
model of illness (SRM) and benefit finding to assess the effectiveness of 
psychological variables to predict both treatment response, and physical and 
psychosocial adjustment within the context of HCV (Helgeson, Reynolds, & 
Tomich, 2006; Leventhal, Meyer, & Nerenz, 1980). The SRM posits that illness 
perceptions and coping strategies guide self-management behaviours in response to 
illness, and are therefore linked to health related outcomes (Hagger & Orbell, 
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2003; Leventhal et al., 1980; Leventhal, Diefenbach, & Leventhal, 1992). A 
number of studies have measured the effectiveness of the SRM in predicting 
biomedical, physical and psychosocial adjustment outcomes across related chronic 
diseases (Broadbent et al., 2015; Chilcot, Wellsted, & Farrington, 2011; Hagger & 
Orbell, 2003). Benefit finding has been described as a process where individuals 
find benefits or meaning in response to adverse life events (e.g., the experience of 
chronic disease) leading to positive physical and psychosocial outcomes (Fortune, 
Richards, Griffiths, & Main, 2005; Helgeson et al., 2006; McMillen & Fisher, 
1998; Pakenham, 2007; Pakenham, 2011; Rogan, Fortune, & Prentice, 2013; 
Seligman & Csikszentmihalyi, 2000; Siegal & Scrimshaw, 2000; Stanton, Bower, 
& Low, 2006; Thompson, 1985). A growing number of studies have shown that 
benefit finding accounted for variance in biomedical treatment, physical and 
psychosocial adjustment outcomes across multiple chronic disease conditions (de 
Ridder, Geenen, Kuijer, & van Middendorp, 2008; Helgeson et al., 2006; 
Littlewood, Vanable, Carey, & Blair, 2008; Luszczynska, Sarkar, & Knoll, 2007; 
McMillen & Fisher, 1998; Park, Chmielewski, & Blank, 2009; Tennen, Affleck, 
Urrows, Higgins, & Mendola, 1992).  
Chronic disease conditions such as HCV, by their very nature, have the 
potential to disrupt individuals’ lives physically, emotionally, and socially (de 
Ridder et al., 2008). For example, mood disturbance, decreased physical 
functioning, and reduced satisfaction with life are commonly reported as comorbid 
problems across a range of chronic disease conditions (de Ridder et al., 2008; 
Rutter & Rutter, 2002). No published research to date has specifically investigated 
the links between depression, physical health as defined by reported physical 
functioning, role limitations due to health concerns, reported bodily pain, and 
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general health perceptions, quality of life as measured by reported satisfaction with 
life, positive affect, and HCV treatment response. Therefore, the final longitudinal 
study reported here assessed whether physical health and psychosocial adjustment 
measures, (depression, life satisfaction, and positive affect) predicted HCV 
treatment response. 
The thesis is organised into several sections. The introductory chapters 
review HCV, chronic disease and adjustment, the SRM, illness perceptions and 
coping, and an overview of the benefit finding model. In Chapters 6 and 7 the two 
empirical studies and their sub-components are reported. Chapter 8 reconciles the 
data with respect to the existing empirical literature and suggestions for future 
research are offered.  
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Chapter 2 
An Introduction to Hepatitis C 
2.1 HCV Overview 
 HCV is a potentially chronic viral illness caused by contact with infected 
blood and is the leading cause of liver related morbidity and mortality in the world 
(Chapko et al., 2005; Chen & Morgan, 2006; Fried et al., 2002; Golden, Conroy, 
O’Dwyer, Golden, & Hardouin, 2006; Hauser et al., 2004; Lee & Abdo, 2003; Lee 
& Harrison, 2005; Rothenhausler et al., 2009; Shiffman et al., 2004; Simmonds, 
2001). HCV treatment costs have a significant impact on the national economy, 
and it is not uncommon for individuals with HCV to experience illness related 
stigmatisation, mental health problems, and discrimination across a range of social, 
healthcare and employment areas given its strong public association with 
intravenous (IV) drug use (Butt, 2008; Brener, Von Hippel & Kippax, 2007; 
Department of Health and Ageing, 2005; Golden et al., 2006; Paterson, Backmund, 
Hirsch, & Yim, 2007; Sacks et al., 2004; Zacks et al., 2006; Zickmund et al., 
2003). Unlike other types of Hepatitis, such as Hepatitis B, no vaccine currently 
exists to protect individuals from contracting HCV (Coppola et al., 2004). 
Approximately 170 million people worldwide, or around 2% of the world’s 
population, are chronically infected by HCV (Chen & Morgan, 2006; Hanafiah, 
Groeger, Flaxman, & Wiersma, 2013; Rothenhausler et al., 2009). Each year in 
Australia approximately 264,000 people are exposed to HCV, and of these, 
approximately 9,700 become infected (Australian National Council on AIDS, 
Hepatitis C and Related Diseases, Hepatitis C Sub-Committee, 2002; Batey, 2002; 
Butler & Quinn, 2003; Crofts, Aitken, & Kaldor, 1999; Department of Health and 
Ageing, 2005; Hepatitis C Virus Projections Working Group, 2002; Law et al., 
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2001; Levy, Baum, & Thomas, 2002; National Centre in HIV Epidemiology and 
Clinical Research, 2004). Recent data suggest that in Australia, approximately 
270,000 individuals live with chronic HCV infection (Gane et al., 2014).  
An estimated 90% of individuals who have been chronically infected with 
HCV never receive treatment (Department of Health and Ageing, 2005; Economic 
Evaluation of Hepatitis C in Australia, 2005; National Centre in HIV 
Epidemiology and Clinical Research, 2010). For the purposes of the present thesis, 
a chronic disease is defined as a health condition that generally exists for periods 
of time greater than three months (Hagger & Orbell, 2003; Vaughan, Morrison, & 
Miller, 2003). When left untreated HCV can lead to a number of medical 
complications such as liver failure, liver cancer and death (Economic Evaluation of 
Hepatitis C in Australia, 2005). In the 2004 – 2005 financial year, approximately 
1,500 deaths in Australia were attributed to the effects of chronic HCV 
(Department of Health and Ageing, 2005; Economic Evaluation of Hepatitis C in 
Australia, 2005).  
Australian data suggest that approximately 7% of new HCV cases result 
from exposure unrelated to IV drug use (Department of Health and Ageing, 2005). 
Examples of this type of transmission can include exposure to contaminated blood 
products, receiving tattoos, and in rare cases through mother to infant contact 
(Department of Health and Ageing, 2005; Heintges, & Wands, 1997; Newell & 
Pembrey, 2002). The remaining 93% of new HCV infections each year in Australia 
are directly attributed to IV drug use (Australian National Council on AIDS, 
Hepatitis C and Related Diseases, Hepatitis C Sub-Committee, 2002; Crofts et al., 
1999; Crofts, 2001; Law & Batey, 2003; National Centre in HIV Epidemiology 
and Clinical Research, 2007).  
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Despite many cases presenting as relatively asymptomatic during the initial 
acute phase of infection, in over 80% of cases, HCV develops into a persistent 
chronic illness and can be the cause of a myriad of serious health conditions 
including liver failure (often requiring a liver transplant), cirrhosis of the liver, 
hepatocellular carcinoma, hepatic steatosis, cellular immune dysfunction, 
musculoskeletal pain, chronic fatigue, cognitive impairment, abdominal pain, 
nausea, decreased appetite, in rare cases vasculitis and peripheral neuropathy, and 
mental health conditions, such as depression, anxiety and mood swings 
(Barkhuizen et al., 1999; Chen & Morgan, 2006; Dusheiko, 1996; Forton et al., 
2003; Fried et al., 2002; Glacken et al., 2003; Hoofnagle, 1997; Iosue, 2002; 
Koziel, 2005; Lee & Abdo, 2003; Lee & Harrison, 2005; Lehman & Cheung, 
2002; Lieber, 2001; Mendez et al., 2001; Ramalho, 2003).  
Since the identification of HCV in 1989 (previously known as either non-A 
or non-B hepatitis), antiviral therapies have been developed and administered, 
which seek to clear the virus or achieve a sustained virological response (Alter, 
1997; Fried et al., 2002; Greenberger, 1998; Iosue, 2002; Koff, 2000; Lee & Abdo, 
2003; Lee & Harrison, 2005; Lin & Keefe, 2001; Moussalli, Opolon, & Poynard, 
2002; Pawlotsky, 2003; Shiffman et al., 2004; Schaefer et al., 2007; Schaefer & 
Mauss, 2008; Schreiber, Busch, Kleinman, & Korelitz, 1996; Soffredini et al., 
2004). A sustained virological response is defined by HCV being undetectable in 
the individual’s blood six months after completing treatment (Fried et al., 2002; 
Koff, 2000; Lee & Abdo, 2003; Pawlotsky, 2003; Soffredini et al., 2004). Research 
has shown that over 95% of patients who achieve a sustained virological response 
remain free of the virus permanently (Lee & Abdo, 2003).  
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A wealth of research has focussed on determining important demographic 
and biomedical markers in predicting HCV treatment outcomes (Lee & Abdo, 
2003; Lee & Harrison, 2005; Martinot-Peignouxa et al., 1998; Shiffman et al., 
2004; Shiratori & Omata, 2000; Vik et al., 2005). For example, Shiffman et al. 
(2004) conducted research to determine which individual demographic and 
biomedical factors predicted treatment outcomes among a group of previous 
treatment non-responders. Results showed that the following factors were 
associated with an increased probability of the individual achieving a sustained 
viral response: (1) previous treatment with interferon monotherapy, (2) HCV 
genotypes 2 or 3, (3) lower HCV serum levels, (4) achievement of a 12 week early 
viral response, (5) an aspartate transaminase (AST): alanine transaminase (ALT) 
ratio less than 1.0, and (6) the absence of cirrhosis of the liver, along with the 
following behavioural predictors: (1) medication adherence, and (2) dosage 
compliance. By definition, an individual attained a sustained viral response if they 
achieved ‘nil HCV detected’ in two sequential blood tests taken at end of treatment 
and then at six months post end of treatment (Lee & Abdo, 2003; Shiffman et al., 
2004). Similarly, Lee and Abdo (2003) identified the individual demographic and 
biomedical factors that are important in predicting HCV treatment response . Their 
review of the literature revealed that: (1) HCV genotypes 2 or 3, (2) lower HCV 
serum levels, (3) combined interferon and ribavirin therapy, (4) shorter duration of 
HCV infection, (5) younger age (<40 years), (6) body weight (BMI within normal 
range), (7) the absence of illicit drug use, (8) the absence of cirrhosis or fibrosis of 
the liver, (9) lower hepatic iron levels, (10) low HCV heterogeneity, (11) female 
gender, (12) a low AST:ALT ratio, (13) the absence of both medical and mental 
health comorbidity, and (14) a 4 week rapid viral response or a 12 week early viral 
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response, were all associated with an increased probability of the patient achieving 
a sustained viral response (Lee & Abdo, 2003). The present thesis explored 
whether illness perceptions and coping (features of the SRM), benefit finding, and 
physical and psychosocial variables predicted HCV treatment response (nil HCV 
detected in any of the 3, 6, and 12 week milestone blood tests taken during 
treatment) after controlling for the following demographic, clinical and 
behavioural markers: (1) age, (2) body weight, (3) HCV genotype, (4) gender, (5) 
likely route of infection, (6) presence of cirrhosis of the liver, (7) other medical 
condition/s, (8) recreational drug use, (9) alcohol consumption, (10) smoking 
cigarettes, (11) comorbid mental health condition/s, (12) previous HCV treatment, 
and (13) HCV treatment adherence.  
At the time the data were collected for the present study, the standard 
treatment protocol for HCV included interferon (once weekly self-administered 
intramuscular injection), ribavirin (daily oral self-administered medication), and 
depending on pre-treatment medical assessment results, an additional protease 
inhibitor drug (either boceprevir or telaprevir) (Gross et al., 2003; Hallinan, Byrne, 
Kingsley, & Dore, 2007; Hepatitis C in Australia, 2007; Jacobson et al., 2012; 
Kaiser, Hass, & Gregor, 2004; Shiffman et al., 2004; Thompson, 2016; 
Wackernah, Lou, & Park, 2011). Similar to ribarvirin, boceprevir and telaprevir 
require the individual to take an oral tablet on a daily basis for the specified 
treatment period (Jacobson et al., 2012). Treatment periods for individuals 
undergoing interferon, ribavirin and protease inhibitor HCV treatment can be 
between 12 to 48 weeks depending on pre-treatment medical assessment results 
(e.g., cirrhosis of the liver typically requires longer treatment) (Jacobson et al., 
2012; Wackernah et al., 2011).  
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For individuals preparing for interferon based HCV treatment, a 
comprehensive psychosocial assessment is often required, in addition to other pre-
treatment biomedical assessments, to determine the individual’s psychological 
preparedness for treatment (Thompson, 2016). The rationale for the inclusion of 
pre-treatment psychosocial assessments is primarily due to the high number of 
potential side effects that can be experienced by individuals undergoing HCV 
treatment. Examples of treatment side effects can include nausea, fatigue, joint and 
muscle pain, chills, fever, anemia, skin conditions, memory loss, apathy, 
neutropenia, psychosis and depression (Foster, 2010; Fried et al., 2002; Hassanein 
et al., 2004; Ho et al., 2001; Lee & Harrison, 2005; Moussalli et al., 2002). Further, 
interferon has been identified has having the potential to exacerbate existing 
mental health conditions, and may cause endogenous depression or in rare cases, 
psychosis (Holmes, Thompson, & Bell, 2013; Sarkar, Sarkar, Berg, & Schaefer, 
2015; Wackernah et al., 2011).  
More recently, a new interferon-free generation of direct-acting anti-viral 
medications (eg., sofosbuvir, ledipasvir, and daclatasvir), with fewer reported side 
effect profiles and higher HCV clearance rates in comparison to interferon based 
treatment protocols, has become available in Australia (Thompson, 2016). 
However, interferon based HCV treatment protocols remain the standard treatment 
in many countries across the world (Gane et al., 2014; Wackernah et al., 2011). In 
Australia, the newer generation direct-acting anti-viral medications are currently 
funded under the national pharmaceutical benefits scheme (PBS) to treat 
individuals with HCV genotypes 1, 2 or 3 (Thompson, 2016). Individuals with 
HCV genotypes 4, 5, or 6 currently remain ineligible to receive subsidised 
treatment under the PBS for the newer direct-acting anti-viral medications and will 
11 
 
need to continue to receive interferon based HCV treatments for the foreseeable 
future (Thompson, 2016). Similar inequities exist related to access to newer 
generation direct-acting anti-viral medications in other parts of the world largely 
based on treatment cost issues (Gane et al., 2014). For example, in the United 
States of America, access to the newer generation of direct-acting HCV anti-viral 
medications is in most cases dependent on the individual’s ability to maintain 
relevant private health insurance cover (Canary, Klevens, & Holmberg, 2015). 
Further, in many developing countries interferon based HCV protocols continue to 
remain the standard treatment, largely due to the cost-prohibitive nature of the 
newer direct-acting anti-viral drugs (Luhmann et al., 2015).   
The quality of life costs associated with HCV are potentially both 
significant and complex (Golden et al., 2006; Iosue, 2002; Lee & Abdo, 2003). For 
example, common symptoms of HCV can range from mild, and in some cases 
asymptomatic, to severe and disabling (Barkhuizen et al., 1999; Forton et al., 2003; 
Glacken et al., 2003; Hassanein et al., 2004; Iosue, 2002; Lee & Harrison, 2005; 
McHutchison et al., 2001). Further, HCV can have far reaching negative effects on 
an individual’s financial and employment potential, along with, in many cases, 
reducing their ability to engage in satisfying relationships (Bonkovsky et al., 2007; 
Golden et al., 2006; Hassanein et al., 2004; McHutchison et al., 2001; Perrillo et 
al., 2004). For example, Mathew, Peiffer, Rhoades, and McGarrity (2006) 
examined health related quality of life among a group of individuals with 
refractory HCV prior to, during, and after undergoing re-treatment with pegylated 
interferon alpha-2b and ribavirin. Results showed lower health related quality of 
life at baseline, across a range of indicators including social, emotional and 
physical functioning, and poorer mental and general health in comparison to 
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national normative data (Mathew et al., 2006). Similarly, Hollander, Foster and 
Weiland (2006) conducted a study among a Swedish cohort examining health 
related quality of life indicators before, during and after combination therapy with 
interferon and ribavirin in patients with chronic HCV. Results indicated 
significantly lower quality of life, particularly among previous IV drug users, at 
baseline when compared to Swedish health related quality of life data (Hollander et 
al. 2006). Further, Forton et al. (2003) conducted a review analysing the 
association between chronic HCV and health related quality of life. The findings 
supported related research that implicated the relationships of fatigue and 
depression to lower perceived health related quality of life among individuals 
chronically infected with HCV. The research also identified the possible biological 
effect that chronic HCV infection can have in contributing directly to 
neurocognitive impairment independent of substance abuse, depression or hepatic 
encephalopathy (Forton et al., 2003). 
Individuals with HCV commonly experience illness related stigmatisation 
and discrimination across social, healthcare and employment related areas due to 
the condition’s strong public association with IV drug use (Butt, 2008; Brener et 
al., 2007; Paterson et al., 2007; Zacks et al., 2006). For example, Zickmund et al. 
(2003) conducted a cross sectional study measuring perceived illness related 
stigma among a group of outpatients receiving treatment for HCV. Results 
demonstrated that a significant proportion of this cohort were experiencing HCV 
illness related stigma regardless of the route of transmission, along with high levels 
of depression and anxiety, lower quality of life and perceived ability to cope, and 
high levels of discrimination across various work, healthcare and personal 
relationship related domains. Further, stigma were higher among female 
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participants, but were not influenced by other demographic variables such as level 
of education, age or occupation (Zickmund et al., 2003). Finally, Golden et al. 
(2006) conducted a cross sectional study to assess stigma and associated levels of 
mood disturbance and illness related adjustment among a group of individuals 
awaiting treatment for HCV. Results revealed high levels of illness related stigma 
and associated anxiety, depression and low levels of illness related adjustment and 
overall quality of life among this participant cohort.  
2.2 Summary  
 The present chapter reviewed the physical, social, and economic costs and 
consequences of living with HCV (Chen & Morgan, 2006; Golden et al., 2006). 
Further, there are high annual health related costs associated with the treatment of 
HCV that have a significant impact on government health budgets here in Australia 
and overseas (Department of Health and Ageing, 2005).  
 A primary goal of the present thesis was to utilise the SRM, which has 
demonstrated efficacy in predicting health related outcomes across a range of 
chronic health conditions within the context of HCV (e.g., Hagger & Orbell, 
2003). Before describing in greater detail the features of an expanded SRM, the 
following chapter: (1) explored some of the key theoretical concepts associated 
with chronic disease and health related outcomes, (2) reviewed models related to 
the SRM, and (3) provided a rationale for the use of an expanded SRM in the 
present thesis.    
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Chapter 3 
Chronic disease and Physical and Psychosocial Adjustment 
The present chapter provides a summary of the key theoretical concepts 
associated with chronic disease and adjustment, and presents a rationale for 
utilising an expanded SRM, including illness perceptions, coping strategies and 
benefit finding, as a framework to predict treatment response and physical and 
psychosocial adjustment among individuals with HCV. Chronic diseases such as 
HCV can have potentially significant negative impacts on an individual’s life (de 
Ridder et al., 2008; Sprangers et al., 2000). Both acute and chronic illness can 
reduce overall quality of life in individuals impacted by various medical 
conditions. Chronic disease can be differentiated from acute illness in terms of 
duration, the former generally persisting for extended periods of time (de Ridder et 
al., 2008; Sprangers et al., 2000). The medical impact on an individual living with 
chronic HCV can range on a continuum from relatively asymptomatic through to 
significant physical and psychosocial consequences (Barkhuizen et al., 1999; Chen 
& Morgan, 2006; Forton et al., 2003; Glacken et al., 2003; Hauser et al., 2004; 
Hoofnagle, 1997; Mendez et al., 2001; Rothenhausler et al., 2009). Prior to the 
experience of chronic disease, individuals tend to have a habitual set of coping 
strategies to help them deal with routine and predictable life events. Chronic 
disease onset however has the potential to force an adjustment of their coping 
strategies in order to deal with their respective health threat (de Ridder et al., 2008; 
Taylor & Aspinwall, 1996). Physical and psychosocial adjustments are the end 
product of the various ways individuals appraise and cope with their chronic 
disease (de Ridder et al., 2008; Taylor & Aspinwall, 1996). Research has shown 
that the majority of individuals living with chronic diseases eventually achieve a 
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positive state of physical and psychosocial adjustment (de Ridder et al., 2008; 
Taylor & Aspinwall, 1996). However, for around 30% of individuals, positive 
physical and psychosocial adjustment outcomes remain elusive or unattainable (de 
Ridder et al., 2008; Taylor & Aspinwall, 1996).  
A number of theoretical models have been reported in the literature that 
investigate links between health related behaviours, the experience of chronic 
disease and adjustment (Caltabiano & Ricciardelli, 2013; Lazarus & Folkman, 
1987). For example, the health belief model (Rosenstock, 1974) investigates the 
likelihood that individuals will engage in health related behaviours following 
assessment of perceived seriousness and susceptibility regarding the illness threat, 
mediated by a cost benefit analysis related to potential success of engaging in 
health related behaviours, and perceptions related to illness threat and perceived 
self-efficacy to deal with the health problem (Rosenstock, 1974). Similarly, the 
theory of planned behaviour investigate links between the assessment of 
individuals beliefs around behaviour, norms and perceived control and the 
engagement behaviours, including health related behaviours (Ajzen, 1991). 
Further, the transactional model of stress and coping outlines a self-regulatory 
process where by individuals firstly engage in a process of cognitively appraising 
stressful events in their lives (assessment of perceived levels of risk or harm), 
including health events, engage in coping behaviours based on their perceived 
coping resources, and then evaluate the success of their coping behaviours on 
dealing with these adverse events (Carver, Scheier, & Weintraub, 1989; Lazarus & 
Folkman, 1987). Within this model a continuous dynamic loop exists between 
appraisal and re-appraisal of cognitive and coping strategies based on perceived 
success in dealing with the stressful event identified by the individual (Carver et 
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al., 1989; Lazarus & Folkman, 1987). Although examples of related health related 
models described here (Ajzen, 1991; Lazarus & Folkman, 1987; Rosenstock, 
1974) reference links between individuals perceptions or attitudes, perceived 
coping and engagement in health related behaviours, unlike these other models, the 
SRM includes these perceptions regarding illness related threats into specific 
illness perception and coping categories or components that can specifically 
measure links between cognitive and emotional representations of illness, coping 
strategies and health related outcomes (Leventhal et al., 1992). Further the SRM 
has been included extensively in research that has investigated links between 
illness perceptions, coping and health related outcomes (Hagger & Orbell, 2003). 
In a review of the literature on adjustment to chronic disease, de Ridder et 
al. (2008) identified the following key elements that were associated with 
successful adjustment to chronic disease: (1) the absence of psychological 
disorders, including depression, (2) positive affect, greater life satisfaction and 
general quality of life, and (3) adequate physical functioning, including the ability 
to attend to daily tasks such as work activities. Several models have been proposed 
that relate to how individuals can achieve better physical and psychosocial 
adjustment in response to chronic disease (de Ridder et al., 2008). These models 
have included cognitive adaptation which emphasises illness acceptance and 
perceived illness related personal control (de Ridder et al., 2008; Taylor, 1983). 
Other models have focussed on links between various personality factors such as 
optimism and neuroticism and adjustment (Adler & Matthews, 1994; de Ridder et 
al., 2008; Taylor, 1983), whereas others have emphasised the role of stress and 
coping strategies, and the concept of self-regulation in accounting for physical and 
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psychosocial adjustment (Adler & Matthews, 1994; Cameron & Leventhal, 2003; 
de Ridder et al., 2008).  
Within the context of chronic disease, self-regulation emphasises links 
between cognitive appraisal of perceived health threats, the adoption of coping 
strategies and biomedical outcomes, and physical and psychosocial adjustment 
(Cameron & Leventhal, 2003; de Ridder et al., 2008). Self-regulation related to 
physical illness refers to the individual actively engaging in cognitive and coping 
strategies to better manage their health conditions, and has been used to predict 
physical and psychosocial adjustment, and biomedical treatment outcomes across 
numerous chronic disease conditions (Cameron & Leventhal, 2003; de Ridder et 
al., 2008; Sharpe & Curran, 2006; Walker, Jackson, & Littlejohn, 2004). The SRM 
(Leventhal et al., 1992) shares a number of key features included in related self -
regulation based models (Cameron & Leventhal, 2003), i.e., active cognitive 
appraisal of health related threats included in self-regulation based models, is 
similar to the formation of cognitive and emotional representations of illness or 
illness perceptions, and coping behaviours that are activated in response to 
awareness of an illness threat (Leventhal et al., 1992). Illness perceptions and 
coping strategies, key features of the SRM, have predicted physical and 
psychosocial adjustment and biomedical treatment outcomes across a range of 
chronic disease conditions (Broadbent et al., 2015; Chilcot et al., 2011; Hagger & 
Orbell, 2003). Therefore, for the present thesis, the SRM provided a strong 
foundation to test whether illness perceptions and coping strategies could predict 
physical and psychosocial adjustment, and treatment response, among individuals 
diagnosed with chronic HCV.  
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In line with a review conducted by de Ridder et al. (2008), the present 
thesis utilised measures of depression, quality of life (including positive affect and 
life satisfaction), and physical health as criterion measures of physical and 
psychosocial adjustment. Importantly, the SRM has predicted physical and 
psychosocial adjustment outcomes in other chronic disease conditions, specifically 
in relation to depression (Fortune, Richards, Griffiths, & Main, 2002; Vaughan, 
Morrison, & Miller, 2003), quality of life, including life satisfaction and positive 
affect (De Gucht, 2015; Rutter & Rutter, 2002; Steed et al., 1999), and physical 
health (Heijmans, 1999; Helder et al., 2002; Scharloo et al., 2000; Steed et al., 
1999). Further, similar to related chronic disease research (Chilcot et al., 2011), the 
present thesis utilised HCV treatment response (nil HCV detected in the 
bloodstream) as the criterion variable to assess whether the SRM could predict 
treatment response. 
Complementing the cognitive strategies associated with the SRM (e.g., 
whether beliefs and subsequent coping behaviours predicted adjustment outcomes 
in chronic disease), research has also focussed on alternative cognitive strategies 
that enhance positive physical and psychosocial adjustment and improved 
biomedical treatment outcomes (de Ridder et al., 2008). For example, arising out 
of positive psychology theory (Seligman & Csikszentmihalyi, 2000), the benefit 
finding model has been utilised to investigate links between the discovery of 
benefits or positive meaning following adverse life experiences (including chronic 
illness) and physical and psychosocial adjustment, and biomedical treatment 
outcomes (de Ridder et al., 2008; Helgeson et al., 2006; McMillen & Fisher, 
1998). In a number of studies, benefit finding accounted for significant variance in 
physical and psychosocial adjustment, and in a limited number of cases it predicted 
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biomedical treatment outcomes, across multiple chronic health conditions (Affleck, 
Tennen, Croog, & Levine, 1987; Bower, Kemeny, Taylor, & Fahey, 1998; Bower 
et al., 2005; Carver & Antoni, 2004; Danoff-Burg & Revenson, 2005; de Ridder et 
al., 2008; Sears, Stanton, & Danoff-Burg, 2003; Littlewood et al.,  2008; 
Luszczynska et al., 2007; Park et al., 2009; Tennen et al., 1992). Specific to the 
present thesis, in studies conducted across chronic disease conditions benefit 
finding accounted for variance in depression (Carver & Antoni, 2004), quality of 
life, including life satisfaction and positive affect (Bower et al., 2005), and 
physical health (Danoff-Burg & Ravenson, 2005) adjustment. Similarly, benefit 
finding predicted biomedical treatment outcomes in a number of chronic disease 
studies (Affleck et al., 1987; Bower et al., 1998). 
In summary, a number of studies have confirmed that illness perceptions 
and coping strategies (i.e., features of the SRM), and benefit finding have 
accounted for variance in physical and psychosocial adjustment and predicted 
biomedical treatment outcomes in chronic disease (Affleck et al., 1987; Bower et 
al., 1998; Broadbent et al., 2015; Chilcot et al., 2011; Bower et al., 2005; Carver & 
Antoni, 2004; Danoff-Burg & Revenson, 2005; de Ridder et al., 2008; Hagger & 
Orbell, 2003; Littlewood et al.,  2008; Luszczynska et al., 2007; Park et al., 2009; 
Tennen et al., 1992). These data provided the rationale to assess whether illness 
perceptions, coping and benefit finding predicted HCV physical and psychosocial 
adjustment and treatment response within an expanded SRM. The following 
chapter reviewed features of the SRM, and evaluated its ability to predict 
biomedical treatment and physical and psychosocial adjustment outcomes across 
the spectrum of chronic disease. 
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Chapter 4 
The SRM 
4.1 Introduction to the SRM 
The SRM is a multidimensional theoretical framework that has been 
utilised to examine the relationships of illness perceptions and coping strategies to 
biomedical treatment outcomes and physical  and psychosocial adjustment across a 
range of related chronic disease conditions including irritable bowel syndrome 
(Boddington, Myers, & Newman, 2002), diabetes (Cartwright & Lamb, 1999), 
chronic fatigue syndrome (Heijmans, 1998), Addison’s disease (Heijmans, 1999), 
human immuno-deficiency virus  (Horne, Cooper, Fisher, Buick, & Weinman, 
2001), epilepsy (Kemp, Morley, & Anderson, 1999), Asthma (Horne & Weinman, 
2002), rheumatoid arthritis (Moss-Morris et al., 2002), cancer (Rees, Fry, & Cull, 
2001), chronic obstructive lung disease (Scharloo et al., 1998), multiple sclerosis 
(Schiaffino & Cea, 1995), atrial fibrillation (Steed et al., 1999), systematic lupus 
erythematosus (Daleboudt, Broadbent, McQueen, & Kaptein, 2013), 
cardiovascular disease (Greco et al., 2014), and hypertension (Theunissen & de 
Ridder, 2001). The SRM has been the focus of substantial empirical enquiry within 
the area of cognitive and emotional responses to illness threats (Hagger & Orbell, 
2003). Important to the present thesis, no published research has assessed whether 
the SRM could predict treatment response and physical and psychosocial 
adjustment among individuals with HCV.   
 The SRM provides an explanatory framework for understanding how 
individuals respond to perceived health threats (Broadbent et al., 2006; Broadbent, 
Kydd, Sanders, & Vanderpyl, 2008; Diefenbach & Leventhal, 1996; Lau & 
Hartman, 1983; Leventhal et al., 1980; Radat et al., 2009). Within this model, 
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Leventhal et al. (1980) originally described five cognitive components related to 
illness perceptions: (a) illness identity (the name or label the individual gives to 
their illness and the symptoms attributed to the disease), (b) cause (individual 
beliefs regarding the cause of the health condition), (c) timeline (personal beliefs 
around how long the condition will last), (d) consequences (perceived impact of 
the illness on the individual’s life), and (e) curability or control (beliefs around 
illness recovery and degree of personal control over health related outcomes). An 
additional emotional representation covering negative reactions such as anger, fear 
and distress was also included in earlier research (Leventhal et al., 1980). Although 
initial research using the SRM often used open ended interviews to measure these 
cognitive and emotional representations of illness or illness perceptions (Leventhal 
et al., 1980), more recent SRM research has employed structured questionnaires 
such as the Brief Illness Perception Questionnaire (BIPQ: Broadbent et al., 2006). 
The BIPQ measures eight cognitive and emotional representations or illness 
perceptions as follows: (a) illness consequence, (b) timeline, (c) personal control, 
(d) treatment control, (e) illness identity, (f) illness concern, (g) illness coherence 
or understanding, and (h) emotional response. An additional item measures 
individual’s beliefs around illness causality (Broadbent et al., 2006).  
The SRM describes a three stage process following the initial awareness of 
a health risk (Broadbent et al., 2006; Hagger & Orbell, 2005; Horne & Weinman, 
2002; Leventhal et al., 1992). Firstly, in order to reduce the potentially negative 
effects associated with perceived health risks such as HCV, an individual forms 
cognitive and emotional representations, or illness perceptions of their health threat 
(Broadbent et al., 2006). The formation of these representations is influenced by 
various social, cultural and psychological factors. Examples include previous 
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illness experiences, and personality and cultural factors related to illness response 
(Horne & Weinman, 2002; Leventhal et al., 1992). Secondly, these illness 
perceptions activate coping behaviours in response to the illness threat. Thirdly, the 
individual then appraises the efficacy of both their perceptions around their illness 
and coping behaviours in relation to health related outcomes (Broadbent et al., 
2006; Leventhal et al., 1992). The SRM incorporates a model based on a 
continuous feed-back loop where the results of the on-going appraisal process are 
continually fed-back into the first two stages of the process (Broadbent et al., 2006; 
Hagger & Orbell, 2005; Leventhal et al., 1992). Within this feedback system, both 
illness representations and coping behaviours are adjusted depending on the 
perceived success or failure of these illness threat responses or coping behaviours 
on health related outcomes (Broadbent et al., 2006; Diefenbach & Leventhal, 1996; 
Hagger & Orbell, 2005; Horne & Weinman, 2002; Leventhal et al., 1992). 
Therefore, the SRM suggests that illness perceptions and coping behaviours 
directly account for variance in health related outcomes (Broadbent et al., 2006). 
The SRM suggests that following illness awareness, an individual forms 
perceptions related to their illness. Illness perceptions then trigger coping 
behaviours, which in turn account for variance in health related outcomes. 
Therefore, Leventhal et al. (1980) proposed that coping has a potential mediating 
role between illness perceptions and health related outcomes. According to Baron 
and Kenny (1986) for mediation to occur as predicted within the SRM, a number 
of conditions must be met. Firstly, illness perception components must predict 
health related outcomes. Secondly, illness perceptions must significantly predict 
coping as the mediating variable. Thirdly, coping must predict the dependent 
variable, health related outcomes, after controlling for illness perception items. 
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Finally, the illness perception coefficient value must decrease after including 
coping into the modelling (Baron & Kenny, 1986). 
A number of studies have investigated whether coping strategies mediate 
the relationship between illness perceptions and health related outcomes in chronic 
disease (Hagger & Orbell, 2003; Hampson, Glasgow, & Toobert, 1990; Heijmans, 
1998; Kemp et al., 1999; Rutter & Rutter, 2002; Scharloo et al., 1998). Relatively 
few studies have found support for coping to mediate the relationship between 
illness perceptions and health related outcomes (Hagger & Orbell, 2003; Heijmans, 
1998; Kemp et al., 1999; Scharloo et al., 1998). For example, Heijmans (1998) 
utilised the SRM to investigate whether illness perceptions and coping strategies 
predicted physical and psychosocial adjustment outcomes among individuals with 
chronic fatigue syndrome, and whether coping strategies mediated the relationship 
between illness perceptions and adjustment outcomes. Results confirmed that 
although illness perceptions alone predicted physical and psychosocial adjustment 
outcomes, coping strategies did not mediate this relationship (Heijmans, 1998).  In 
comparison, Rutter and Rutter (2002) investigated the role of illness perceptions 
and coping in predicting health related outcomes among a cohort of irritable bowel 
syndrome sufferers, and to assess the potential mediating role of coping within this 
predictive framework. They identified coping as a mediator of the relationship in 
some, but not all, of the predictive models. For example, in investigating whether 
illness perception components and coping strategies to account for variance in 
quality of life outcomes, results identified the use of acceptance as a coping 
strategy, to mediate the relationship of illness consequences to quality of life 
outcomes (Rutter & Rutter, 2002). The present thesis provided an opportunity to 
additionally assess whether coping strategies mediated the relationship between 
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illness perceptions and physical and psychosocial adjustment outcomes within the 
context of HCV.      
In summary, some tests of the  SRM have tended to support the 
hypothesised relations among its components, though not consistently (Broadbent, 
2010; Broadbent et al., 2006; Callegari, Michelini, Sguazzin, Catona, & Klersy, 
2005; Dubernard, Rouzier, David-Montefiore, Bazot, & Darai, 2008; Fusar-Poli et 
al., 2008; Lau & Hartman, 1983; Meyer et al., 1985; Petrie, Weinman, Sharpe, & 
Buckley, 1996; Petrie, Cameron, Ellis, Buick, & Weinman, 2002; Petrie, Jago, & 
Devcich, 2007; Pimm & Weinman, 1998; Rothenhausler et al., 2009; Rutter & 
Rutter, 2002; Steed et al., 1999). To date, the majority of research on the SRM has 
focussed on related chronic health conditions other than HCV. The present thesis 
addressed this gap in the literature by investigating whether benefit finding 
predicted treatment response and physical and psychosocial adjustment among a 
cohort of individuals preparing for and undertaking HCV treatment, and whether 
coping strategies mediate these relationships. The following sections describe 
features of the SRM, illness perceptions and coping, including an evaluation of 
each of these features to account for variance in biomedical treatment and physical 
and psychosocial adjustment outcomes across chronic disease conditions. 
4.2 Illness Perceptions 
The SRM has been used to investigate the illness perceptions of individuals 
across a range of chronic physical illnesses such as end-stage renal disease, human 
immuno-deficiency virus, diabetes, heart disease, tuberculosis, and multiple 
sclerosis (Broadbent et al., 2015; Chilcot et al., 2011; Hagger & Orbell, 2003; 
Mohammed, Nagla, Morten, Asma, & Arja, 2015;  Vaughan et al., 2003). For 
example, Vaughan et al. (2003) reported that illness perceptions included a strong 
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illness identity, serious illness consequences, limited illness control, and a more 
chronic illness timeline in individuals with multiple sclerosis. Additionally, illness 
perceptions were also linked with weak beliefs associated with a treatment cure, 
which is consistent with the medical understanding and nature of multiple 
sclerosis. Previous research has also identified important inter-relationships 
between each of the illness perception components within the SRM (Buick, 1998; 
Hagger & Orbell, 2003; Heijmans, 1998; Vaughan et al., 2003). For example, 
Vaughan et al. (2003) reported that illness identity, chronic timeline, and low 
personal control were related to greater illness concern. These results highlight and 
support the need to understand and assess illness perceptions as a group of 
cognitions, as it appears that once individuals become aware of a medical condition 
they utilise a number of illness perception components in an effort to make sense 
of what is happening  (Hagger & Orbell, 2003; Vaughan et al., 2003).  
The majority of early research exploring the SRM focused on confirming 
the relationships between illness perceptions, health related behaviours, and coping 
(Hagger & Orbell, 2003; Hampson et al., 1990). Results from these earlier studies 
revealed links between illness perceptions and various health related behaviours 
and coping strategies such as adherence to medication, medical assistance seeking 
behaviours, and motivation to engage in self-management related activities 
(Hagger & Orbell, 2003, Hampson et al., 1990; Vaughan et al., 2003). More recent 
research has begun to explore the relationship between illness perceptions and 
biomedical treatment outcomes as well as physical and psychosocial adjustment 
(Broadbent et al., 2015; De Gucht, 2015; Chilcot et al., 2011; Greco et al., 2014; 
Heijmans, 1998, 1999; Helder et al., 2002; Lee, Chaboyer, & Wallis, 2008; Moss-
Morris, Petrie, & Weinman, 1996; Scharloo et al., 1998; Vaughan et al., 2003). A 
26 
 
number of these studies have confirmed a role for illness perceptions in predicting 
biomedical treatment outcomes and accounting for variance in physical and 
psychosocial adjustment across the spectrum of chronic disease (Daleboudt et al., 
2013; Chilcot et al., 2011; Fortune et al., 2002; Greco et al., 2014; Griva, Myers, & 
Newman, 2000; Horne & Weinman, 2002; Rutter & Rutter, 2002; Schiaffino, 
Shawaryn, & Blum, 1998; Stafford, Berk, & Jackson, 2009; Vaughan et al., 2003). 
For example, Rutter and Rutter (2002) reported significant links between illness 
perceptions and psychosocial adjustment individuals with irritable bowel 
syndrome; stronger beliefs associated with illness consequence predicted lower 
physical and psychosocial adjustment. Similarly, Greco et al. (2014) demonstrated 
that illness identity predicted emotional well-being among a cohort of individuals 
with cardiovascular disease. Further, Daleboudt et al. (2013) identified the 
important role of illness perceptions in the physical functioning of individuals with 
systematic lupus erythematosus; stronger negative emotional perceptions related to 
this condition predicted poorer physical functioning related to intimate relations. 
Specific to biomedical treatment outcomes, Chilcot et al. (2011) reported that 
perceptions related to treatment control predicted survival among individuals with 
end-stage renal disease.  
In summary, there is a wealth of evidence linking illness perceptions with 
biomedical treatment outcomes, physical health and psychosocial adjustment 
across a range of chronic health conditions (Covic, Seica, Gusbeth, Gavrilovici, & 
Goldsmith, 2004; Frostholm et al., 2007; Hagger & Orbell, 2003; Paddison, 
Alpass, & Stephens, 2008). No published research to date however, has tested 
these links in individuals diagnosed with HCV. The present thesis addressed this 
gap. The next section describes coping as a feature of the SRM, along with 
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research that has detailed its association with biomedical treatment outcomes, 
physical health and psychosocial adjustment in chronic disease conditions. 
4.3 Coping and the SRM 
Coping plays a significant role in predicting health related outcomes 
(Broadbent et al., 2006; Fitzell & Pakenham, 2010; Fowler, 2007; Kyngas et al., 
2000; Pakenham, 2006). Coping has been defined as both cognitive and 
behavioural efforts that individuals adopt to manage internal and environmentally 
related stressful demands that have been appraised as exceeding normal resources 
(Carver & Scheier, 1983; Folkman & Lazarus, 1980; Folkman & Lazarus, 1988; 
Holahan & Moos, 1987; Lazarus & Folkman, 1984; Lazarus & Folkman, 1987). 
Chronic health conditions such as HCV can  make significant demands on an 
individual’s life (Felton & Revenson, 1987; Pierret, 2003) For example, when a 
chronic health condition such as HCV has an unpredictable course, or severe 
symptoms, an individual’s coping resources or adaptive strategies can be 
compromised (De Ridder, Depla, Severens, & Malsh, 1997; Kyngas et al., 2000; 
Roesch & Weiner, 2001). Chronic health conditions such as HCV can create 
uncertainty, potentially disrupt daily routines, and permeate an individual’s work 
life and personal relationships (De Ridder et al., 1997; Felton & Revenson, 1987; 
Kyngas et al., 2000; Pierret, 2003; Roesch & Weiner, 2001; Weinman, Wright, & 
Johnston, 1995). Research has suggested that stress caused by chronic health 
conditions can vary between individuals due in part to their perceived coping 
abilities (Carver, Scheier, & Weintraub, 1989; Lazarus & Folkman, 1984; 
Weinman et al., 1995). Early research indicated that individuals had relatively 
limited ways of coping with particular stressors (Weinman et al., 1995). More 
recent research has indicated that individuals tend to use a range of coping 
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behaviours to deal with different aspects of the same stressor (Carver et al., 1989; 
Lazarus & Folkman, 1984; Weinman et al., 1995). For example, Carver (1997) 
developed the Brief COPE to examine 14 different coping strategies (active 
coping, planning, social support, emotional support, self-blame, religion, positive 
re-interpretation, acceptance, venting emotions, denial, humour, behavioural 
disengagement, substance abuse, and self-distraction). Research has demonstrated 
that coping behaviours are not static, and that they can evolve and change over 
time. Further, environmental and personal factors such as illness perceptions can 
influence the choice of coping strategies (Broadbent et al., 2006; Weinman et al., 
1995). 
A growing body of research has confirmed the efficacy of illness 
perceptions to predict biomedical treatment outcomes, physical health and 
psychosocial adjustment across a range of chronic diseases (Chilcot et al., 2011; 
Daleboudt et al., 2013; De Gucht, 2015; Fortune et al., 2002; Greco et al., 2014; 
Miglioretti, Mazzini, Oggioni, Testa, & Monaco, 2008). In comparison, there is 
mixed support for coping strategies to predict physical and psychosocial 
adjustment outcomes. For example, Rutter and Rutter (2002) reported that coping 
strategies of behavioural disengagement and suppression predicted higher 
depression after first controlling for the contribution of illness perceptions in 
irritable bowel syndrome sufferers. Similarly, Helder et al. (2002) reported that 
coping strategies related to lower illness acceptance, greater focus on venting 
emotions, and behavioural and mental disengagement were all independent 
predictors of poorer mental health in a cohort of Huntington’s disease sufferers. 
Scharloo et al. (2000) conducted a longitudinal study among individuals with 
psoriasis to investigate links between coping and biomedical, physical health and 
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psychosocial adjustment outcomes. At 1 year follow up, patients who adopted 
coping strategies associated with greater expression of emotions, higher levels of 
seeking social support, greater use of distraction strategies, and active coping, 
reported fewer psoriasis related symptoms, were less anxious and depressed, and 
reported better overall physical health compared to those who did not adopt such 
strategies (Scharloo et al., 2000). Alternatively, although Heijmans (1999) reported 
that illness perceptions predicted physical and psychosocial adjustment outcomes 
in Addison’s disease, coping strategies did not add significantly to the predictive 
model. Similarly, in a study examining whether the SRM could account for 
physical and psychosocial adjustment among a cohort of individuals with atrial 
fibrillation, coping strategies only made minimal contributions to the prediction 
model after first controlling for the contribution of illness perception components 
(Steed et al., 1999). 
Although a number of studies have demonstrated the utility of the SRM to 
predict both physical and psychosocial outcomes across multiple chronic diseases 
(Rutter & Rutter, 2002; Scharloo et al., 2000), there are more reports implicating 
illness perceptions than coping strategies as key variables in such relationships 
(Hagger & Orbell, 2003). Hagger and Orbell (2003) suggested that many coping 
measures used in chronic disease studies generally lack acceptable levels of 
specificity in relation to the particular medical condition under review. However, 
to date no general consensus appears to have been reached as to why illness 
perceptions have more consistently demonstrated the ability to predict physical and 
psychosocial adjustment in comparison to coping strategies within the context of 
chronic disease (Hagger & Orbell, 2003). The present thesis provided an 
opportunity to investigate the relative contributions of coping strategies to predict 
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treatment response, physical and psychosocial adjustment outcomes within the 
context of HCV, along with exploring the potential mediating role of coping in the 
relationship between illness perceptions and adjustment outcomes. The following 
section will outline the benefit finding model. A summary of research that has 
assessed whether benefit finding could account for variance in physical and 
psychosocial adjustment and biomedical treatment outcomes across a number of 
chronic disease conditions is provided.  
4.4 Benefit Finding and HCV 
Although the SRM has demonstrated links between illness perceptions, 
coping behaviours and health related outcomes, other research has identified 
associations between positive meaning, personal growth and physical and 
psychosocial adjustment (Helgeson et al., 2006; Leventhal et al., 1992). For 
example, cognitive factors such as benefit finding and meaning making have been 
linked to positive adjustment outcomes in chronic health conditions such as 
multiple sclerosis (Pakenham, 2007). Benefit finding, is also known by other 
related terms such as posttraumatic growth and adversarial growth, and has been 
described as a process where individuals find meaning in the context of adverse 
life events and situations, including the experience of chronic disease (Algoe & 
Stanton, 2009; Antoni et al., 2001; Belizzi & Blank, 2006; Cordover, Cunningham, 
Carlson, & Andrykowski, 2001; Fortune et al., 2005; Linley & Joseph, 2004; 
Pakenham, 2011; Rogan et al., 2013; Seligman & Csikszentmihalyi, 2000; Siegal 
& Scrimshaw, 2000; Taku et al., 2007; Thompson, 1985; Thornton & Perez, 2006; 
Tomich & Helgeson, 2004). Chronic illnesses such as HCV can challenge and 
undermine an individual’s sense of meaning and perceptions about their mortality. 
Restoring a sense of meaning within the context of chronic illness has been linked 
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to positive physical and psychosocial adjustment outcomes (Littlewood et al., 
2008; Lechner, Carver, Antoni, Weaver, & Phillips, 2006; Luszczynska et al., 
2007; Park et al., 2009; Tennen et al., 1992). In response to adversity, examples of 
benefits found by individuals have included strengthened relationships, a greater 
appreciation of life, spiritual and personal growth, changes in life priorities and 
goals, changes in health behaviours, and illness acceptance (Helgeson et al., 2006; 
Pakenham, 2011; Stanton et al., 2006). 
The ‘assumptive world theory’ developed by Janoff-Bulman (1992) 
provides an appropriate context for the benefit finding model. Janoff-Bulman 
asserts that most individuals see the world as a safe, meaningful and benevolent 
place. Adversarial and traumatic events, including the experience of illness, can 
‘shatter’ these assumptions, potentially undermining a sense of meaning and 
purpose. One of the primary uses of  benefit finding in the context of these 
‘shattered assumptions’ is in providing a process for helping individuals to restore 
meaning and purpose, and order and predictability, by providing an opportunity for 
them to reflect on the potentially positive benefits associated with their respective 
crises of meaning (Janoff-Bulman, 1992; Pakenham, 2011). 
One of the key assumptions associated with the benefit finding model is 
that an adverse event must be of sufficient perceived severity to trigger the benefit 
finding process (de Ridder et al., 2008). Once the benefit finding process is 
commenced, a number of factors can contribute to the level of individual 
engagement (de Ridder et al., 2008). For example, younger age, higher social 
status, higher severity and intensity related to the reported adverse event, and 
personality factors such as higher optimism, hopeful disposition, and extravert 
personality have been linked to higher benefit finding engagement following 
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adverse life events (de Ridder et al., 2008). Other factors such as socioeconomic 
status, educational achievement levels, and duration of the reported adverse event 
have less consistently been associated with benefit finding (de Ridder et al., 2008). 
Further, studies have not established links between gender and degree of 
engagement with benefit finding activities following adversity (Danoff-Burg & 
Revenson, 2005; de Ridder et al., 2008). Similarly, although greater illness severity 
been associated with more prevalent benefit finding activities, one study on breast 
cancer sufferers found that stronger perceptions of illness threat were linked to 
reduced benefit finding (Lechner et al., 2003).    
To date, a number of studies have demonstrated predictive links between 
benefit finding and physical and psychosocial adjustment and biomedical treatment 
outcomes across a number of chronic illness conditions including cancer (Bower et 
al., 2005; McGregor et al., 2004; Park et al., 2009;), rheumatoid arthritis (Danoff-
Burg & Revenson, 2005; Tennen et al., 1992), and human immunodeficiency virus 
(Littlewood et al., 2008; Luszczynska et al., 2007; Siegal & Schrimshaw, 2000). 
For example, Littlewood et al. (2008) reported that greater benefit finding 
predicted increased physical activity and decreased depression, among a group of 
individuals diagnosed with human immunodeficiency virus. Other studies however 
have produced less consistent results (Bower et al., 2005; Helgeson et al., 2006; 
McMillen & Fisher, 1998; Sears et al., 2003; Tomich & Helgeson, 2004). For 
example, Helgeson et al. (2006) investigated relationships between benefit finding 
and both psychosocial and physical health adjustment following traumatic life 
events, including the experience of chronic disease, reported that benefit finding 
was associated with lower depression, but was unrelated to physical health 
adjustment outcomes. Counterintuitively, a number of studies have identified 
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personal growth through benefit finding to co-exist simultaneously with more 
negative chronic illness related adjustment outcomes such as depression, physical 
pain and lowered physical functioning (McMillen & Fisher, 1998; Tomich & 
Helgeson, 2004). McMillen and Fisher (1998) commented that their results show 
the potential for individuals to discover benefits in the midst of adversity whilst 
struggling at the same time with depression. The present thesis examined these 
relationships within the context of HCV. 
Research to date has not examined relationships of features of the SRM, 
i.e., illness perceptions and coping strategies, and benefit finding to physical and 
psychosocial adjustment and biomedical treatment response among individuals 
with HCV. A number of studies conducted on chronic disease have shown benefit 
finding to predict depression (Carver & Antoni, 2004), physical functioning 
(Danoff-Burg & Revenson, 2005), life satisfaction, and positive affect adjustment 
outcomes (Bower et al., 2005). Similarly, research has also identified the role of 
benefit finding in predicting biomedical treatment outcomes in chronic diseases 
(Bower et al., 1998; de Ridder et al., 2008; McGregor et al., 2004). However, 
research that has focussed on the associations between benefit finding and physical 
and psychosocial adjustment in chronic illness has produced inconsistent findings 
(Helgeson et al., 2006; McMillen & Fisher, 1998; Sears et al., 2003; Tomich & 
Helgeson, 2004). The present thesis thus investigates the role of benefit finding to 
predict biomedical treatment response, physical health and psychosocial 
adjustment among individuals with HCV, after first accounting for the 
contributions of illness perceptions and coping strategies within an expanded SRM 
model. Additionally, the present thesis conducted tests to assess whether benefit 
finding mediated the relationship between illness perceptions and physical and 
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psychosocial adjustment within the context of an expanded SRM. Finally, a 
number of studies have shown that multi-item measures such as the Perceived 
Benefit Scale have identified at least one area of benefit following adversity across 
a number of related areas of chronic disease  (de Ridder et al., 2008; McMillen & 
Fisher, 1998), hence this measure was used in the present investigation.  
 
4.5 Summary of Limitations in the Current Literature 
 The preceding chapters provided an overview of HCV, introduced the SRM 
and benefit finding as potentially useful psychological variables for predicting 
treatment response and physical and psychosocial adjustment within the context of 
HCV. A review of existing biopsychosocial research relevant to the SRM, benefit 
finding, HCV, and related chronic health conditions identified the following gaps 
in the literature: 
(1) Few studies have focussed on the efficacy of psychological variables to predict 
physical and psychosocial adjustment and treatment response within the context of 
HCV. To date the majority of published literature has focussed on predicting HCV 
treatment outcomes using biomedical variables only (Shiffman et al., 2004). 
(2) A wealth of published studies have assessed the efficacy of the SRM to account 
for physical and psychosocial adjustment (Broadbent et al., 2015; Hagger & 
Orbell, 2003), and in more limited cases biomedical treatment outcomes (Chilcot et 
al., 2011), across a range of chronic health conditions. However, these results have 
been inconsistent with regards to the relative efficacy of illness perceptions in 
comparison to coping to contribute to these predictive models (Hagger & Orbell, 
2003). Further, only a limited number of studies have shown coping to mediate the 
relationship between illness perceptions and health related outcomes (Hagger & 
Orbell, 2003; Rutter & Rutter, 2002). To date, no published literature has 
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investigated whether components of the SRM predict physical and psychosocial 
adjustment or treatment response after controlling for demographic, clinical and 
behavioural co-variates among individuals with HCV.   
(3) A number of studies have assessed whether benefit finding could account for 
variance in physical and psychosocial adjustment and biomedical treatment 
outcomes across a number of chronic disease conditions (de Ridder et al., 2008; 
Helgeson et al., 2006; McMillen & Fisher, 1998). To date, these studies have 
reported inconsistent or counter-intuitive results (de Ridder et al., 2008; McMillen 
& Fisher, 1998). No published research has determined whether benefit finding 
predicts physical and psychosocial adjustment and treatment response after 
controlling for demographic, clinical and behavioural variables in HCV. Further, 
no studies to date have assessed whether benefit finding mediates the relationship 
between illness perceptions and physical and psychosocial adjustment outcomes in 
HCV. 
(4) There is currently no evidence to confirm whether illness perceptions, coping, 
and benefit finding, predict physical and psychosocial adjustment or predict 
treatment response after controlling for demographic, clinical and behavioural co-
variates among individuals with HCV.  
(5) No published literature has specifically assessed the efficacy of the following 
physical and psychosocial variables; physical health, depression, life satisfaction, 
and positive affect to predict HCV treatment response after controlling for clinical, 
demographic, and behavioural covariates.  
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4.6 Aims of the Present Thesis 
Gaps in the literature confirm the need to investigate the efficacy of the 
traditional SRM (i.e., illness perceptions and coping), as well as benefit finding, to 
predict treatment response, physical health and psychosocial adjustment among 
individuals diagnosed with HCV. The research reported here also determined 
whether physical health and psychosocial adjustment predicted HCV treatment 
response after controlling for relevant demographic, clinical and behavioural 
variables (Chen & Morgan, 2006; Lee & Abdo, 2003; Shiffman et al., 2004). 
Study 1.1 and Study 1.2 employed a cross-sectional design to assess 
whether an expanded SRM (including illness perceptions, coping strategies, and 
benefit finding) accounted for variance in physical health and psychosocial 
adjustment (depression, life satisfaction, positive affect). Study 1.1 employed the 
traditional order of entry as outlined by Leventhal et al. (1992). Illness perceptions 
were entered at Step 1 coping strategies at Step 2, and benefit finding at Step 3. 
Study 1.1 also investigated whether coping strategies and benefit finding mediated 
the relationships between illness perceptions and HCV physical and psychosocial 
adjustment. Study 1.2 determined whether coping strategies independently 
predicted HCV physical and psychosocial adjustment before variance in illness 
perceptions was accounted for (Heijmans, 1999). Accordingly, the traditional SRM 
order of entry was reversed to confirm which features were more robust predictors 
of physical and psychosocial adjustment.  
For Study 1.1 and Study 1.2, illness perceptions were measured by the 
Brief Illness Perception Questionnaire (BIPQ), coping strategies by the Brief 
COPE, and benefit finding by the Perceived Benefits Scale (PBS) (Broadbent et 
al., 2006; Carver, 1997; McMillen & Fisher, 1998). The BIPQ has been used in 
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related chronic disease studies (Broadbent et al., 2015), and one of the measure’s 
advantages over other measures of cognitive appraisal is that it allows a multiple 
individual illness perception components to be measured independently (Broadbent 
et al., 2006). The Brief COPE has been used in a number of studies to assess the 
efficacy of the SRM to account for variance in physical and psychosocial 
adjustment in chronic disease (Hagger & Orbell, 2003). The Brief COPE was 
chosen for the present study due to its ability to determine multiple coping 
strategies, and employ categorical groupings (i.e. adaptive and maladaptive 
coping) (Hagger & Orbell, 2003; Rogan et al., 2013; Rutter & Rutter, 2002). The 
PBS was selected as it has been used to predict psychosocial adjustment in 
previous chronic disease work. The measure is also easily modified for specific 
illnesses, including HCV (McMillen & Fisher, 1998).  
To allow direct comparison between HCV and other chronic diseases a 
measure of physical health (Heijmans, 1999; Steed et al., 1999) and indices of 
depression (Fortune et al., 2002; Vaughan et al., 2003), life satisfaction (De Gucht, 
2015; Rutter & Rutter, 2002), and positive affect (de Ridder et al., 2008) , served 
as the criterion variables for Study 1.1 and Study 1.2. Physical health has been 
utilised in a number of chronic disease studies that have assessed the efficacy of 
the SRM to predict adjustment outcomes (Heijmans, 1999; Helder et al., 2002; 
Rutter & Rutter, 2002). Life satisfaction (Gucht, 2015; Rutter & Rutter, 2002; 
Steed et al., 1999), depression (Hagger & Orbell, 2003) and positive affect (de 
Ridder et al., 2008) were selected as a cognitive quality of life measures that have 
been used in multiple chronic disease studies. The use of these criterion measures 
permitted direct comparison between the cognitive characteristics of HCV and 
other manifestations of chronic illness.  
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Symptoms associated with depression were measured using the depression 
subscale of the Depression, Anxiety and Stress Scales (DASS-21: Lovibond & 
Lovibond, 1995). The DASS-21 has been used to evaluate reported depression 
within chronic disease populations in other studies (e.g., Covic et al., 2011). 
Importantly, the DASS-21 depression sub-scale items focus more on the cognitive 
and affective features of depression rather than somatic features such as insomnia, 
appetite, fatigue and concentration, which can also be potential medical symptoms 
related to chronic disease conditions rather than mood related causes (Covic et al., 
2011; Lovibond & Lovibond, 1995). Physical health was measured by the physical 
summary component of the RAND 36-item Health Survey 1.0 questionnaire 
(RAND-36) (Covic et al., 2004; VanderZee, Sanderman, Heyink, & de Haes, 
1996). Apart from minor differences in scoring, the RAND-36 is identical to the 
physical health items of the MOS 36-item Short-Form Health Survey (SF-36) 
which has been utilised in previous chronic disease studies (Brazier et al., 1992; 
Hagger & Orbell, 2003). A particular strength relevant to the use of the RAND-36 
in the present thesis is the inventory’s ability to measure health related quality of 
life across a number of dimensions of physical health including physical 
functioning, role functioning (physical), bodily pain, and general health 
perceptions (Brazier et al., 1992; Covic et al., 2004; VanderZee et al., 1996), which 
fits well with the range of physical symptoms experienced by individuals with 
HCV. The five-item Satisfaction with Life Scale (Diener, Emmons, Larsen, & 
Griffin, 1985) and the Bradburn Affect Balance Scale (BABS) (Bradburn, 1969) 
were used to measure psychosocial quality of life. Both the Satisfaction with Life 
Scale and the BABS have been utilised as measures of adjustment in other chronic 
disease studies (Heckman, 2003; Nabi, Kivimaki, Vogli, Marmot, & Singh-
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Manoux, 2008), and both measures appear to have high face validity related to the 
psychosocial quality of life constructs measured (Bradburn, 1969; Diener et al., 
1995).  
Pre-treatment illness perceptions, benefit finding, and coping strategies 
have shown to account for variance in biomedical health outcomes following 
treatment across a number of chronic disease studies (Broadbent et al., 2015; 
Chilcot et al., 2011; de Ridder et al., 2008;  Hagger & Orbell, 2003; Helgeson et 
al., 2006; McMillen & Fisher, 2008). At this time however, no published studies 
have determined whether illness perceptions, coping and benefit finding (i.e., an 
expanded SRM) at pre-treatment could predict HCV treatment response after first 
controlling for important demographic, behavioural and clinical variables at pre-
treatment (Chen & Morgan, 2006; Lee & Abdo, 2003; Shiffman et al., 2004). 
Therefore, using a longitudinal design for each of the following three analyses, 
Study 2.1 investigated whether the traditional features of the SRM (i.e., illness 
perceptions and coping strategies) at pre-treatment predicted HCV treatment 
response, whilst Study 2.2 determined whether an expanded SRM that included 
benefit finding predicted HCV treatment response. Treatment response measured 
at Time 2 assessed whether (1) HCV was detected following a series of milestone 
blood tests (non-response) or (2) not detected (treatment response). This method 
for assessing HCV treatment response has been used in a number of previous 
biomedical studies (Chen & Morgan, 2006; Lee & Abdo, 2003; Shiffman et al., 
2004). Finally, Study 2.3 investigated the efficacy of the criterion variables used in 
Study 1.1 and Study 1.2 (depression, physical health, life satisfaction and positive 
affect), to predict HCV treatment response after controlling for the same 
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demographic, behavioural and clinical variables that demonstrated significant 
relationships with HCV treatment response reported in Study 2.1 and Study 2.2.    
  
41 
 
Chapter 5 
 General Method 
5.1 Participants  
 A sample of 126 individuals (68 males and 58 females) completed the pre-
treatment (Time 1) survey (M = 41.6 years; SD = 11.9). Out of this cohort, 32 
participants (13 males and 19 females; M = 43.3 years; SD = 13.5) completed the 
post-commencement of HCV treatment (Time 2) survey. Inclusion criteria 
included a current HCV diagnosis, being at least 18 years of age (HCV treatment is 
not available to individuals under the age of 18), access to the internet, and a 
current e-mail address. Ethical approval and informed consent were obtained prior 
to data collection.   
5.2 Biomedical, Clinical, Behavioural and Demographic Information (Time 1)  
At Time 1, participants responded to specific questions related to age, body 
weight, HCV genotype, gender, and most likely route of HCV infection. They also 
provided yes/no responses to the following socio-demographic and clinical 
questions: (1) “Did the liver biopsy or scan results indicate the presence of 
cirrhosis of the liver?” (2) “Do you have any other medical conditions that you are 
currently receiving treatment for?” (3) “In the past week, have you used 
recreational drugs?” (4) “In the past week, have you consumed any alcohol?” (5) 
“In the past week, have you smoked any cigarettes?”  (6) “Do you have any mental 
health condition/s that you are currently receiving medication based treatment 
for?”(e.g., depression/anxiety/psychosis), and (7) “Have you ever had previous 
treatment for Hepatitis C?”  
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5.3 Illness Perceptions  
Illness perceptions were measured using the Brief Illness Perception 
Questionnaire (BIPQ: Broadbent et al., 2006). The BIPQ is a nine-item measure 
that has been used across a range of chronic illness conditions and has 
demonstrated sound psychometric properties (Broadbent et al., 2015). The BIPQ is 
a shorter version of the earlier 84-item Illness Perceptions Questionnaire – Revised 
(IPQ-R: Broadbent et al., 2006). The BIPQ has demonstrated acceptable 
associations with the IPQ-R across all of the equivalent illness perception 
components (Broadbent et al., 2006). The BIPQ has eight items that focus on the 
measurement of illness perceptions (a ninth item that assesses causality using an 
open ended question was not included in the present study), each of which is rated 
on an 11-point Likert scale. Scores on each item range between 0 and 10. Higher 
scores reflect a greater endorsement of the given perception (e.g., higher scores 
indicate a greater illness understanding, higher negative illness impact, and more 
severe illness symptoms). For each of the BIPQ items, the word ‘illness’ was 
replaced by ‘HCV’. Each of the eight BIPQ items was as follows: (1) “How much 
does your HCV affect your life?” (illness consequences), (2) “How long do you 
think your HCV will continue?” (illness timeline), (3) “How much control do you 
feel you have over your HCV?” (personal control), (4) “How much do you think 
your treatment can help your HCV?” (treatment control), (5) “How much do you 
experience symptoms from your HCV?” (illness identity), (6) “How concerned are 
you about your HCV?” (illness concern), (7) “How well do you feel you 
understand your HCV?” (illness understanding or coherence), and (8) “How much 
does your HCV affect you emotionally? (e.g., does it make you angry, scared, upset 
or depressed?), (emotional response) (Broadbent et al., 2006). Consistent with the 
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majority of research that has utilised the BIPQ, scoring was performed at an 
individual item level, with five items measuring cognitive illness representations 
(illness consequences, timeline, personal control, treatment control, and identity), 
two items measuring emotional representations (concern and emotions), and one 
item measuring illness understanding (Broadbent et al., 2015; Hagger & Orbell, 
2003). Higher scores on the illness consequence, timeline, identity, concern and 
emotions subscales are indicative of more negative or threatening illness 
perceptions. Conversely, higher scores on the personal control, treatment control 
and illness understanding subscales indicate more positive illness related 
perceptions.  The BIPQ has shown good test-retest reliability and concurrent 
validity along with good predictive and discriminant validity (Broadbent et al., 
2006). In the present study, Cronbach’s alpha for the BIPQ was .69. 
5.4 Coping 
Coping was measured by the Brief COPE (Carver, 1997), which is a short 
28-item version of the original 60-item COPE measure. Sample items include “I 
take action to try to make the situation better” and “I blame myself for the things 
that happened”. Individuals rate both items for each of the 14 subscales from 1 
(don’t do this at all) to 4 (do this a lot). Scores for each subscale range from 2 to 8. 
Higher scores on individual subscales indicate the extent to which each coping 
strategy was used (Carver et al., 1989; Weinman, Wright, & Johnston, 1995). 
Following Rogan, Fortune, and Prentice (2013), coping strategies for the present 
study were divided into adaptive (mental disengagement, active coping, use of 
emotional support, use of instrumental support, positive reframing, planning, use 
of humour, acceptance and use of religion), and maladaptive (denial, substance 
use, venting, self-blame and behavioural disengagement) subscales (Carver, 1997; 
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Rogan et al., 2013). Both the adaptive (Cronbach’s alpha = .57 to .82) and 
maladaptive (Cronbach’s alpha = .50 to .90) subscales have achieved acceptable 
internal consistency values in previous research (Carver, 1997; Cooper, Katona, & 
Livingston, 2008; Rogan et al., 2013). In the present study, excellent internal 
consistency coefficients were obtained for the adaptive (Cronbach’s alpha = .90), 
and maladaptive (Cronbach’s alpha = .86) coping strategies. 
5.5 Benefit Finding  
Benefit finding was measured by the Perceived Benefits Scale (PBS: 
McMillen & Fisher, 1998). The PBS has 38 items of which 30 reflect benefits 
since diagnosis. The measure includes 8 items reflecting negative changes, and in 
accord with the scoring procedures, responses to these items were excluded from 
analyses (McMillen & Fisher, 1998). Participants were asked to indicate how well 
“each statement describes your experience” on a five-point Likert scale ranging 
from 0 (not at all like my experience) to 4 (very much like my experience). Sample 
items from the PBS include “Because of this illness, I have learned how good 
people can be” and “This illness has made me a stronger person” (McMillan & 
Fisher, 1998). Higher scores on the PBS reflect higher levels of positive benefit 
finding. The PBS has shown good test-retest reliability and concurrent validity 
along with good predictive and discriminant validity (McMillan & Fisher, 1998; 
Park et al., 2009). A Cronbach alpha of .96 was obtained for the present study.      
5.6 Depression  
Mental health was measured by the depression subscale of the Depression, 
Anxiety and Stress Scales (DASS-21: Lovibond & Lovibond, 1995). The DASS-
21 is a 21-item short form version of the 42-item self-report DASS. The seven-
item depression subscale requires respondents to rate the extent to which he or she 
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experienced each symptom over the past week on a 4-point Likert scale (0 = did 
not apply to me at all to 3 = applied to me very much or most of the time).  Sample 
items from the depression subscale include “I couldn’t seem to experience any 
positive feeling at all” and “I felt that life was meaningless”. To provide 
equivalence of scoring with the longer version of the DASS, a total score was 
created by summing all items within the subscale and then multiplying the total 
score by two. (Lovibond & Lovibond, 1995; Miller et al., 2006). Scores for the 
Depression subscale range from 0 to 42, with higher scores indicative of greater 
depression (Lovibond & Lovibond, 1995; Miller et al., 2006). The DASS-21 
depression subscale has demonstrated a high internal consistency of Cronbach’s 
alpha = .92 (Lovibond & Lovibond, 1995), in addition to adequate construct, 
convergent, and discriminant validity (Clara, Cox, & Enns, 2001; Henry & 
Crawford, 2005; Lovibond & Lovibond, 1995; Miller et al., 2006). In the present 
study, the DASS-21 demonstrated strong internal consistency (Cronbach’s alpha 
= .91). 
5.7 Life Satisfaction 
The five-item Satisfaction with Life Scale (SLS; Diener, Emmons, Larsen, 
& Griffin, 1985) was used to measure life satisfaction. Participants rated each item 
from 1 (strongly disagree) to 7 (strongly agree). Possible scores ranged from 0 to 
35, with higher scores indicative of greater life satisfaction. Sample statements 
from the SLS include “In most ways, my life is close to ideal” and “I am satisfied 
with my life” (Diener et al., 1985). The SLS has demonstrated good internal 
consistency (Cronbach’s alpha = .87) in previous research (Diener et al., 1985; 
Pavot & Diener, 1993). Similarly, the scale demonstrated strong internal 
consistency in the present study (Cronbach’s alpha = .90). The SLS has also 
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demonstrated sound convergent validity with similar measures of subjective well-
being (Diener et al., 1985; Pavot & Diener, 1993). 
5.8 Positive Affect 
 Positive affect was measured by the Bradburn Affect Balance Scale 
(BABS) (Bradburn, 1969). The BABS is a 10-item rating scale containing five 
statements reflecting positive feelings and five statements reflecting negative 
feelings (Bradburn, 1969). Only the five positive items of the BABS were utilised 
in the present thesis. Participants indicate on a 5-point scale from 1 (not at all) to 5 
(very often) how relevant each of the statements was to them over the past few 
weeks (Bradburn, 1969; van Schuur & Kruijtbosch, 1995). For the five positive 
statements, scale scores range from 5 to 25 with higher scores indicating better 
adjustment. Sample statements include “Particularly excited or interested in 
something” and “That things were going your way”. Overall, the BABS has 
demonstrated sound psychometric properties in terms of acceptable reliability in 
both clinical and non-clinical samples (e.g., Cronbach’s alpha =.94; Pakenham & 
Cox, 2008). The BABS demonstrated strong internal consistency in the present 
study (Cronbach’s alpha =.88). 
5.9 Physical Health  
The physical summary component of the RAND 36-item Health Survey 1.0 
questionnaire (RAND-36) was used to measure aspects of physical health (Covic, 
Seica, Gusbeth-Tatomir, Gavrilovici, & Goldsmith, 2004; VanderZee, Sanderman, 
Heyink, & de Haes, 1996). The physical summary component of the RAND-36 
measures physical health status based on the subjective self-reports across four 
dimensions: physical functioning, role limitations related to physical health issues, 
bodily pain, and general health (Brazier et al., 1992; Covic et al., 2004; VanderZee 
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et al., 1996). For example, the physical functioning subscale measures perceptions 
of physical functioning as a component of general health status. Individuals 
respond to the following question “Does your health now limit you in these 
activities? If so, how much?” Activities covered include “running”, “walking”, 
“carrying groceries”, and “bathing and dressing”. Items are rated on a three point 
Likert scale ranging from 1 (Yes, Limited a Lot) to 3 (No, Not Limited at All).  
Total scores for each subscale range from 0 to 100, with higher scores indicating 
better physical functioning and more positive health perceptions (Brazier et al., 
1992; Covic et al., 2004; Ngo-Metzger, Sorkin, Mangione, Gandek, & Hays, 2008; 
VanderZee et al., 1996). Apart from some differences related to scoring methods, 
the RAND -36 is identical to the items of the MOS 36-item Short-Form Health 
Survey (SF-36) which has achieved good internal consistency (Cronbach’s alpha 
= .85) (Brazier et al., 1992).  In the present study the RAND-36 achieved 
acceptable internal consistency (Cronbach’s alpha = .78). 
5.10 HCV Treatment Outcome Assessment and Adherence (Time 2) 
HCV treatment response was the outcome measure evaluated at Time 2 (3 
months post commencement of HCV treatment). At Time 2, participants were 
asked to indicate what blood tests (known as polymerase chain reaction (PCR) 
tests) they had since commencing HCV treatment, and to indicate the outcome for 
each test. Three questions covered week four, week eight, and week twelve PCR 
blood tests respectively. For each question, participants were asked to indicate 
either (1) ‘Hepatitis C virus was detected in my blood’ or (2) ‘Hepatitis C virus 
was not detected in my blood’. A response indicating nil detection of HCV for at 
least one of the three milestone PCR blood tests was recorded as a ‘treatment 
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response’ result for future statistical analysis. Additionally, the Time 2 survey 
asked participants to make a yes/no response to the following treatment adherence 
question: “In reference to taking your Hepatitis C medication since commencing 
treatment; during the first 12 weeks of treatment, did you take your medication as 
prescribed?” 
5.11 Procedure 
A number of recruitment strategies were utilised, including internet-based 
advertising methods (e.g., contacting Hepatitis C peak body websites across 
Australia), and traditional hard-copy advertising flyers mailed to the residences of 
individuals preparing for HCV treatment at the Gold Coast University Hospital 
liver clinic. Data was collected over 22 months.  
Volunteers were directed to the study website. After providing informed 
consent they were given a unique personal login identifier and password that 
granted access to the Time 1 anonymous online pre-treatment questionnaires. 
Relevant information was also collected to illustrate key socio-demographic and 
medical characteristics of the cohort. Completion of the Time 1 survey took 
between 30 and 40 minutes per person. Participants were contacted three months 
post commencement of HCV treatment and were invited to complete a second 
online survey questionnaire (Time 2). At Time 2 participants responded to 
questions related to HCV treatment outcome, and to treatment adherence relevant 
to the treatment period. The Time 2 online survey took between 5 and 10 minutes 
to complete.  
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Chapter 6 
Study 1.1 - Illness Perceptions, Coping, Benefit Finding, and Adjustment in 
Hepatitis C 
6.1 Introduction 
As previously described in chapter 2, HCV is a chronic blood borne illness 
associated with significant physical and psychological difficulties, and is the 
leading cause of liver morbidity and mortality in the world (Chen & Morgan, 2006; 
Zimmer, Schiedermaier, & Grandt, 2004; Lee & Abdo, 2003; Lee & Harrison, 
2005; Shiffman et al., 2004; Simmonds, 2001). Estimates suggest that 
approximately 170 million individuals worldwide live with chronic HCV, but 
despite the availability of a potential treatment cure, only a small percentage 
undergo anti-viral treatment (Lee & Abdo, 2003; Shiffman et al., 2004). To 
improve biomedical treatment outcomes for individuals who do undertake 
treatment, a wealth of studies have assessed whether a range of biomedical markers 
could predict HCV treatment response (Lee & Abdo, 2003; Shiffman et al., 2004). 
However, in comparison, little research has been conducted that has focused on the 
efficacy of psychological variables to account for variance in physical (perceptions 
related to general health and physical functioning) and psychosocial (psychological 
well-being) adjustment among individuals with HCV (Hagger & Orbell, 2003).   
As previously outlined in chapter 4, Leventhal et al. (1992) developed a 
psychological framework, the SRM, to explain the links between cognitive and 
emotional representations of illness, coping behaviours and health related 
outcomes (Leventhal et al., 1992; Rogan et al., 2013). The SRM suggests that on 
becoming aware of an illness threat, individuals respond by constructing illness 
perceptions which form the basis for subsequent health related coping behaviours 
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(Leventhal et al., 1992). Illness perceptions and coping behaviours are linked to 
health related outcomes within a continuous feedback loop, where both illness 
perceptions and coping behaviours are adjusted in response to health related 
outcomes (Broadbent, Petrie, Main, & Weinman, 2006;. Lau & Hartman, 1983; 
Leventhal et al., 1992). 
A number of studies have investigated the efficacy of the SRM to predict 
both physical and psychosocial adjustment, and in a limited number of studies, 
biomedical treatment outcomes (Chilcot, Wellsted, & Farrington, 2011; Hagger & 
Orbell, 2003) across a range of chronic diseases. For example, Paddison et al. 
(2008) investigated the relationships between illness perceptions and physical and 
psychosocial outcomes among a cohort of individuals with Type 2 diabetes. In this 
study, illness perceptions accounted for significant variance in metabolic control 
and reported quality of life. Within the context of chronic disease, illness 
perceptions have consistently predicted variance in both physical and psychosocial 
adjustment (Fortune et al., 2002; Heijmans, 1999; Rutter & Rutter, 2002; Scharloo 
et al., 2000; Steed, Newman, & Hardman, 1999; Vaughan et al., 2003). For 
example, Vaughan et al. (2003) conducted a study investigating whether illness 
perceptions was linked to adjustment in individuals diagnosed with multiple 
sclerosis. Results indicated that illness perceptions predicted physical and 
psychosocial adjustment outcomes, including reported illness intrusiveness, 
physical functioning, depression, anxiety, and self-esteem (Vaughan et al., 2003). 
However, coping strategies have produced less consistent results, with a number of 
studies demonstrating significant predictive ability related to physical and 
psychosocial adjustment outcomes (Helder et al., 2002; Rutter & Rutter, 2002), 
whereas other studies have not demonstrated the same predictive ability (Steed et 
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al., 1999). For example, in a study conducted among individuals diagnosed with 
Huntington’s disease, both illness perceptions and coping strategies made 
significant contributions to physical and psychosocial adjustment (Helder et al., 
2002). In contrast, Steed et al. (1999) conducted a study to investigate whether 
illness perceptions and coping could predict psychosocial adjustment among a 
cohort of individuals with atrial fibrillation. Results identified a significant role for 
illness perceptions in contributing to psychosocial adjustment outcomes, but not 
for coping (Steed et al., 1999). A number of potential factors may have contributed 
to the less consistent role of coping to predict adjustment in comparison to illness 
perceptions as reported across a number of health related studies (Hagger & Orbell, 
2003). For example, it may be that different coping measures used across a number 
of studies in comparison to the more consistent use of illness perception measures 
may have contributed to variance in the ability of coping to predict adjustment 
(Hagger & Orbell, 2003). The present thesis provided an opportunity to test the 
efficacy of illness perceptions and coping, original features of Leventhal’s et al. 
(1980) SRM within the novel area of HCV. 
Leventhal et al. (1980) proposed a mediational role for coping strategies 
within the SRM. Leventhal et al. hypothesised that coping strategies would 
mediate the relationship between illness perception components and health related 
outcomes. To date, the majority of SRM studies have not identified a role for 
coping in mediating the relationship between illness perceptions and health related 
outcomes (Hagger & Orbell, 2003; Heijmans, 1998; Kemp et al., 1999; Moss-
Morris et al., 1996; Scharloo et al., 1998). For example, Scharloo et al. (1998) 
assessed the potential for coping strategies to mediate the relationship between 
illness perceptions and physical and psychosocial adjustment among individuals 
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diagnosed with either rheumatoid arthritis, chronic obstructive lung disease, or 
psoriasis. The findings of this study indicated that coping did not demonstrate a 
mediating role between illness perceptions and adjustment. Further, coping did not 
account for significant variance across any of the criterion variables. In 
comparison, illness perceptions demonstrated significant contributions to the 
predictive models regardless of their entry into the regression models (Scharloo et 
al., 1998). In a limited number of related studies, coping has mediated the 
relationship between illness perceptions and health related outcomes (Rutter & 
Rutter, 2002).  For example, Rutter and Rutter (2002) demonstrated a role for 
coping in mediating some, but not all of the relations between illness perceptions 
and adjustment outcomes. Specifically, the following coping strategies; (1) 
acceptance, (2) active coping, (3) venting emotions, and (4) behavioural 
disengagement, demonstrated utility in mediating links between illness perception 
components and adjustment outcomes (Rutter & Rutter, 2002).  
No published studies have assessed whether coping strategies could 
mediate the relationships between illness perceptions and physical and 
psychosocial adjustment within the context of HCV. The approach reported here 
will allow comparison with results of mediation tests conducted across other 
chronic disease areas, and some of the inconsistencies reported to date regarding 
the role of coping as a mediator between illness perceptions and health related 
outcomes within the spectrum of chronic disease (Leventhal et al., 1980).  
Important to the present thesis, other psychological models have identified 
associations between positive meaning, personal growth, and physical and 
psychosocial adjustment (Helgeson, Reynolds, & Tomich, 2006; Leventhal et al., 
1992). For example, cognitive factors such as benefit finding have been linked to 
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physical and psychosocial adjustment outcomes across a range of chronic health 
conditions (Helgeson et al., 2006). Benefit finding has been described as a process 
where individuals find meaning in the context of adverse life events and situations, 
including the experience of chronic disease (Fortune, Richards, Griffiths, & Main, 
2005; Pakenham, 2007; Pakenham, 2011; Rogan, Fortune, & Prentice, 2013; 
Seligman & Csikszentmihalyi, 2000; Siegal & Scrimshaw, 2000; Thompson, 
1985). In response to adversity, examples of benefits found by individuals have 
included strengthened relationships, a greater appreciation of life, spiritual and 
personal growth, changes in life priorities and goals, changes in health behaviours, 
and illness acceptance (Helgeson et al., 2006; Pakenham, 2011; Stanton, Bower, & 
Low, 2006).  
A number of studies have demonstrated predictive links between benefit 
finding and physical and psychosocial adjustment within the context of chronic 
disease (Littlewood, Vanable, Carey, & Blair, 2008; Luszczynska, Sarkar, & 
Knoll, 2007; Park, Chmielewski, & Blank, 2009; Tennen, Affleck, Urrows, 
Higgins, & Mendola, 1992). Other studies have produced less consistent results 
(Helgeson et al., 2006; McMillen & Fisher, 1998; Sears, Stanton, & Danoff-Burg, 
2003; Tomich & Helgeson, 2004). For example, Bower et al. (2005) investigated 
whether benefit finding accounted for variance in psychosocial adjustment among 
a cohort of breast cancer survivors. Results indicated that benefit finding was 
associated with positive affect measured at time periods between 1–10 years post 
diagnosis. However, in a related study, benefit finding measured at four months 
post diagnosis of breast cancer was not associated with positive affect (Tomich & 
Helgeson, 2004). Further, Danoff-Burg and Revenson (2005) conducted a 
longitudinal study to investigate whether benefit finding predicted adjustment 
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outcomes among a group of individuals living with rheumatoid arthritis. The 
majority of individuals who participated in this study (71.3%) reported the 
discovery of at least one interpersonal benefit related to their chronic condition. At 
12 months follow up the data indicated that benefit finding predicted lower 
reported physical disability among this group of individuals. Other studies have 
produced more counter-intuitive results where benefit finding has co-existed 
simultaneously with more negative adjustment outcomes such as depression and 
reduced physical functioning (de Ridder et al., 2008; McMillen & Fisher, 1998; 
Tomich & Helgeson, 2004). However, these results may indicate that the ability to 
find meaning following an adverse event can occur simultaneously with lower 
mood (McMillen & Fisher, 1998). 
Several ideas have been offered to account for the inconsistent findings 
associated with the role of benefit finding in predicting physical and psychosocial 
adjustment among individuals living with chronic disease. For example, the 
measurement of benefit finding at relatively shorter time periods after initial 
diagnosis has generally been associated with lower benefit finding (de Ridder et 
al., 2008; Helgeson et al., 2006; McMillen & Fisher, 1998), whereas longer time 
intervals have been associated with higher benefit finding and more favourable 
physical and psychosocial adjustment (de Ridder et al., 2008; Helgeson et al., 
2006; McMillen & Fisher, 1998). Additionally, other factors related to personality 
differences, severity of illness experience and whether benefit finding interventions 
where provided to individuals living with chronic disease have been linked to 
variance in findings reported in benefit finding literature (de Ridder et al., 2008; 
Helgeson et al., 2006; McMillen & Fisher, 1998). Specifically, more optimistic 
personality types, greater illness severity and benefit finding interventions have 
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been linked to greater benefit finding ability and improved adjustment (De Ridder 
et al., 2008; Helgeson et al., 2006; McMillen & Fisher, 1998). Overall, Benefit 
finding has demonstrated an important role in predicting physical and psychosocial 
adjustment across a number of chronic disease conditions (de Ridder et al., 2008; 
Helgeson et al., 2006). Further, providing opportunities for individuals to discover 
positive meaning in response to their illness experience has been associated with a 
greater potential for improved illness related adjustment (de Ridder et al., 2008; 
Helgeson et al., 2006). Including the investigation of links between benefit finding 
and adjustment in the present study will provide an opportunity to assess the 
relative importance of benefit finding within the context of adjustment to HCV. 
Further, benefit finding would be activated following initial awareness of various 
illness threats and the subsequent formation of illness perceptions, and therefore 
provides an additional opportunity to explore whether it mediates the relationships 
between illness perceptions and adjustment outcomes. (de Ridder et al., 2008; 
Hagger & Orbell, 2003; Helgeson et al., 2006). 
Research to date has not examined relationships between traditional 
features of the SRM, benefit finding and physical and psychosocial adjustment 
among individuals with HCV. Therefore, the primary aim of Study 1.1 was to 
investigate whether features of an expanded SRM, would predict physical and 
psychosocial adjustment outcomes. A secondary aim was to test if coping 
strategies and benefit finding mediated the relationships between illness perception 
components and health related outcomes. The potential for benefit finding to 
demonstrate a mediational role between illness perceptions and health related 
outcomes has not been investigated in any other published chronic disease studies.  
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Illness perceptions, adaptive and maladaptive coping strategies were 
expected to predict physical health, life satisfaction, and positive and negative 
mood adjustment outcomes.  Benefit finding was also expected to make significant 
contributions to the predictive model after controlling for the combined 
contributions of the SRM features, illness perceptions, and adaptive and 
maladaptive coping. Finally, both coping strategies and benefit finding were 
expected to mediate the relationships between illness perceptions and physical and 
psychosocial adjustment outcomes across a number, but not all of the predictors.  
6.2 Methods 
Study 1.1 was provided research ethics approval by both the Bond 
University Human Research Ethics Committee, and the Gold Coast Hospital and 
Health Service Human Research Ethics Committee. Both ethics committees are 
located in the state of Queensland, Australia. 
6.2.1 Participants  
 There were 126 individuals with HCV who were recruited for Study 1.1. 
Inclusion criteria included a current HCV diagnosis, at least 18 years of age (HCV 
treatment is not available to individuals under the age of 18), access to the internet, 
and a current e-mail address. Table 6.1 summarises clinical, behavioural and 
demographic information.   
Table 6.1  
Sample Characteristics (N = 126) 
Characteristic  N  (%)  M  SD 
Age      41.6  11.9 
Gender         
Male  68  54.0     
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Female  58  46.0     
Liver cirrhosis (n = 86)  29  33.7     
Medical co-morbidity   49  38.9     
Recreational drug use (n = 
121) 
 41  33.9     
Alcohol consumption   38  30.2     
Nicotine dependence    40  31.7     
 
6.2.2 Measures  
Illness perceptions  
Illness perceptions were measured using the Brief Illness Perception 
Questionnaire (BIPQ: Broadbent et al., 2006). The psychometric properties of the 
measure are described in Chapter 5.  
Coping 
  Coping was measured by the Brief COPE (Carver, 1997). As described in 
chapter 5, the Brief COPE is a multidimensional coping inventory that was 
developed on theoretical grounds (Carver, 1997).  
Benefit Finding 
 Benefit finding was measured by the 38-item Perceived Benefits Scale 
(PBS: McMillen & Fisher, 1998). The psychometric properties of the measure are 
described in Chapter 5.  
Depression 
 Mental health was measured by the depression subscale of the Depression, 
Anxiety and Stress Scales (DASS-21; Lovibond & Lovibond, 1995). As described 
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in chapter 5, the DASS-21 is a 21-item short form version of the 42-item self-
report DASS.  
Physical health  
The physical summary component of the RAND 36-item Health Survey 1.0 
questionnaire (RAND-36) (Covic et al., 2004; VanderZee et al., 1996) was used to 
measure aspects of reported physical health related quality of life (Covic et al., 
2004; VanderZee et al., 1996). As described in chapter 5, the physical summary 
component of the RAND-36 measures health related quality of life across four 
dimensions of physical health: physical functioning, role functioning (physical), 
bodily pain, and general health (Brazier et al., 1992; Covic et al., 2004; VanderZee 
et al., 1996).  
Life satisfaction 
The five-item Satisfaction with Life Scale (Diener et al., 1985) was used to 
measure life satisfaction. The psychometric properties of the measure are described 
in Chapter 5.  
Positive Affect  
Positive affect was measured by the Bradburn Affect Balance Scale 
(BABS) (Bradburn, 1969). As described in chapter 5, the BABS is a 10-item rating 
scale containing five statements reflecting positive feelings and five statements 
reflecting negative feelings (Bradburn, 1969). The present analysis used the five 
positive items of the scale. The psychometric properties of the measure are 
described in Chapter 5. 
6.2.3 Procedure 
 Recruitment strategies included internet-based advertising (e.g., contacting 
Hepatitis C peak body websites across Australia), and traditional hard-copy 
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advertising flyers mailed to the residences of individuals preparing for HCV 
treatment at the Gold Coast University Hospital liver clinic (35 advertising flyers 
mailed out). Online and hard-copy advertising strategies provided background 
information to the present anonymous study and included a link to the study 
website. The website contained background information and material related to the 
consent process. After providing informed consent via the website, participants 
were provided a unique personal login identifier and password that enabled access 
to the anonymous online questionnaires. Completion of the online survey took 
between 30 and 40 minutes. There was no incentive offered to participants for 
completing the survey. 
6.2.4 Results 
 Analyses were performed using the IBM Statistical Package for Social 
Sciences (SPSS) Version 23.0. Tests of significance were considered reliable at p 
< .05. Prior to the main tests variables were examined for accuracy of data entry, 
missing values, and fit between their distributions and assumptions of regression 
analysis. Analysis of missing values across the study variables revealed no obvious 
pattern and missing values were replaced by the group mean on the measure 
(Tabachnick & Fidell, 2001). The data were screened for normality, skewness, 
kurtosis, and outliers. Inspection of the Normal Probability Plots (P-P) of the 
Regression Standardised Residuals and Scatterplots for each of the dependent 
variables indicated reasonably normal distribution of the data (Tabachnik & Fidell, 
2001). There were no univariate outliers (based on results for each of the 
independent and criterion variables; z < 3.29), and therefore analysis was 
conducted on the full data set (Tabachnik & Fidell, 2001).  
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Kolmogorov-Smirnov tests for normality were performed (Tabachnick & 
Fidell, 2001); illness consequence (p < .001), illness timeline (p < .001), personal 
control (p < .001), treatment control (p < .001), illness identity (p < .001), illness 
concern (p < .001), illness coherence (p < .001), emotional response (p < .001), 
adaptive coping (p = .041), maladaptive coping (p = .051), benefit finding (p 
= .081), depression (p = .006), positive affect (p = .017), life satisfaction (p 
= .039), and physical health (p = .082). Further, inspection of relevant histograms 
and normal probability plots for each of the independent and dependent variables 
suggested that the data were reasonably normally distributed (Tabachnick & Fidell, 
2001).  
Negative skewness was identified in the eight illness perception 
components, and in adaptive coping, benefit finding, positive affect, and life 
satisfaction. Positive skewness was identified in maladaptive coping, depression 
and physical health. The direction for each of the Skewness values across the 
independent and dependent variables were generally as would be expected. For 
example, it would be generally expected that life satisfaction data would indicate 
negative skewness, whereas depression would generally be expected to indicate 
positive skewness values. Therefore the data remained untransformed in the 
statistical analyses (Pallant, 2007). Descriptive data for the predictor and criterion 
variables are shown in Table 6.2.  
A post hoc power analysis was completed using G*power statistical 
software (Faul, Erdfelder, Lang, & Buchner, 2007). N = 126 was used for the 
power analyses and 11 predictor variables were entered into the model. An 
anticipated effect size (f 2 = .15) was entered into the power analysis equation. A p 
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< .05 alpha level was used. Post hoc analyses revealed an adequate power of .82 
for this study (Faul et al., 2007).  
The inter-correlations between predictor variables are shown in Table 6.3. 
Hierarchical multiple regression analyses were used to investigate whether illness 
perceptions, maladaptive and adaptive coping strategies, and benefit finding 
predicted depression, physical health, life satisfaction, and positive affect. Entry of 
the predictor variables was determined based on research related to Leventhal’s 
self-regulatory model (SRM; Leventhal et al., 1992). Therefore, for each of the 
four predictive models, the illness perception components were entered on Step 1, 
adaptive and maladaptive coping strategies were entered on Step 2, and benefit 
finding was entered at Step 3. The unstandardised coefficients, beta weights, and 
confidence intervals for all variables and tests are shown in Table 6.4. 
Based on mediation theory as outlined by Baron and Kenny (1986), a 
number of standard regression and hierarchical regression tests were conducted to 
assess the ability of (1) coping to mediate the relationship between illness 
perception components and study criterion variables, and (2) benefit finding to 
mediate the relationship between illness perception components and physical and 
psychosocial adjustment outcomes. Only the illness perception components, 
coping strategies and benefit finding predictor variables that demonstrated 
significant predictive links with criterion variables in earlier hierarchical regression 
analyses (refer to Table 6.4) were included in subsequent tests of mediation. Sobel 
tests were utilised to evaluate whether mediation had been established following 
tests to measure predictive links between illness perception items and criterion 
variables, and tests to measure predictive links between illness perception 
components and respective mediator variables (Preacher & Hayes, 2004).     
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Table 6.2  
Descriptive Statistics for Predictor and Criterion Variables (N = 126) 
Variables  Mean  SD  Range  
Illness consequences  5.8  2.6  0 – 10  
Illness timeline  6.0  2.6  0 – 10  
Personal control  5.2  2.7  0 – 10  
Treatment control  7.1  2.1  0 – 10  
Illness identity  5.4  2.6  0 – 10  
Illness concern  7.0  2.4  0 – 10  
Illness coherence  6.5  2.4  0 – 10  
Emotional response  5.8  2.8  0 – 10  
Adaptive Coping  46.9  10.2  18 – 72  
Maladaptive Coping  20.0  6.4  10 – 40  
Benefit Finding  60.6  25.8  0 – 120  
Depression  16.5  11.0  0 – 42  
Physical Health  52.7  20.9  0 – 100  
Life Satisfaction  19.5  7.1  5 – 35  
Positive Affect  15.0  4.1  5 – 25  
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Table 6.3 
Inter-correlations among Study Predictors. 
Note. *p < .05 **p < .01 
 
Predictors of Depression 
There were a number of significant zero-order correlations among illness 
perception components, coping strategies, benefit finding and depression scores. 
Greater illness consequence (r = .38), longer illness duration (r = .29), greater 
identification with illness related symptoms (r = .39), higher levels of illness 
concern (r = .25), and higher emotional responses to HCV (r = .47) were 
associated with higher depression. Conversely, higher personal control (r = -.18) 
and greater illness understanding (r = -.18) were associated with lower depression. 
Both adaptive coping (r = .16) and maladaptive coping (r = .53) were significantly 
 1 2 3 4 5 6 7 8 9 10 
1. Illness consequence           
2. Illness timeline .43**          
3. Personal control .07 -.01         
4. Treatment control .08 -.20* .27**        
5. Illness identity .56** .28** .16 .06       
6. Illness concern .48** .33** -.10 .05 .44**      
7. Illness coherence .07 -.05 .28** .35** .11 -.02     
8. Emotional response .69** .34** -.01 .10 .52** .49** .11    
9. Maladaptive coping .27** .16 .07 -.03 .19* .04 -.11 .37**   
10. Adaptive coping .11 .13 .12 .23* .09 .07 .27 .18* .38**  
11. Benefit Finding .23* -.02 .38** .11 .34** .06 .17 .18* .23* .34** 
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and positively associated with depression. Similarly, benefit finding (r = .27) was 
significantly and positively associated with depression. 
 At Step 1, the model was significant, F (8,117) = 8.02, p < .001, and the 
illness perceptions accounted for 35% of the variance in depression scores, R = .60, 
F (8, 117) = 8.02, p < .001. Increased perceptions related to personal control (2%; 
β = .17, t = 2.04, p = .043) and illness coherence (3%; β = -.18, t = 2.22, p = .028) 
were significant unique predictors of lower depression, whereas higher HCV 
illness identity (4%; β = .25, t = 2.61, p = .010) and greater emotional responses 
(6%; β = .35, t = 3.26, p = .001) predicted higher depression. At Step 2, the model 
accounted for 48% of the variance in depression scores and after controlling for the 
illness perception components the combined contribution of the adaptive and 
maladaptive coping strategies accounted for an additional 13% of the variance in 
depression scores (R = .70, F Change (2, 115) = 14.34, p < .001), which was 
significant, and the overall model remained significant, F (10,115) = 10.74, p 
< .001.  Maladaptive coping strategies was the only unique contributor (10%; β 
= .40, t = 4.81, p < .001) such that more maladaptive coping predicted higher 
depression. At Step 3, the combined contributions of the illness perception 
components, coping strategies and benefit finding accounted for 53% of the 
variance in depression and the full model was significant, F (11,114) = 11.46, p 
< .001. After controlling for the contributions of the illness perception components 
and coping strategies, benefit finding accounted for an additional 4% in the 
variance in depression scores (R = .73, F Change (1, 114) = 10.10, p = .002), such 
that greater benefit finding predicted higher depression scores (β = .25, t = 3.18, p 
= .002).  
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Predictors of Physical Health 
 There were a number of significant zero-order correlations among predictor 
variables and physical health ratings. Increased negative illness related 
consequence (r = -.46), illness identity (r = -.47), greater illness related concern (r 
= -.33), a greater negative emotional response to HCV (r = -.42), and higher 
adoption of more maladaptive coping strategies (r = -.37) were all associated with 
poorer physical health. Perceptions related to shorter illness duration (r = -.28) 
were associated with better physical functioning. 
 At Step 1, the combined illness perception components made a significant 
contribution to the model, R = .58, R
2
 = .33, F (8, 117) = 7.34, p < .001. Higher 
illness identification was the only significant component to predict physical health 
scores (6%) such that greater illness identification predicted poorer physical health 
outcomes (β = -.33, t = 3.37, p = .001). At Step 2, the model was significant, F 
(10,115) = 7.76, p < .001, accounting for 40% of the variance.  Coping made a 
significant additional contribution to the prediction of physical health scores (7%) 
(R = .64, R
2 
Change = .07, F Change (2, 115) = 6.63, p = .002). Maladaptive 
coping (7%) was the only significant contributor such that greater maladaptive 
coping predicted poorer physical health (β = -.32, t = 3.63, p < .001). At Step 3, the 
full model accounted for 40% of variance in physical health scores, and the model 
remained significant, F (11,114) = 7.02, p < .001. Benefit finding however, failed 
to add to the model, R = .64, R
2 
Change = .001, F Change (1, 114) = .17, p = .682.  
Predicting Life Satisfaction 
 Greater personal control (r = .50), perceptions related to shorter illness 
duration (r = -.20), greater treatment control perceptions (r = .16), greater illness 
understanding or coherence (r = .26), greater adaptive (r = .25) and maladaptive (r 
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= .22) coping, and increased benefit finding (r = .48) were all significant zero-
order correlates of greater life satisfaction. Greater illness concern (r = -.23) was 
associated with lower life satisfaction. 
At Step 1, the illness perception components accounted for 33% of the 
variance in life satisfaction, R = .57, F (8, 117) = 7.14, p < .001. Perceptions 
related to a shorter illness duration or timeline (2% of variance; β = -.18, t = 2.03, p 
= .045) and greater personal control (16% of variance; β = .44, t = 5.21, p < .001) 
predicted greater life satisfaction. At Step 2, the overall model remained 
significant, F (10,115) = 7.84, p < .001, with the combined contributions of the 
illness perception components and coping strategies accounting for 41% of the 
variance in life satisfaction. Coping strategies made a significant contribution to 
the model (R = .64, R
2
 Change = .07, F Change (2, 115) = 7.47, p = .001). 
Maladaptive coping (3% of variance) was the only unique significant contributor; 
more maladaptive coping strategies predicted greater life satisfaction (β = .22, t = 
2.44, p = .016). At Step 3, the full model was significant (F (11,114) = 8.84, p 
< .001), and contributed 46% to the variance in life satisfaction scores. Benefit 
finding explained an additional 6% of the variance in life satisfaction, R = .68, F 
Change (1, 114) = 11.61, p = .001; greater benefit finding was associated with 
greater life satisfaction, β = .29, t = 3.41, p = .001.  
Predicting Positive Affect 
 There were a number of significant zero-order relationships between the 
predictors and positive affect. Increased personal (r = .51) and treatment control (r 
= .18) perceptions, greater illness understanding or coherence (r = .21), greater 
adoption of adaptive (r = .38) and maladaptive (r = .33) coping strategies, and 
increased benefit finding (r = .58) were associated with higher positive affect.  
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At Step 1, illness perceptions accounted for 27% of the variance in positive 
affect scores, R = .52, F (8, 117) = 5.40, p < .001. Greater perception of personal 
control (18%) was the only significant predictor of positive affect (β = .47, t = 
5.36, p < .001). At Step 2, the model was significant, F (10,115) = 9.06, p < .001, 
accounting for 44% of the variance in positive affect. Coping strategies contributed 
significantly to the prediction of positive affect, R = .66, R
2
 Change = .17, F 
Change (2, 115) = 17.59, p < .001. Adaptive coping (4%; β = .24, t = 2.93, p 
= .004) and maladaptive coping (6%; β = .30, t = 3.48, p = .001) were both 
positively associated with positive affect. At Step 3, the full model was significant, 
F (11,114) = 12.69, p < .001, and together the predictors accounted for 55% of the 
variance in positive affect. Benefit finding added a further 11% of explanatory 
power to the model, which was significant, R = .74, F Change (1, 114) = 27.84, p 
< .001; greater benefit finding predicted greater positive affect (β = .41, t = 5.28, p 
< .001).  
Table 6.4 
Unstandardised Coefficients, Beta Weights and 95% Confidence Intervals for 
Hierarchical Regression Analyses for the Prediction of each Outcome Variable by 
the Predictor Variables (N = 126) 
 Unstandardised 
Coefficients 
 Standardised 
Coefficient 
 95% Confidence 
Intervals For B 
 B Std. Error  Beta  Lower 
Bound 
Upper 
Bound 
Depression        
Step 1 
(Constant) 
Illness consequences 
Illness timeline 
Personal control 
Treatment control 
Illness identity 
Illness concern 
Illness coherence  
Emotional response 
Step 2 
(Constant) 
Adaptive coping 
Maladaptive coping 
Step 3 
(Constant) 
 
13.74 
.19 
.38 
-.67 
-.33 
1.06 
-.45 
-.83 
1.40 
 
.08 
.01 
.69 
 
-.89 
 
4.41 
.47 
.36 
.33 
.45 
.41 
.42 
.38 
.43 
 
4.92 
.09 
.14 
 
4.75 
  
 
.05 
.09 
-.17* 
-.06 
.25* 
-.10 
-.18* 
.35** 
 
 
.01 
.40** 
 
 
  
5.01 
-.74 
-.34 
-1.32 
-1.21 
.25 
-1.29 
-1.58 
.55 
 
-9.67 
-.16 
.41 
 
-10.30 
 
22.46 
1.12 
1.10 
-.02 
.56 
1.86 
.39 
-.09 
2.24 
 
9.84 
.18 
.98 
 
8.52 
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Benefit finding .11 .03 .25** 
 
 
.04 .18 
Physical health        
Step 1 
(Constant) 
Illness consequences 
Illness timeline 
Personal control 
Treatment control 
Illness identity 
Illness concern 
Illness coherence  
Emotional response 
Step 2 
(Constant) 
Adaptive coping 
Maladaptive coping 
Step 3 
(Constant) 
Benefit finding 
 
70.55 
-1.66 
-.46 
1.09 
.10 
-2.62 
.01 
.98 
-.73 
 
81.18 
.32 
-1.06 
 
81.45 
-.03 
 
8.46 
.90 
.70 
.63 
.86 
.78 
.81 
.72 
.82 
 
9.99 
.17 
.29 
 
10.06 
.07 
  
 
-.21 
-.06 
.14 
.01 
-.33** 
.00 
.11 
-.10 
 
 
.15 
-.32** 
 
 
-.04 
 
  
53.80 
-3.44 
-1.83 
-.16 
-1.60 
-4.16 
-1.60 
-.45 
-2.36 
 
61.38 
-.03 
-1.64 
 
61.53 
-.17 
 
87.29 
.12 
.92 
2.33 
1.80 
-1.08 
1.62 
2.40 
.89 
 
100.99 
.66 
-.48 
 
101.37 
.11 
Life satisfaction        
Step 1 
(Constant) 
Illness consequences 
Illness timeline 
Personal control 
Treatment control 
Illness identity 
Illness concern 
Illness coherence  
Emotional response 
Step 2 
(Constant) 
Adaptive coping 
Maladaptive coping 
Step 3 
(Constant) 
Benefit finding 
 
16.82 
.30 
-.48 
1.12 
-.10 
.21 
-.51 
.36 
-.20 
 
9.14 
.10 
.24 
 
8.43 
.08 
 
2.87 
.31 
.24 
.21 
.29 
.26 
.28 
.25 
.28 
 
3.38 
.06 
.10 
 
3.24 
.02 
  
 
.11 
-.18* 
.44** 
-.03 
.08 
-.17 
.12 
-.08 
 
 
.15 
.22* 
 
 
.29** 
  
11.13 
-.31 
-.95 
.69 
-.68 
-.31 
-1.06 
-.13 
-.75 
 
2.46 
-.02 
.05 
 
2.02 
.03 
 
22.51 
.90 
-.01 
1.53 
.48 
.73 
.04 
.84 
.36 
 
15.83 
.22 
.44 
 
14.85 
.13 
Positive affect        
Step 1 
(Constant) 
Illness consequences 
Illness timeline 
Personal control 
Treatment control 
Illness identity 
Illness concern 
Illness coherence  
Emotional response 
Step 2 
(Constant) 
Adaptive coping 
Maladaptive coping 
Step 3 
(Constant) 
Benefit finding 
 
10.31 
.03 
-.01 
.70 
.06 
.12 
-.02 
.12 
-.14 
 
3.59 
.10 
.20 
 
3.00 
.07 
 
1.76 
.19 
.14 
.13 
.18 
.16 
.17 
.15 
.17 
 
1.92 
.03 
.06 
 
1.73 
.01 
  
 
.02 
-.00 
.47** 
.03 
.07 
-.01 
.07 
-.10 
 
 
.24** 
.30** 
 
 
.41** 
  
6.83 
-.34 
-.29 
.44 
-.30 
-.20 
-.35 
-.18 
-.48 
 
-.22 
.03 
.08 
 
-.43 
.04 
 
13.79 
.40 
.28 
.96 
.41 
.44 
.31 
.42 
.20 
 
7.40 
.16 
.31 
 
6.44 
.09 
*p < .05  **p < .01 
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Mediation Analysis – Illness Perceptions, Coping, and Adjustment 
 A series of path analyses were conducted to determine the extent to which 
the relationships between each of the individual illness perception components and 
physical and psychosocial adjustment outcomes were mediated by adaptive or 
maladaptive coping strategies. Sixteen separate analyses were conducted and only 
results that identified mediation by coping are reported. The remaining tests were 
not significant.  
 First, the ability of maladaptive coping strategies to mediate the 
relationship between illness identity and depression was investigated. The results 
are shown in Figure 1. In separate standard regression tests, illness identity 
accounted for 14% of the variance in depression scores, R = .39, F (1, 124) = 
21.80, p < .001, β = .39, and 4% of the variance in maladaptive coping, R = .19, F 
(1, 124) = 4.79, p = .031, β = .19. A hierarchical regression was conducted to 
determine whether maladaptive coping strategies would predict depression after 
controlling for illness identity. Illness identity was entered at Step 1 and 
maladaptive coping strategies were entered at Step 2. After controlling for illness 
identity, maladaptive coping strategies added a significant 22% of variance to the 
prediction of depression (R = .61, F Change (2, 123) = 42.31, p < .001, β = .48). 
When maladaptive coping was entered at Step 2 of the model, the coefficient for 
illness identity decreased to β = .30, but continued to make a significant 
contribution to the model, p < .001. A Sobel test revealed that the decrease in the 
coefficient for illness identity was significant (z = 2.075, p = .037), indicating that 
maladaptive coping mediated the relationship between illness identity and 
depression.  
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 .19* .48** 
 
  
 
                         .39** 
 
Figure 6.1  
The direct and mediated pathways between illness identity and depression **p < 
.01 *p < .05.  
 
  Second, standard and hierarchical regressions were conducted to assess 
whether maladaptive coping mediated the relationship between emotional response 
and depression (see Fig. 2). Following a standard regression, emotional response 
accounted for 22% of the variance in depression scores, R = .47, F (1, 124) = 
35.41, p < .001, β = .47. In a subsequent standard regression, emotional response 
accounted for 14% of the variance in maladaptive coping, R = .37, F (1, 124) = 
20.10, p < .001, β = .37. A hierarchical regression was used to assess the efficacy 
of maladaptive coping strategies to predict depression after controlling for 
emotional response. Emotional response was entered at Step 1 and maladaptive 
coping strategies were entered at Step 2. After accounting for the contributions of 
emotional response at Step 1, maladaptive coping strategies added a further 15% of 
the variance in depression which was significant (R = .61, F Change (2, 123) = 
 Maladaptive Coping 
Illness Identity Depression 
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28.80, p < .001, β = .41). When maladaptive coping was entered at Step 2, 
emotional response continued to make a significant contribution to the model (p < 
.001) following earlier independent standard regression analysis, but the coefficient 
decreased to β = .32. A Sobel test indicated that the decrease in the coefficient for 
emotional response was significant (z = 3.436, p < .001), confirming that 
maladaptive coping mediated the relationship between emotional response and 
depression. 
 
 
 
 
 .37** .41** 
 
  
 
                         .47** 
Figure 6.2  
The direct and mediated pathways between emotional response and depression **p 
< .01 *p < .05.  
 
A third set of regressions assessed whether maladaptive coping mediated 
the relationship between illness identity and physical health (see Fig. 3). Identity 
accounted for 22% of the variance in physical health, R = .47, F (1, 124) = 35.16, p 
< .001, β = -.47, and 4% of the variance in maladaptive coping, R = .19, F (1, 124) 
= 4.79, p = .031, β = .19. A hierarchical regression was then utilised to determine 
the efficacy of maladaptive coping to account for variance in physical health 
 Maladaptive Coping 
Emotional Response Depression 
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ratings after controlling for illness identity. Illness identity was entered at Step 1 
and maladaptive coping strategies were entered at Step 2. Maladaptive coping 
added a significant 8% of the variance in physical health ratings after controlling 
for illness identity (R = .55, F Change (2, 123) = 14.42, p < .001, β = -.29). 
Although illness identity continued to make a significant contribution at Step 2 (p 
< .001) its contribution decreased (β = -.41). A Sobel test indicated that the 
decrease in the coefficient for illness identity at Step 1 of the model was 
marginally significant (z = -1.896, p = .057), indicating that maladaptive coping 
had partially mediated the relationship between illness identity and physical health.  
 
 
 
 
 
 .19* -.29** 
 
  
 
                        - .47** 
 
Figure 6.3 The direct and mediated pathways between illness identity and physical 
health **p < .01 *p < .05.  
Mediation Analysis – Illness Perceptions, Benefit Finding, and Adjustment 
 The relationships between individual illness perception components and 
physical and psychosocial adjustment outcomes were further investigated using 
path analyses to determine the extent to which the relationships between each of 
 Maladaptive Coping 
Illness Identity Physical Health 
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the individual illness perception components and physical and psychosocial 
adjustment outcomes were mediated by benefit finding. In total eight separate 
analyses were conducted. Only results that identified mediation by benefit finding 
are reported. 
First, standard and hierarchical regressions were conducted to assess 
whether benefit finding mediated the relationship between personal control and life 
satisfaction (see Fig. 4). Results of separate standard regressions indicated that 
personal control predicted 25% of the variance in life satisfaction scores, R = .50, 
R
2
 = .03, F (1, 124) = 41.44, p < .001, β = .50, and 15% of the variance in benefit 
finding, R = .38, F (1, 124) = 21.14, p <.001, β = .38. A hierarchical regression was 
utilised to investigate whether benefit finding could account for variance in life 
satisfaction after first controlling for the contributions of personal control. Personal 
control was entered at Step 1 and benefit finding was entered at Step 2. Benefit 
finding contributed a significant 10% of the variance in life satisfaction results (R 
= .59, F Change (2, 123) = 17.78, p < .001, β = .33). Personal control continued to 
make a significant contribution at Step 2 of the model (p < .001). However, the 
level of contribution decreased (β = .37). Sobel test results indicated that the 
decrease in the co-efficient for personal control was significant (z = 3.074, p = 
.002), indicating that benefit finding mediated the relationship between personal 
control and life satisfaction.  
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 .38** .33** 
 
  
 
                        .50** 
 
Figure 6.4  
The direct and mediated pathways between personal control and life satisfaction 
**p < .01 *p < .05.  
 
Standard and hierarchical regressions were used to assess whether benefit 
finding mediated the relationship between personal control and positive affect (see 
Fig. 5).  Results of separate standard regression tests indicated that personal control 
predicted 26% of the variance in positive affect scores, R = .51, F (1, 124) = 43.05, 
p < .001, β = .51 and 15% of the variance in benefit finding, R = .38, F (1, 124) = 
21.14, p <.001, β = .38. A hierarchical regression investigated whether benefit 
finding predicted variance in positive affect after controlling for personal control. 
Personal control was entered at Step 1 and benefit finding was entered at Step 2. 
Benefit finding contributed an additional 18% of the variance in positive affect 
above that predicted by personal control (R = .66, F Change (2, 123) = 38.12, p < 
.001, β = .45). Personal control continued to make a significant contribution at Step 
2 of the model (p < .001). However, the level of contribution to the model 
decreased (β = .34). A Sobel test indicated that the decrease in the coefficient for 
 Benefit Finding 
Personal Control Life Satisfaction 
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personal control was significant (z = 3.666, p < .001), indicating that benefit 
finding mediated the relationship between personal control and positive affect.  
 
 
 
 .38** .45** 
 
  
 
                        .51** 
Figure 6.5  
The direct and mediated pathways between personal control and positive affect **p 
< .01 *p < .05.  
 
6.3 Discussion 
 Study 1.1 explored relationships between illness perceptions, adaptive and 
maladaptive coping strategies, and benefit finding as predictors, and the illness 
adjustment outcomes of depression, physical health, life satisfaction, and positive 
affect as criterion variables within the context of HCV. Mediation tests were also 
conducted to identify the role of coping strategies and benefit finding to mediate 
relationships between illness perception components and criterion variables. First, 
consistent with related chronic disease studies, the combined illness perception 
components, and both adaptive and maladaptive coping strategies, made significant 
contributions in explainable variance across all four adjustment areas (Fortune et 
al., 2002; Helder et al., 2002; Rutter & Rutter, 2002; Scharloo et al., 2000). Benefit 
finding predicted depression, life satisfaction and positive affect adjustment 
 Benefit Finding 
Personal Control Positive Affect 
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outcomes, but not physical health. These results are consistent with the 
contribution of benefit finding reported in related studies (Helgeson et al., 2006; 
Littlewood et al., 2008; Park et al., 2009; Tennen et al., 1992). Second, both coping 
strategies and benefit finding mediated the relationships between illness 
perceptions and physical and psychosocial adjustment. Further, to the finding that 
coping strategies mediated the relationships between illness perceptions and 
physical and psychosocial adjustment are consistent with results reported by Rutter 
and Rutter (2002). 
Personal control, illness identity, illness coherence, and emotional response 
all made unique contributions to the variance in depression scores. These results 
are consistent with a number of related studies where illness perceptions accounted 
for significant variance in depression in other chronic diseases (Fortune et al., 
2002; Helder et al., 2002; Rutter & Rutter, 2002; Scharloo et al., 2000; Vaughan et 
al., 2003). Specifically, a number of related studies identified illness identity as 
accounting for variance in depression across a number of chronic disease 
conditions including chronic fatigue syndrome (Heijmans 1998), rheumatoid 
arthritis, chronic obstructive pulmonary disease (Scharloo et al., 1998), psoriasis 
(Fortune et al., 2002), addisons disease (Heijmans, 1999), multiple sclerosis 
(Vaughan et al, 2003), breast cancer (Gibbons, Groarke, & Sweeney, 2016), and 
Huntington’s disease (Helder et al., 2002). Taken together, the results reported for 
HCV and other chronic conditions identify common themes of higher illness 
symptom reporting predicting increased mood disturbance among individuals 
living with HCV and other chronic diseases.  
Personal control made significant contributions to the variance in 
depression among individuals living with HCV. However, the role of personal 
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control in predicting depression has not been reported in a number of other related 
chronic disease studies (Heijmans, 1998; Heijmans, 1999; Scharloo et al., 1998; 
Helder et al., 2002). It should be noted that these studies used a combined 
control/cure variable, included in earlier versions of illness perception 
questionnaires, reflecting how much personal control an individual believes they 
have over their illness, and how much they believe treatment can assist with 
managing their illness measured in a single variable. This may have contributed to 
the discrepancies reported between the role of personal control in predicting 
depression among individuals with HCV in comparison to these other chronic 
conditions.  
In the present study higher levels of illness coherence or understanding 
predicted lower depression, whereas greater negative emotional responses to HCV 
predicted higher depression. These results are consistent with a study conducted 
among individuals diagnosed with type 2 diabetes (Joshi, Dhungana, & Subba, 
2015). In this study, a higher emotional response to diabetes predicted greater 
depression, whilst a greater illness understanding or coherence predicted lower 
depression (Joshi et al., 2015). Similar to personal control, illness coherence and 
emotional response were not included in early illness perception questionnaires. 
This may have contributed to possible under reporting of the potential for these 
variables to make significant contributions to prediction of depression in related 
chronic disease conditions, in comparison to illness identity which has been 
included in earlier and more recent versions of illness perception measures (Moss-
Morris et al., 2002).  
Chronic illness has been associated with more negative consequences for 
individuals living with longer term health conditions (Broadbent et al., 2015). 
78 
 
Often chronic conditions have the potential to negatively impact a range of areas in 
an individual’s daily life. This has been reflected in a number of studies that have 
investigated the role of illness consequence in predicting depression among 
individuals impacted by longer term illness (Fortune et al., 2002; Heijmans, 1999; 
Rutter & Rutter, 2002; Vaughan et al., 2003). Interestingly, in contrast to these 
related chronic disease studies that have consistently found significant positive 
associations between illness consequence and depression (Fortune et al., 2002; 
Heijmans, 1999; Rutter & Rutter, 2002; Vaughan et al., 2003), illness consequence 
did not predict depression among individuals living with HCV. This finding 
suggests that the impact of living with HCV as reported here was not associated 
with lower mood, in comparison to individuals living with other related chronic 
disease conditions such as multiple sclerosis where the reporting of higher levels of 
negative consequence is more consistently reported (Vaughan et al., 2003). In 
contrast, a reasonably high degree of variance in the reporting of illness related 
symptoms associated with the experience of living with HCV as reported in the 
literature may have contributed to this finding (Forton et al., 2003; Lee & Abdo, 
2003; Lee & Harrison, 2005).      
Illness identity was the only illness perception component to make a unique 
contribution to the prediction of physical health outcomes. A number of related 
studies have found similar associations between increased identification with 
illness symptoms and decreased physical health (Heijmans, 1998; Heijmans, 1999; 
Helder et al., 2002; Scharloo et al., 2000). For example, Scharloo et al. (2000) 
reported strong negative associations between illness identity and physical health 
among individuals with psoriasis. However, Vaughan et al. (2003) did not identify 
a significant predictive relationship between illness identity and physical health 
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among a group of individuals diagnosed with multiple sclerosis. Other studies 
demonstrated significant predictive links between illness consequence and physical 
health, not found in the present analysis among individuals living with HCV 
(Fortune et al., 2002; Heijmans, 1998; Heijmans, 1999; Rutter & Rutter, 2002; 
Vaughan et al., 2003). It may be that among individuals living with HCV, the 
identification and reporting of symptoms associated with their condition is more 
strongly associated with reported depression and physical functioning in 
comparison to a number of related chronic conditions where both illness identity 
and illness consequence have accounted for variance in physical health and 
depression outcomes (Broadbent et al., 2015; Hagger & Orbell, 2003; Heijmans, 
1998; Heijmans, 1999).   
Personal control made unique and significant contributions to both life 
satisfaction and positive affect. These significant individual contributions highlight 
the important associations between how much an individual believes their actions 
can control their illness and perceived quality of life, and are consistent with a 
number of related chronic disease studies (Rutter & Rutter, 2002; Vaughan et al., 
2003). Further, shorter illness duration predicted increased life satisfaction 
independent of coping and benefit finding. These data are inconsistent with a 
number of related chronic disease studies that failed to demonstrate a link between 
illness timeline and psychological well-being (Fortune et al., 2002; Rutter & 
Rutter., 2002; Vaughan et al., 2003), and may be related to the unique potential for 
a treatment cure that potentially exists for HCV that sets this disease apart from 
other chronic health conditions where the focus is generally more on longer term 
management (e.g., multiple sclerosis).  
80 
 
After controlling for illness perceptions, maladaptive coping and adaptive 
coping were less reliable predictors of HCV physical and psychosocial adjustment 
outcomes when compared to the relative contributions of illness perception 
components. However, similar to a number of related chronic disease studies, 
increased adoption of maladaptive coping strategies was associated with higher 
depression (Helder et al., 2002; Rogan et al., 2013; Rutter & Rutter, 2002; 
Scharloo et al., 2000). Collectively, the greater adoption of illness related denial, 
substance use, use of emotional venting, self-blame, and behavioural 
disengagement coping strategies predicted higher depression. Similarly, Helder et 
al. (2002) found significant links between the adoption of emotional venting 
coping strategies and depression, and Rutter and Rutter identified greater 
behavioural disengagement strategies as contributing to higher depression in other 
chronic disease conditions. Together, these data suggest that individuals who adopt 
maladaptive coping strategies in response to their chronic illness, including HCV, 
are more likely to experience higher levels of mood disturbance.  Further, greater 
adoption of maladaptive coping strategies was associated with poorer physical 
health outcomes. These data are consistent with Helder et al. (2002) who 
demonstrated the role of increased behavioural disengagement in contributing to 
reduced physical health among a cohort of individuals with psoriasis. Interestingly, 
at a more adaptive level, active coping strategies accounted for variance in health 
related outcomes among individuals with irritable bowel syndrome (Rutter & 
Rutter, 2002). A number of factors may have contributed to the variability across 
chronic disease studies in reporting links between maladaptive coping strategies 
and depression and physical health adjustment relevant to the present study. For 
example, a number of chronic disease studies have not included the measurement 
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of coping, focussing instead on the contributions of illness perceptions to the 
prediction of physical and psychosocial adjustment (Hagger & Orbell, 2003). 
Further, studies that have included coping strategies have used a variety of 
standardised coping measures (Broadbent et al., 2015; Hagger & Orbell, 2003). 
Collectively, these factors may have limited the ability to compare the relative 
contributions of coping strategies reported for HCV in comparison to other chronic 
health conditions, and may have contributed to the under-reporting of the role of 
coping in predicting adjustment within the context of chronic disease.   
Increased adoption of maladaptive coping strategies predicted higher life 
satisfaction and positive affect. This finding has not been reported in other chronic 
disease studies which have more identified inverse relationships between 
maladaptive coping strategies and quality of life outcomes (Heijmans, 1998; 
Helder et al., 2002; Rutter & Rutter, 2002). For example, Helder et al. (2002) 
identified associations between lower avoidance, less emotional and improved 
quality of life among individuals living with chronic fatigue syndrome. These 
results may indicate the potential for both adaptive and maladaptive coping 
strategies within the context of HCV to contribute to improved quality of life, 
reflecting the variance in individual perceptions and coping behaviours that can 
exist across the spectrum of chronic disease. Perhaps for some individuals living 
with the experience of HCV, adopting more maladaptive coping strategies 
associated with denial or substance use may help to suppress unpleasant feelings 
and emotions associated with their HCV, leading to improved life satisfaction. 
Further, consistent with other chronic disease studies, adaptive coping strategies 
were positively and uniquely associated with positive affect (Rutter & Rutter, 
2002). Specifically, Rutter and Rutter (2002) identified an important role for 
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increased illness related acceptance in predicting better quality of life among 
individuals living with irritable bowel syndrome.  
  Results concerning the efficacy of benefit finding to account for variance 
across HCV physical and psychosocial adjustment were in line with a number of 
related studies, however, inconsistent findings have also been reported (Helgeson 
et al., 2006; McMillen & Fisher, 1998; Sears et al., 2003; Tomich & Helgeson, 
2004). For example, in the present study, greater benefit finding predicted higher 
depression after controlling for illness perceptions and coping. Similarly, 
McMillen and Fisher (1998) identified links between three benefit finding features; 
increased compassion, greater positive lifestyle changes, increased family 
closeness, and higher depression among individuals who had experienced an 
adverse life event, that included chronic illness. In accounting for these relatively 
counter-intuitive findings, McMillen and Fisher suggested that benefit finding and 
depression could theoretically and practically occur simultaneously, such that 
individuals may potentially discover benefits from their experience of chronic 
disease whilst continuing to experience decreased mood (McMillen & Fisher, 
1998).  
Consistent with results reported by Helgeson et al. (2006), benefit finding 
failed to predict physical health outcomes after controlling for the combined 
contributions of both illness perceptions and coping strategies. However, in a 
related study, Luszczynska et al. (2007) found that increased benefit finding 
predicted increased physical functioning among a group of women and men 
diagnosed with the human immunodeficiency virus. It may be that issues related to 
differences in study methodology contributed to the discrepancy in findings 
reported across these studies. For example, findings reported in Helgeson et al. 
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(2006) were drawn from 87 cross-sectional studies following a meta-analysis 
design that investigated relations between benefit finding and psychosocial and 
physical adjustment among individuals who had experienced adverse life events, 
including chronic disease. In contrast, results published by Luszczynska et al. 
(2007) followed a single cross-sectional study (n = 104) measuring benefit finding 
among individuals diagnosed with human immunodeficiency virus.  
Greater benefit finding predicted both increased positive affect and greater 
life satisfaction. These results are consistent with other work that identified 
important associations between benefit finding and positive wellbeing (Helgeson et 
al., 2006; Park et al., 2009; Tennen at al., 1992). For example, Tennen et al. 
identified the efficacy of benefit finding to predict positive well-being among a 
cohort of individuals with rheumatoid arthritis. However, other chronic disease 
studies failed to demonstrate these predictive relationships. For example, Tomich 
and Helgeson (2004) reported that benefit finding did not predict positive affect 
outcomes (in a sample of breast cancer sufferers).  
Consistent with Rutter and Rutter (2002), coping strategies mediated some, 
but not all of the relationships between illness perceptions and physical and 
psychosocial adjustment. In the present study, illness identity and maladaptive 
coping strategies were strong predictors of depression. Results also indicated that 
maladaptive coping strategies mediated the relationship between illness identity 
and depression. Individuals reporting more symptoms associated with their HCV 
were more likely to engage in maladaptive coping strategies and report greater 
depressive symptomology. Similarly, the relationship between emotional response 
perceptions and depression was mediated by maladaptive coping. Greater 
emotional response to HCV and maladaptive coping strategies predicted significant 
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variance in depression scores, and individuals reporting greater negative emotional 
responses to their HCV were more likely to engage with maladaptive coping 
strategies. Further, maladaptive coping partially mediated the relationship between 
illness identity and physical health outcomes. Higher reporting of identification 
with HCV symptoms and greater adoption of maladaptive coping strategies 
partially predicted poorer physical health, and individuals reporting more HCV 
symptoms were more likely to engage in maladaptive coping strategies.  
A few related chronic disease studies have assessed whether coping 
strategies mediated the relationship between illness perceptions and physical and 
psychosocial adjustment (Hagger & Orbell, 2003; Rutter & Rutter, 2002). For 
example, Rutter and Rutter (2002) reported that among individuals diagnosed with 
irritable bowel syndrome; (1) acceptance mediated the relationship between illness 
consequence and psychosocial adjustment. Individuals reporting lower negative 
consequences associated with their illness were more likely to accept their 
condition and reported improved quality of life, (2) active coping mediated the 
relationship between cure/control perceptions and physical health adjustment. 
Individuals who reported higher illness related personal and treatment control 
beliefs were more likely to engage in active coping strategies and report greater 
satisfaction regarding their health, and (3) behavioural disengagement mediated the 
relationship between cure/control perceptions, whilst negative venting of emotions 
mediated the relationship between psychological causation beliefs, illness 
consequence and anxiety. These differences in mediation mechanisms between 
HCV and irritable bowel syndrome highlight how differences in disease processes 
can contribute to differences in the manifestation of illness perceptions and coping 
strategies which can in turn contribute to variance in health related outcomes. They 
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also highlight how variations in both illness perception and coping measures used 
across chronic disease studies can account for differences in adjustment outcomes. 
For example, emotional response was measured in the present study but not in 
Rutter and Rutter. Despite these differences, results reported for HCV identify the 
potential for psychological interventions that specifically assist individuals to 
improve their ability to self-regulate symptoms associated with their HCV, and 
refrain from adopting maladaptive coping strategies, may contribute to improved 
mood and physical health. Similarly, addressing perceptions related to emotional 
response and providing interventions that decrease the adoption of maladaptive 
coping strategies, may also contribute less depression. 
No published research to date has assessed whether benefit finding 
mediated the relationships between illness perceptions and physical and 
psychosocial adjustment outcomes within the context of HCV. In the present 
study, benefit finding mediated the relationships of personal control to life 
satisfaction and positive affect. In both models, personal control and benefit 
finding predicted significant variance in life satisfaction and positive affect. 
Mediation test results suggested that individuals with stronger perceptions related 
to illness related personal control were likely to engage with higher levels of 
benefit finding contributing to improved quality of life in relation to their HCV. In 
comparison, a relatively small number of studies have assessed whether benefit 
finding mediated the relationship between illness perceptions and adjustment 
outcomes in related chronic diseases (Helgeson et al., 2006; Luszczynska et al., 
2007). In one study, Luszczynska et al. investigated links between self-efficacy (a 
closely related construct of personal control), benefit finding, medication 
adherence and physical health among a cohort of individuals living with the human 
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immunodeficiency virus. Results suggested that benefit finding mediated the 
relationship between self-efficacy, medication adherence and physical adjustment. 
Individuals who reported greater illness specific self-efficacy were more likely to 
discover positive benefits and meaning in relationship to their illness and report 
increased medication adherence and improved physical health (Luszczynska et al., 
2007). The results reported in the present study and in Luszczynska et al. (2007) 
identify common links between greater self-efficacy/personal control perceptions, 
higher benefit finding and improved health outcomes for individuals living with 
both HCV and the human immunodeficiency virus.    
The results reported in Study 1.1 support the role of illness perceptions and 
coping strategies in predicting physical and psychosocial adjustment among 
individuals with HCV (Fortune et al., 2002; Helder et al., 2002; Rutter & Rutter, 
2002; Scharloo et al., 2000). The results reported here also demonstrate the 
efficacy of benefit finding to predict psychosocial adjustment outcomes in 
individuals with HCV. Further, these results identified the efficacy of coping 
strategies and benefit finding to mediate relationships between illness perception 
components and physical and psychosocial adjustment outcomes. Finally, in 
clinical practice, previous research has demonstrated the effectiveness of 
psychological interventions in improving illness related adjustment among 
individuals with chronic illness (Daleboudt et al., 2013; Goodman, Morrissey, 
Graham, & Bossingham, 2005). Results reported here support the potential 
application of psychological interventions that focus on modifying illness 
perceptions, increasing adaptive coping strategies, and assisting individuals to 
identify illness related benefits, with the aim of increasing physical and 
psychosocial adjustment among individuals with HCV. 
87 
 
6.4 General comments 
The limitations relevant to the present study are reported in greater detail in 
Chapter 8. Results reported here have demonstrated that illness perceptions and 
coping strategies (as proposed by the SRM) along with benefit finding are 
important predictors of physical and psychosocial adjustment outcomes in HCV. In 
some, but not all cases, coping mediated relationships between illness perceptions 
and physical and psychosocial adjustment. Further, benefit finding mediated some 
of the relationships between illness perception components and adjustment.  
In related chronic disease research (Hagger & Orbell, 2003; Vaughan et al., 
2003) there has been significant debate as to the relative importance of coping 
strategies to the prediction of adjustment outcomes among individuals with chronic 
disease. Study 1.2 assesses whether coping strategies can independently predict 
physical and psychosocial adjustment among individuals with HCV, along with 
assessing the predictive ability of illness perceptions when the traditional SRM 
order of entry into predictive models is reversed (Leventhal et al., 1980). 
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Study 1.2 - The Role of Coping in Adjustment Outcomes in Hepatitis C  
Introduction 6.5 
As reported in Study 1.1, illness perceptions and coping strategies made 
significant contributions to predicting variance in physical and psychosocial 
adjustment. Further, following the traditional order of entry into the SRM as 
outlined by Leventhal et al. (1980), maladaptive coping strategies mediated the 
relationships of illness identity and emotional response to depression, but only 
partially mediated the relationship between illness identity and physical health. 
These results are consistent with a growing body of research that has confirmed the 
efficacy of illness perceptions to predict physical and psychosocial adjustment 
outcomes across a range of chronic diseases (Daleboudt et al., 2013; De Gucht, 
2015; Fortune et al., 2002; Greco et al., 2014). 
The results reported in Study 1.1 indicated that coping strategies were a 
significant predictor of physical and psychosocial adjustment in HCV. These 
results were in contrast to numerous studies that have investigated the efficacy of 
the coping strategies to predict variance in adjustment across the spectrum of 
chronic disease, which have not consistently found such relationships (Hagger & 
Orbell, 2003; Helder et al., 2002; Heijmans, 1999; Steed et al., 1999). Overall, 
there are more reports implicating illness perceptions than coping strategies as key 
variables in accounting for variance in adjustment outcomes across the spectrum of 
chronic disease (Broadbent et al., 2015; Hagger & Orbell, 2003).  
The majority of studies of chronic disease that have investigated the 
efficacy of the SRM to predict adjustment have followed the traditional order of 
entry, as outlined by Leventhal et al. (1992), which typically involves illness 
perception components being entered into the regression models at Step 1, and 
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coping strategies entered at Step 2 (Fortune et al., 2002; Rutter & Rutter, 2002; 
Steed et al., 1999). Other studies either performed separate tests for the illness 
perceptions and coping strategies (Helder et al., 2002), or varied the order of entry 
of SRM features into separate regression models (Heijmans, 1999). Further, a 
number of studies have not included coping strategies within SRM predictive 
frameworks due to data suggesting that illness perceptions are better predictors of 
physical and psychosocial adjustment (Heijmans, 1998; Moss-Morris et al., 1996; 
Vaughan et al., 2003). Results reported in Study 1.1 however, indicated a 
significant role for maladaptive coping in predicting physical and psychosocial 
adjustment outcomes across all four criterion variables in HCV. In comparison, 
adaptive coping strategies only contributed to the variance in the positive affect 
adjustment outcome. In light of these reported inconsistencies both across existing 
chronic disease literature (Hagger & Orbell, 2003), and in Study 1.1, the primary 
aim of Study 1.2 was to assess whether coping strategies independently predicted 
physical and psychosocial adjustment outcomes among individuals diagnosed with 
HCV.  
Following an approach similar to the one used by Heijmans (1999), for 
each of the regression tests a non-traditional approach was adopted and the order of 
entry into the regression models was reversed (Leventhal et al., 1980). Therefore, 
for each of the regression tests, coping strategies were entered at Step 1 and illness 
perceptions at Step 2.  Entering coping strategies at Step 1 provided an opportunity 
to assess whether both adaptive and maladaptive coping independently predicted 
physical and psychosocial adjustment, and whether the components of illness 
perception predicted adjustment outcomes after first controlling for coping. 
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  Study 1.2 employed the same indices of depression (Fortune et al., 2002; 
Vaughan et al., 2003), life satisfaction, positive affect (De Gucht, 2015; Rutter & 
Rutter, 2002) as measures of psychosocial adjustment, and physical health as a 
measure of physical adjustment (Heijmans, 1999; Steed et al., 1999) as used in 
Study 1.1. Hypotheses were (1) Adaptive and maladaptive coping strategies would 
make significant contributions to the adjustment models independent of illness 
perception components. (2) After entry at Step 2 of the predictive models, illness 
perception components would make significant contributions to the four criterion 
variables.  
6.6 Method 
The same participants, measures, and procedure used in Study 1.1 were employed 
in Study 1.2  
6.6.1 Data Analysis 
 Hierarchical regression analyses were conducted to confirm the relative 
contributions of illness perceptions and coping strategies in predicting physical and 
psychosocial adjustment outcomes. Separate analysis was conducted for each of 
the criterion variables (depression, physical health, life satisfaction, and positive 
affect). For each test coping strategies were entered at Step 1, and illness 
perception components were entered at Step 2.   
6.6.2 Results 
Model for Predicting Depression 
 Hierarchical regression analysis was conducted to assess (1) the 
contribution of coping strategies to variance in depression independent of the 
illness perception components, and (2) the efficacy of illness perceptions to predict 
depression after first controlling for the contributions of coping strategies. The 
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unstandardised coefficients, beta weights, and confidence intervals for all variables 
and tests are summarised in panel 1 of Table 6.5. At Step 1, the model was 
significant, F(2,123) = 24.53, p < .001, with coping strategies accounting for 29% 
of the variance in depression scores, R = .53,  F(2, 123) = 24.53, p < .001. Only 
maladaptive coping made a significant contribution to the prediction of depression 
accounting for 26% of the variance in depression scores, which was significant, β 
= .55, t = 6.67, p < .001. Greater adoption of maladaptive coping predicted greater 
depression. At Step 2, the full model was significant, F(10,115) = 10.74, p < .001, 
and the combined contributions of the illness perception components and coping 
strategies accounted for 48% of the variance in depression scores. At Step 2, the 
illness perception components accounted for an additional 20% of variance in 
depression, which was significant, R = .70, F Change (8, 115) = 5.50, p < .001. 
Only personal control (4%), β = -.21, t = 2.80, p = .006, and illness identity (3%), β 
= .24, t = 2.77, p = .007, made unique and significant contributions to prediction of 
depression.  
Model for Predicting Physical Health.  
To determine whether a non-traditional SRM was able to predict physical 
health, coping strategies were entered at Step 1 and illness perception components 
at Step 2. The unstandardised coefficients, beta weights, and confidence intervals 
for all variables and tests are summarised in panel 2 of Table 6.5. 
As can be seen in the table, the model was significant at Step 1, R = .40, R
2
 
= .16, F(2,123) = 11.65, p < .001, and together coping strategies accounted for 
16% of the variance in physical health. Maladaptive coping was the only 
significant unique predictor (16%), β = -.43, t = 4.83, p < .001; more maladaptive 
coping predicted poorer physical health. At Step 2, the combined contributions of 
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the illness perception components and coping strategies accounted for 40% of the 
variance in physical health scores, and the full model was significant, F(10,115) = 
7.76, p < .001. The addition of the illness perception components made a 
significant contribution to predicting physical health, adding an additional 24% to 
the model, R = .63, F Change(8, 115) = 5.87, p < .001. Illness identity made a 
significant unique contribution to the prediction of physical health adjustment 
(6%), β = -.31, t = 3.41, p = .001; those who reported greater illness identity tended 
to report poorer physical health. Further, personal control predicted physical health 
(2%), β = .17, t = 2.15, p =.034; greater perceptions related to personal control 
predicted better physical health.    
Model for Predicting Life Satisfaction. 
 A third hierarchical regression was performed on life satisfaction. Coping 
strategies were entered at Step 1 and illness perception components at Step 2.  The 
unstandardised coefficients, beta weights, and confidence intervals for all variables 
and tests are summarised in panel 3 of Table 6.5. At Step 1 the model was 
significant, R = .28, R
2
 = .08, F(2,123) = 5.40, p = .006, and together coping 
strategies collectively accounted for 8% of variance in life satisfaction. At an 
individual level, only greater adoption of adaptive coping strategies (3%) predicted 
increased life satisfaction, β = .20, t = 2.10, p = .038. At Step 2, the combined 
contributions of the illness perception components and coping strategies predicted 
41% of the variance in life satisfaction which was significant, R = .64, F(10,115) = 
7.84, p < .001. At Step 2, the illness perception components made a significant 
contribution to predicting life satisfaction, adding an additional 33% of explained 
variance to the model, R = .64, F Change (8, 115) = 7.85, p < .001. Personal 
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control (14%), β = .41, t = 5.14, p < .001, and illness timeline (3%), β = -.21, t = 
2.48, p = .015, were the only significant unique predictors of life satisfaction.  
Model for Predicting Positive Affect. 
 A fourth test assessed whether coping strategies entered at Step 1, and 
illness perception components entered at Step 2, could predict positive affect. The 
unstandardised coefficients, beta weights, and confidence intervals for all variables 
and tests are summarised in panel 4 of Table 6.5. At Step 1 the model was 
significant, R = .43, R
2
 = .19, F(2,123) = 13.99, p < .001, and together coping 
strategies collectively accounted for 19% of variance in positive affect. Greater 
adoption of both adaptive (8%), β = .30, t = 3.46, p < .001, and maladaptive coping 
strategies (4%), β = .21, t = 2.39, p = .018, predicted positive affect. At Step 2, the 
combined contributions of the coping strategies and illness perception components 
predicted 44% of the variance in positive affect which was significant, R = .66, 
F(10,115) = 7.84, p < .001. At Step 2, the illness perception components made a 
significant contribution accounting for an additional 26% the variance in positive 
affect, R = .66, F Change (8, 115) = 6.56, p < .001. Personal control (15%), β 
= .43, t = 5.55, p < .001, and emotional response (3%), β = -.27, t = 2.47, p = .015, 
were the only significant unique predictors of positive affect.  
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Table 6.5  
Unstandardised Coefficients, Beta Weights and 95% Confidence Intervals for 
Multiple Regression Analyses for the Prediction of each Outcome Variable by the 
Coping Strategies and Illness Perception Components (N = 126) 
 Unstandardised 
Coefficients 
 Standardised 
Coefficient 
 95% Confidence 
Intervals For B 
 B Std. Error  Beta  Lower 
Bound 
Upper 
Bound 
Depression        
Step 1 
(Constant) 
Adaptive coping 
Maladaptive coping 
Step 2 
(Constant) 
Illness consequences 
Illness timeline 
Personal control 
Treatment control 
Illness identity 
Illness concern 
Illness coherence  
Emotional response 
 
 
-.33 
-.05 
.95 
 
.08 
.10 
.31 
-.83 
-.29 
1.01 
-.06 
-.50 
.70 
 
4.16 
.09 
.14 
 
4.92 
.43 
.33 
.30 
.41 
.37 
.39 
.36 
.41 
  
 
-.05 
.55* 
 
 
.03 
.08 
-.21* 
-.05 
.24* 
-.01 
-.11 
.18 
  
-8.56 
-.23 
.67 
 
-9.67 
-.74 
-.34 
-1.42 
-1.10 
.29 
-.83 
-1.21 
-.11 
 
7.91 
.13 
1.24 
 
9.84 
.95 
.97 
-.24 
.53 
1.74 
.71 
.21 
1.51 
Physical Health        
Step 1 
(Constant) 
Adaptive coping 
Maladaptive coping 
Step 2 
(Constant) 
Illness consequences 
Illness timeline 
Personal control 
Treatment control 
Illness identity 
Illness concern 
Illness coherence  
Emotional response 
 
65.82 
.32 
-1.42 
 
81.19 
-1.41 
-.56 
1.30 
-.25 
-2.53 
-.56 
.19 
.12 
 
8.53 
.18 
.29 
 
9.10 
.86 
.67 
.60 
.84 
.74 
.79 
.73 
.83 
  
 
.16 
-.43* 
 
 
-.18 
-.07 
.17* 
-.02 
-.31* 
-.06 
.02 
.01 
 
  
48.93 
-.04 
-1.10 
 
61.38 
-3.12 
-1.89 
.10 
-1.90 
-4.00 
-2.13 
-1.26 
-1.52 
 
 
82.70 
.69 
-.84 
 
100.99 
.30 
.77 
2.50 
1.41 
-1.06 
1.01 
1.64 
1.76 
Life Satisfaction        
Step 1 
(Constant) 
Adaptive coping 
Maladaptive coping 
Step 2 
(Constant) 
Illness consequences 
Illness timeline 
Personal control 
Treatment control 
Illness identity 
Illness concern 
Illness coherence  
Emotional response 
 
Positive Affect 
Step 1 
(Constant) 
 
9.96 
.14 
.16 
 
9.14 
.30 
-.56 
1.05 
-.17 
.20 
-.37 
.39 
-.50 
 
 
 
6.41 
 
3.02 
.07 
.10 
 
3.38 
.29 
.23 
.20 
.28 
.25 
.28 
.25 
.28 
 
 
 
1.67 
  
 
.20* 
.14 
 
 
.11 
-.21* 
.41* 
-.05 
.07 
-.12 
.13 
-.20 
 
 
 
 
  
3.99 
.01 
-.05 
 
2.46 
-.28 
-1.01 
.64 
-.73 
-.30 
-.89 
-.09 
-1.05 
 
 
 
3.11 
 
   15.94 
.26 
.37 
 
15.83 
.88 
-.11 
1.45 
.39 
.70 
.16 
.88 
.06 
 
 
 
9.71 
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Adaptive coping 
Maladaptive coping 
Step 2 
(Constant) 
Illness consequences 
Illness timeline 
Personal control 
Treatment control 
Illness identity 
Illness concern 
Illness coherence  
Emotional response 
 
 
.12 
.14 
 
3.59 
.04 
-.08 
.65 
-.01 
.11 
.10 
.14 
-.39 
.04 
.06 
 
1.92 
.17 
.13 
.12 
.16 
.14 
.15 
.14 
.16 
 
.30* 
.21* 
 
 
.02 
-.05 
.43* 
-.01 
.07 
.06 
.08 
-.27* 
 
 
 
 
 
. 
.05 
.02 
 
-.22 
-.29 
-.34 
.42 
-.33 
-.17 
-.20 
-.14 
-.71 
.19 
.25 
 
7.40 
.37 
.17 
.88 
.30 
.39 
.40 
.41 
-.08 
*p <.05 
 
6.7 Discussion 
Study 1.2 assessed whether coping strategies predicted physical and 
psychosocial adjustment outcomes independently of illness perceptions. Consistent 
with the results reported in Study 1.1, and with previous chronic disease related 
research (Fortune et al., 2002; Helder et al., 2002; Rutter & Rutter, 2002; Scharloo 
et al., 2000), and as hypothesised, both coping strategies and illness perceptions 
made significant contributions to adjustment.  
The coping strategies data in the present study were in line with a number 
of related chronic disease studies (Fortune et al., 2002; Heijmans, 1999; Helder et 
al., 2002; Rutter & Rutter, 2002) that reported a relationship between maladaptive 
coping and depression. For example, both Fortune et al. (2002) and Heijmans 
(1999) reported that avoidant coping strategies predicted higher depression among 
individuals diagnosed with chronic disease. Further, Rutter and Rutter (2002) 
reported that engagement of coping strategies related to behavioural 
disengagement and suppression in response to chronic disease predicted higher 
depression among individuals with irritable bowel syndrome. Together, these data 
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suggest greater adoption of maladaptive coping strategies predicts higher 
depression, irrespective of chronic disease type. 
As reported in Study 1.1, and consistent with related research (Fortune et 
al., 2002; Helder et al., 2002; Rutter & Rutter, 2002; Scharloo et al., 2000; 
Vaughan et al., 2003), illness perceptions related to personal control, illness 
identity, illness coherence, and emotional response to HCV each made significant 
and unique contributions to predicting  depression.  In the present study, after 
controlling for the contribution of coping strategies, only personal control and 
illness identity continued to make significant unique contributions to the model. 
These data highlight the relative robustness of these illness perception variables in 
adjustment for individuals with HCV. 
Maladaptive coping strategies predicted poorer physical health, decreased 
physical and role functioning, increased physical pain and more negative 
perceptions of general health both independently, and after controlling for the 
contributions of illness perceptions. Consistent with these results, Fortune et al. 
(2002) identified the unique role of avoidance related to behavioural 
disengagement in contributing to variance in physical functioning. Similarly, 
Helder et al. (2002) described the role of behavioural disengagement in accounting 
for variance in physical health. 
Illness identity accounted for significant variance in physical health 
independent of (reported in Study 1.1), and after controlling for, the contribution of 
coping strategies. Similar to related research (Heijmans, 1999; Helder et al., 2002; 
Scharloo et al., 2000), greater identification with the symptoms related to HCV 
was associated with poorer physical health. After controlling for coping strategies, 
personal control emerged as a significant predictor of physical health. These data 
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are in line with Rutter and Rutter (2002) who identified the role of increased illness 
related personal control in predicting higher satisfaction with health among a group 
of individuals with irritable bowel syndrome. Taken together, the results reported 
here highlight the relative importance of the relations between illness identity, 
personal control and physical health adjustment in comparison to that of other 
illness perception components, and support interventions for individuals that 
present with HCV that seek to increase a greater sense of illness related self-
efficacy or personal control, along with interventions that promote more adaptive 
symptom management strategies with the aim of improving physical health 
adjustment.   
The data reported in Study 1.2 are consistent with Rutter and Rutter (2002), 
who indicated that stronger adoption of adaptive coping strategies predicted 
increased life satisfaction independent of the illness perception components. This 
result was in contrast to results reported in Study 1.1, where after controlling for 
the contributions of illness perceptions only maladaptive coping strategies 
contributed to the model. As reported in Study 1.1, these results indicate that the 
adoption of both adaptive and maladaptive coping strategies can simultaneously 
contribute to improved life satisfaction which may be relatively unique to HCV.  
Similar to results reported in Rutter and Rutter (2002), in the present study, 
personal control accounted for significant variance in life satisfaction results after 
controlling for the contribution of coping strategies. These results demonstrate the 
predictive link between higher perceptions of illness related personal control and 
higher perceptions of life satisfaction, and have important implications for clinical 
practice. The data reported in Studies 1.1 and 1.2 that identified perceptions related 
to a shorter illness timeline predicting higher life satisfaction, regardless of order of 
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entry into predictive models, reflect the relatively unique potential for a treatment 
cure for individuals presenting with HCV in comparison to most other chronic 
disease conditions (Hagger & Orbell, 2003).   
As reported in Studies 1.1 and 1.2, maladaptive and adaptive coping 
strategies made significant contributions to the prediction of positive affect 
regardless of their order of entry into predictive models. Taken together with the 
results reported in Studies 1.1 and 1.2 in relation to the predictive links between 
adaptive and maladaptive coping strategies and life satisfaction, these results 
highlight the relatively unique potential in HCV for greater adoption of both 
adaptive and maladaptive coping strategies to contribute to improved quality of 
life. 
As reported in Studies 1.1 and 1.2, personal control predicted positive 
affect independently and after controlling for the contributions of coping strategies. 
The results reported here for personal control are consistent with a number of other 
chronic disease studies that identified links between greater personal control 
perceptions and improved quality of life (Rutter & Rutter, 2002; Vaughan et al., 
2003), Interestingly, lower negative emotional response to HCV emerged as a 
predictor of increased positive affect after controlling for coping strategies. 
Importantly, this result supports providing interventions that promote more 
adaptive emotional self-regulation strategies where high levels of negative illness 
related emotional impact levels are identified among individuals presenting with 
HCV.  
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6.8 General Comments 
Results reported in Studies 1.1 and 1.2 suggest that clinicians and 
researchers should consider the role of illness perceptions and coping strategies in 
predicting adjustment outcomes among individuals living with HCV. Such 
considerations could incorporate the design of clinical interventions and research 
models that focus on improving the adjustment, and therefore the quality of life of 
individuals diagnosed with HCV, and related chronic illnesses. Both illness 
perception components and coping strategies predicted physical and psychosocial 
adjustment among a cohort of individuals with HCV regardless of their respective 
order of entry into predictive models. Further, as reported in Study 1.1, coping 
strategies mediated the relationship of some but not all of the relationships between 
illness perceptions and physical and psychosocial adjustment. Taken together, 
these results partially confirm the utility of the SRM to identify important links 
between illness perceptions, coping and adjustment within the context of HCV, 
including supporting the theoretical considerations related to the role of coping in 
mediating relations between illness perceptions and health related outcomes 
outlined in earlier SRM literature (Leventhal et al., 1980). 
The following chapter reports on a longitudinal design employed to 
investigate whether illness perceptions and coping strategies (i.e., SRM) and 
benefit finding are able to predict biomedical treatment outcomes in HCV. Study 
2.1 assessed the efficacy of illness perceptions and coping strategies to predict 
HCV treatment outcomes after first controlling for biomedical, clinical and 
behavioural markers that have been utilised in previous HCV treatment research 
(Lee &  Abdo, 2003; Shiffman et al., 2004). Study 2.2 investigated whether benefit 
finding could predict HCV treatment response after controlling for SRM features 
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and biomedical, clinical and behavioural variables identified in the first analysis as 
significant predictors of HCV treatment response. Finally, no previous published 
research has investigated in a single study whether depression, physical health 
markers as outlined in Chapter 5, life satisfaction, and positive affect adjustment 
variables could predict HCV treatment response after controlling for clinical, 
behavioural and demographic markers. This gap in the literature provided an 
opportunity to extend the investigations reported in Studies 1.1, 1.2, 2.1, and 2.2, 
and conduct a further investigation (Study 2.3) to assess whether these variables 
could establish similar links to HCV treatment response outcomes reported in 
earlier studies.  
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Chapter 7 
Study 2.1-Illness Perceptions, Coping and Treatment Outcomes in Hepatitis C  
 
7.1 Introduction 
The results from Studies 1.1 and 1.2 reported in Chapter 6 demonstrated the 
efficacy of illness perceptions and coping, to predict physical and psychosocial 
adjustment regardless of order of entry into predictive models. Benefit finding also 
predicted psychosocial adjustment outcomes among individuals with HCV (Study 
1.1). Further, coping and benefit finding mediated relationships between illness 
perceptions and physical and psychosocial adjustment measures (Study 1.1). Taken 
together, these data suggest that the assessment of cross-sectional models reported 
in Studies 1.1 and 1.2 demonstrated the utility of an expanded SRM to predict 
physical and psychosocial adjustment within the novel area of HCV. Further, 
results reported in Study 1.1 identified the role of coping to mediate relations 
between illness perception components and adjustment, are consistent with the 
expected interrelations between illness perceptions, coping and health related 
outcomes reported in earlier SRM literature (Leventhal et al., 1980).  
There is a wealth of literature that has confirmed demographic and clinical 
markers as reliable predictors of biomedical outcomes among individuals 
undertaking treatment for their HCV (Chen & Morgan, 2006; Lee & Abdo, 2003; 
Shiffman et al., 2004). Research utilising the SRM has demonstrated its efficacy to 
predict physical and psychosocial adjustment outcomes across a number of forms 
of chronic illness (Boddington et al., 2002; Cartwright & Lamb, 1999; Heijmans, 
1998; Heijmans, 1999; Helder et al., 2002; Horne et al., 2001; Horne & Weinman, 
2002; Kemp et al., 1999; Moss-Morris et al., 2002; Rees et al., 2001; Scharloo et 
al., 1998; Schiaffino & Cea, 1995; Steed et al., 1999; Theunissen & de Ridder, 
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2001). The data reported in Studies 1.1 and 1.2 has confirmed the utility of the 
SRM to predict psychological and physical health in HCV prior to treatment. To 
date however, few studies have investigated whether the SRM could predict 
biomedical treatment outcomes in chronic disease conditions. For example, Chilcot 
et al. (2011) investigated whether illness perceptions predicted survival rates 
among a cohort of individuals with end stage renal disease. Results of this study 
identified the important role of perceptions related to treatment control as a 
predictor of survival after controlling for a number of clinical covariates such as 
depression, medical comorbidity, age in years, and two renal specific medical 
markers, serum albumin and haemoglobin levels (Chilcot et al., 2011). Similarly, 
Paddison et al. (2008) conducted a study that investigated the relative contributions 
of illness perception components to explaining variance in metabolic control and 
quality of life among a cohort of individuals living with type 2 diabetes. Poor 
metabolic control is associated with an increased risk of diabetes related 
complications (Paddison et al., 2008). Findings indicated that illness perceptions 
related to shorter illness timeline and greater negative illness related consequences 
predicted poor metabolic control status after controlling for clinical co-variates, 
length of time since first diagnosis, body mass index, and type of treatment 
regimen (insulin or no insulin) (Paddison et al., 2008). Taken together the results 
reported in Chilcot et al. (2011) and Paddison et al. (2008) demonstrate the 
important role of illness perceptions in predicting biomedical outcomes over and 
above the contributions of clinical, behavioural and demographic markers.  
To date, no published research has investigated whether illness perceptions 
and coping strategies can predict HCV treatment response after controlling for 
biomedical, clinical and behavioural markers that have been utilised in previous 
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HCV research (Lee & Abdo, 2003; Shiffman et al., 2004). Similar to the approach 
of Chilcot et al. (2011) and Paddison et al. (2008), the present study investigated 
whether illness perceptions and coping would predict HCV treatment response 
(measured at 4, 8, and 12 weeks post–commencement of HCV treatment) after first 
controlling for a number of biomedical, clinical and behavioural markers utilised in 
previous HCV biomedical treatment prediction research (Lee & Abdo, 2003; 
Shiffman et al., 2004). For example, Lee & Abdo (2003) identified important links 
between a number of pre-HCV treatment bio-medical, clinical and behavioural 
markers included in Study 2.1, and HCV treatment response measured at 12 weeks. 
Further, HCV genotype 1, age in years, absence of cirrhosis of the liver, gender 
and patient body weight have all been identified as important predictors of HCV 
treatment response (Lee & Abdo, 2003). In line with results reported in Study 1.1 
and 1.2, and in previous related research (Chilcot et al., 2011; Paddison et al., 
2008), it was hypothesised that illness perceptions and coping would predict HCV 
treatment response after controlling for bio-medical, clinical and behavioural 
markers.  
  
7.2 Method 
7.2.1 Participants  
 The first pre-treatment survey was completed by 126 individuals with HCV 
who were recruited via the study website. Out of this cohort, 32 participants 
completed the second survey post-commencement of HCV treatment. Table 7.1 
summarises biomedical, clinical, behavioural and demographic information. 
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Table 7.1  
Biomedical, Demographic, behavioural and clinical data (N = 32) 
Characteristic  N  (%)  M  SD 
Age      43.3  13.5 
Weight (KG)          78.6      16.1 
Gender         
Male  13  40.6     
Female  19  59.4     
Treatment adherence  30  93.8     
IV drug use   11  34.4     
Cirrhosis (n =23)  7  30.4     
Genotype 1 (n = 26)   14  53.8     
Previous HCV treatment  8  25.0     
Medical comorbidity  12  37.5     
Recreational drugs  7  21.9     
Alcohol use  8  25.0     
Smoking tobacco  10  31.3     
Mental health condition  7  21.9     
 
7.2.2 Measures  
Biomedical, Clinical, behavioural and demographic information – Time 1 
 As outlined in greater detail in chapter 5, participants at Time 1 responded 
to specific questions related to age, weight, HCV genotype, gender, and most 
likely route of HCV infection. They also provided Time 1 yes/no responses to 
biomedical, socio-demographic and clinical questions related to: (1) cirrhosis of 
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the liver, (2) other medical conditions, (3) use of recreational drugs, (4) 
consumption of alcohol, (5) smoking cigarettes, (5) mental health condition/s, and 
(6) previous treatment for Hepatitis C.  
Illness perceptions 
 Illness perceptions were measured using the Brief Illness Perception 
Questionnaire (BIPQ: Broadbent et al., 2006) as described in chapter 5.  
Coping  
Coping was measured by the Brief COPE (Carver, 1997) as outlined in 
chapter 5).  
Outcome Assessment and Adherence to medication – Time 2 
HCV treatment response was the outcome measure evaluated at Time 2 
(post commencement of HCV treatment). Additionally, a single question related to 
treatment adherence was also measured at Time 2. Specific details related to both 
the HCV treatment response questions and treatment adherence question are 
described in greater detail in chapter 5. 
7.2.3 Procedure 
Recruitment strategies for Time 2 were identical to those reported for the 
previous cross-sectional studies. Participants were contacted by email three months 
post commencement of HCV treatment and were invited to complete a second 
online survey questionnaire (Time 2). At Time 2 they responded to questions 
related to HCV treatment outcome, and to treatment adherence relevant to the 
treatment period. The Time 2 online survey took between 5 and 10 minutes to 
complete.  
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7.2.4 Statistical Analysis 
 An alpha level of .05 was utilised to determine statistical significance. Due 
to attrition between Time 1 (n = 126) and Time 2 (n = 32), independent samples t-
tests, chi-square analyses and Fisher’s exact tests were performed to assess for 
differences in biomedical, clinical, behavioural, and demographic characteristics 
(refer Table 7.1), between participants who completed the post-treatment 
questionnaire and those who did not. The only significant result to emerge was age 
in years; those who completed the post-treatment questionnaire (M = 46.98 years, 
SD = 13.55) were significantly older than participants who only completed the pre-
treatment questionnaire (M = 41.58 years, SD = 11.12), t(51) = 2.07, p = .04.  
  
7.2.5 Results  
Differences in Treatment Response in Biomedical, Clinical, Behavioural and 
Demographic Markers. 
Independent t-tests, chi-square analyses and Fisher’s exact tests were used 
to assess differences in the variables of interest as a function of treatment response. 
Results revealed significant differences between treatment responders and non-
responders related to use of recreational drugs (Fisher’s exact test p < .05) and the 
presence of a mental health condition (Fisher’s exact test p < .05). There were no 
significant differences  between responders and non-responders as a function of 
treatment adherence (Fisher’s exact test p >.05), gender (χ² (1, 32) = .00, p > .05), 
IV drug use transmission (χ² (1, 32) = .00, p > .05), cirrhosis of the liver (Fisher’s 
exact test p >.05), HCV Genotype 1 (χ² (1, 26) = 2.59, p > .05), previous HCV 
treatment (Fisher’s exact test p >.05), reported medical comorbidity (χ² (1, 32) = 
1.88, p > .05), recent alcohol use (Fisher’s exact test p >.05), or regular cigarette 
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smoking (Fisher’s exact test p >.05). Treatment non-responders were not different 
in age (M = 42.84 years, SD = 12.48) from treatment responders (M = 43.73 years, 
SD = 14.91), t(30) = -.19, p = .85.  Treatment non-responders did not differ in 
weight (M = 78.35 kg, SD = 16.58) from non-responders (M = 78.80 kg, SD = 
16.03), t(30) = 0.08, p = .94.  
Treatment Responders vs. Non-Responders: Illness Perceptions and Coping  
 To investigate differences in illness perception components and coping 
strategies as a function of treatment response, a multivariate analysis of variance 
(MANOVA) was performed. The eight illness perception components were 
included (illness consequence, illness timeline, personal control, treatment control, 
illness identity, illness concern, illness coherence, and emotional response), along 
with adaptive and maladaptive coping strategies. Table 7.2 presents descriptive 
statistics, univariate F-values and effect sizes for treatment non-responders versus 
treatment responders on each of the dependent variables. Overall, only treatment 
control demonstrated a significant association with treatment response such that 
treatment responders reported greater treatment control than did non-responders. 
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Table 7.2 
Means and standard deviations for the illness perception variables and coping 
strategies as a function of treatment response 
 
 
 
Variable 
No Treatment 
Response 
(n = 17) 
Treatment Response 
(n = 15) 
Univariate 
 
M SD M SD F P   Eta 
Illness consequence 6.24 1.95 5.73 2.71 0.37 .55 .01 
Illness timeline 6.53 2.15 5.00 3.18 2.59 .12 .08 
Personal Control 4.59 2.60 4.00 2.51 0.42 .52 .01 
Treatment Control 6.35 1.69 7.87 1.64 6.55 .02 .18 
Illness identity 5.65 2.34 4.73 2.60 1.09 .30 .04 
Illness concern 7.71 1.90 7.73 2.58 0.00 .97 .00 
Illness coherence 
Emotional response 
Adaptive coping 
Maladaptive coping 
6.42 
5.88 
45.41 
19.07 
2.37 
2.89 
12.26 
6.61 
7.53 
5.53 
46.47 
17.07 
1.68 
3.07 
6.10 
3.61 
2.32 
0.11 
0.09 
1.08 
 .14 
.74 
.77 
.31 
.07 
.00 
.00 
.04 
 
 
Multivariate Prediction of Treatment Response 
 A logistic regression was performed to assess whether treatment response 
could be independently predicted by each of the variables found to differentiate 
responders from non-responders as described above (refer Table 7.3). Accordingly, 
mental health condition, substance use and treatment control were entered into the 
regression model. The full model containing the three predictor variables was 
statistically significant, χ² (3, N = 32) = 18.73, p < .001. The logistic model overall 
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explained between 44% (Cox and Snell R square) and 59% (Nagelkerke R 
squared) of the variance in treatment response outcomes, and correctly classified 
84% of the cases. Table 7.3 indicates that all three of the predictor variables made 
individual and statistically significant contributions to the prediction of treatment 
response outcomes. More specifically, at pre-treatment the presence of a comorbid 
mental health condition, substance use, and a stronger perception of the 
effectiveness of HCV treatment uniquely predicted treatment response. 
 
 
Table 7.3 
Results of logistic regression for predicting treatment response in patients with 
HCV 
 
 
 
 
  
         95% CI 
           for Exp(B) 
 
B S.E. Wald P Exp(B) Lower   Upper 
Recreational Drugs 3.75 1.69 4.93 .03 42.50 1.55 1162.22 
Mental Health Condition 3.06 1.42 4.64 .03 21.22 1.32 341.89 
Treatment Control .80 .36 4.95 .03 2.22 1.10 4.49 
Constant -7.04 2.83 6.17 .01 .001   
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7.3 Discussion 
 Results of Study 2.1 demonstrated the efficacy of the illness perception of 
treatment control measured at Time 1 to predict HCV treatment response measured 
at Time 2 after controlling for clinical, behavioural and demographic variables 
measured at Time 1. Specifically, perceptions related to a greater belief in the 
efficacy of HCV treatment predicted treatment response (i.e., nil detection of HCV 
following milestone blood tests). These results are consistent with Chilcot et al. 
(2011) who demonstrated that treatment control predicted survival rates among 
individuals with end stage renal disease after controlling for relevant clinical 
markers. Further, mental health comorbidity and use of recreational drugs made 
unique and significant contributions to the prediction of HCV treatment response, 
such that the presence of mental health comorbidity and the use of recreational 
drugs predicted a more favourable treatment response. Despite the relatively 
counter-intuitive direction of these results, a few studies that have investigated the 
role of recreational drug use and the presence of mental health comorbidity in 
accounting for variance in HCV treatment response outcomes have identified 
comparable treatment response outcome rates between recreational drug users, and 
individuals reported mental health comorbidity compared with non-drug using 
cohorts and individuals not reporting mental health co-morbidity (Edlin, 2002; Liu 
et al., 2014; Sylvestre, 2002). Further, other studies have directly identified links 
between recreational drug use during HCV treatment and improved HCV treatment 
response outcomes (Costiniuk, Mills, & Cooper, 2008; Sylvestre, Clements, & 
Malibu, 2016). A related study did not identify any links between recreational drug 
use whilst receiving HCV treatment and treatment response (Liu et al., 2014). 
Relevant to mental health comorbidity, improved HCV response outcomes was 
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associated with the early identification and appropriate treatment of depression 
among individuals presenting for HCV treatment (Sockalingam & Abbey, 2009). It 
may be that particular recreational drugs may have specific effects that ameliorate, 
to a degree some of the potentially negative HCV treatment side-effects that can be 
experienced during treatment, along with the positive psychological benefits 
associated with psychotropic medications prescribed to address mental health 
conditions, taken together may potentially contribute to improved HCV treatment 
response.   
Contrary to hypothesised expectations there were no significant differences 
between treatment non-responders and treatment responders on the adaptive and 
maladaptive coping strategies. Therefore, adaptive and maladaptive coping 
strategies were not entered into subsequent logistic regression analysis.    
 The SRM proposes that when individuals become aware of an illness 
experience they construct a number of illness related perceptions in an attempt to 
create understanding of what is happening. These illness perceptions are then 
proposed to drive coping behaviours with the aim of attaining favourable illness 
related outcomes (Broadbent et al., 2006; Leventhal et al., 1980). Within the 
present study the data highlighted the important role of treatment control within the 
HCV treatment predictive framework. In addition to the number of clinical 
markers that have been identified in HCV literature as contributing to the 
prediction of treatment response, such as particular HCV genotype and BMI (Chen 
& Morgan, 2006; Lee & Abdo, 2003; Shiffman et al., 2004), a significant factor 
that contributes to this outcome is the ability to effectively engage in self-
management behaviours whilst on treatment (Shiffman et al., 2004). For example, 
despite no difference in Study 2.1 between responders and non-responders as a 
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function of HCV medication adherence, adherence to HCV anti-viral regimens 
often requires self-administration of anti-viral medications on a daily basis and has 
been linked to treatment response in a number of studies (Lee & Abdo, 2003; 
Shiffman et al., 2004). Perhaps the low sample size (n = 32) reported in Study 2.1 
contributed to these non-significant findings related to medication adherence 
compared to other studies that reported larger sample sizes and identified links 
between medication adherence and HCV treatment response (Lee & Abdo, 2003; 
Shiffman et al., 2004). Based on the findings reported in the majority of HCV 
treatment studies that have included measuring links between medication 
adherence and HCV treatment response (Lee & Abdo, 2003; Shiffman et al., 
2004), in partly accounting for the results reported for treatment control reported in 
Study 2.1, it may be therefore, that levels of motivation to engage with required 
medication regimens are likely to be influenced by perceptions of the efficacy of 
the prescribed treatments. Therefore greater treatment control perceptions would 
potentially have a significant influence on adherence behaviours. In other words, 
an individual might be unlikely to adhere to the requirements associated with HCV 
treatment if they held low perceptions related to treatment control.  
 The SRM assumes that the cognitions associated with individual illness 
perceptions are amenable to psychological intervention (Chilcot et al., 2011; 
Hagger & Orbell, 2003; Leventhal et al., 1980). The results of Study 2.1 highlight 
the potential importance of assessing the illness perceptions of individuals 
preparing for HCV treatment, and implementing psychological interventions that 
address maladaptive illness perceptions and strengthen more adaptive illness 
perceptions with the aim of creating optimal psychological platforms prior to the 
commencement of HCV treatment. Overall, the results of the present study support 
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previous research conducted within the context of chronic disease that have 
demonstrated the efficacy of illness perceptions related to treatment control to 
predict treatment outcomes (Chilcot et al., 2011; Rutter & Rutter, 2002; Steed et 
al., 1999).  
7.4 General Comments 
In summary, the results of Study 2.1 further support the inclusion of illness 
perceptions as an important factor in predicting HCV treatment response (Shiffman 
et al., 2004). Study 2.2, expanded on the results of Study 2.1, and tested the 
efficacy of benefit finding to predict HCV treatment response after controlling for 
mental health conditions, recreational drugs, and treatment control. The primary 
rationale for the order of entry of psychological variables investigated in Studies 
2.1 and 2.2 was based on SRM theoretical considerations (Leventhal et al., 1980). 
Therefore, Study 2.1 investigated the traditional features of the SRM, illness 
perceptions and coping to predict HCV treatment response after first controlling 
for the contributions of clinical, behavioural, and demographic markers. In line 
with one of the primary aims of the present thesis, Study 2.2 provided the 
opportunity to extend the utility of the traditional features of the SRM to predict 
HCV treatment response, and assess whether an expanded model, including benefit 
finding could make significant contributions to the prediction of HCV treatment 
response beyond traditional features of the SRM and other relevant clinical, 
behavioural and demographic variables.       
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Study 2.2 - Biomedical Markers, Illness Perceptions, Benefit Finding and 
Hepatitis C Treatment Outcomes 
7.5 Introduction 
 In line with one of the primary aims of the present thesis, to assess whether 
an expanded SRM could predict HCV treatment response, Study 2.2 investigated 
whether benefit finding predicted HCV treatment response after controlling for 
comorbid mental health conditions, recreational drug use, and illness perceptions 
related to treatment control. The use of recreational drugs and reported mental 
health comorbidity along with treatment control were included in the present study 
due to their respective significant associations with the treatment response criterion 
variable reported in Study 2.1.  
 As reported in Study 1.1, benefit finding predicted psychosocial adjustment 
outcomes among individuals with HCV. These results are consistent with a number 
of studies across chronic health conditions that have identified the role that benefit 
finding can have in predicting psychosocial adjustment (Helgeson et al., 2006). 
The role of benefit finding was not associated with physical health adjustment 
prior to HCV treatment in the present thesis. However, a number of chronic disease 
studies have identified the efficacy of benefit finding to predict both physical 
health adjustment and biomedical treatment outcomes (de Ridder, 2008). To date, 
no published research has focussed on whether benefit finding could predict HCV 
treatment response within an expanded SRM, which provided the impetus for 
Study 2.2.  
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It was hypothesised that benefit finding would predict HCV treatment 
response over and above the contributions of treatment control, mental health 
comorbidity and recreational drug use. 
7.6 Method 
The participants, measures and procedure are the same as for Study 2.1 
7.6.1 Results  
 To investigate differences in treatment control and benefit finding as a 
function of treatment response, a multivariate analysis of variance (MANOVA) 
was performed. Treatment control and benefit finding demonstrated a significant 
association with treatment response. Table 7.4 presents descriptive statistics, 
univariate F-values and effect sizes for treatment non-responders versus treatment 
responders on each of the dependent variables included in the present study, 
treatment control and benefit finding.  
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Table 7.4 
Means and standard deviations for the illness perception variable and benefit 
finding as a function of treatment response 
 
 
 
Variable 
No Treatment 
Response 
(n = 17) 
Treatment Response 
(n = 15) 
Univariate 
 
M SD M SD F P   Eta 
Treatment control 6.35 1.69 7.87 1.64 6.55 .02 .18 
Benefit finding 62.47 33.82 41.33 19.72 4.50 .04 .13 
 
 
Multivariate Prediction of Treatment Response 
 A logistic regression (refer Table 7.5) assessed whether treatment response 
could be independently predicted by each of the variables found to differentiate 
responders from non-responders as described above. Accordingly, mental health 
condition, substance use, treatment control and benefit finding were entered into 
the regression model. The full model containing the four predictor variables was 
statistically significant, χ² (4, N = 32) = 24.20, p < .001. The logistic model overall 
explained between 53% (Cox and Snell R square) and 71% (Nagelkerke R 
squared) of the variance in treatment response outcomes, and correctly classified 
84% of the cases. Table 7.5 indicates that treatment control and benefit finding 
were significant predictors of treatment response. The presence of a comorbid 
mental health condition, and recreational drug use, failed to contribute to the 
model.  
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Table 7.5 
Results of logistic regression for predicting treatment response in patients with 
HCV. 
 
 
 
 
  
         95% CI 
           for Exp(B) 
 
B S.E. Wald P Exp(B) Lower   Upper 
Recreational Drugs 4.12 2.22 3.45 .06 61.63 .79 4784.11 
Mental Health Condition 2.83 1.55 3.32 .07 16.88 .81 352.35 
Treatment Control 1.22 .50 5.97 .02 3.40 1.23 9.03 
Benefit Finding -.05 .03 4.08 .04 .95 .91 .99 
Constant -7.23 3.22 5.06 .02 .001   
 
7.7 Discussion 
 Study 2.2 investigated whether benefit finding predicted treatment response 
over and above the contributions of mental health comorbidity, recreational drug 
use and treatment control within the context of an expanded SRM. These three 
predictor variables were included as covariates in the present study following their 
association with in treatment response as confirmed in Study 2.1.  
 Consistent with results reported Study 2.1, treatment control made a 
significant individual contribution to the prediction model. Illness perceptions 
related to treatment control (i.e. “how much do you think your treatment can help 
your HCV?”) predicted treatment response. Contrary to Study 2.1, mental health 
comorbidity and the use of recreational drugs did not make a significant 
contribution to the predictive model. These results are inconsistent with previous 
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studies that have demonstrated the efficacy of clinical and behavioural markers 
such as reported in the present analysis, mental health co-morbidity and the use of 
recreational drugs, to predict HCV treatment response (Chen & Morgan, 2006; Lee 
& Abdo, 2003; Shiffman et al., 2004).  
Counter to expectations, lower benefit finding predicted HCV treatment 
response.  No previous published research has investigated whether benefit finding 
predicted biomedical HCV treatment response outcomes and therefore comparison 
of the data reported here and current empirical work is not possible. The exact 
reason for these results is unclear. However, it is important to note that similar 
counter-intuitive results have been reported in other chronic disease studies related 
to benefit finding, biomedical treatment outcomes, and physical and psychosocial 
adjustment (de Ridder et al., 2008; McMillen & Fisher, 1998; Helgeson et al., 
2006). For example, in a study conducted among individuals who had recently 
been diagnosed up to four months previously with breast cancer, greater benefit 
finding predicted high levels of depression at 3 - 9 month follow up (Tomich & 
Helgeson, 2004). However, in a related study, individuals who had been diagnosed 
with breast cancer 3-12 months previously, greater benefit finding predicted 
decreased depression at 4-7 year follow up (Carver & Antoni, 2004). Relevant to 
the present thesis, it could be that the time period between the measurement of 
benefit finding and collection of outcome data could in some part explain the more 
counter-intuitive results reported here (de Ridder et al., 2008). As reported in the 
present thesis, collection of treatment outcome data similar to the Tomich and 
Helgeson (2004) study occurred at a relatively shorter follow up period, with 
similar reporting of predictive relations between benefit finding and outcome. 
Further, Stanton and Bower (2006) in a study conducted among cancer survivors 
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suggested that relatively earlier measurement of benefit finding could represent a 
type of avoidance behaviour. Additionally, Tomich and Helgeson (2004) suggested 
that earlier collection of benefit finding data may be qualitatively different from 
benefit finding data collected at later follow up time periods. However, other 
related chronic disease research found that benefit finding interventions conducted 
in shorter time periods following diagnosis were associated with more favourable 
outcomes (Antoni et al., 2001; de Ridder et al., 2008). Future studies that explore 
the relationship between benefit finding and treatment response outcomes among 
individuals with HCV may benefit from considering the findings of these studies 
when designing research models (Antoni et al., 2001; Carver & Antoni, 2004; de 
Ridder et al., 2008; Stanton & Bower, 2006; Tomich & Helgeson, 2004).  
7.8 General Comments 
The results of Study 2.2 support the utility of an expanded SRM to predict 
HCV treatment response. Further, consistent with results reported in Study 2.1, 
perceptions related to HCV treatment control predicted treatment response rates. 
As reported previously, these results are supported by other studies that have 
demonstrated the efficacy of illness perceptions to predict physical and 
psychosocial adjustment and biomedical treatment outcomes across varied areas of 
chronic disease (Chilcot et al., 2011; Fortune et al., 2002; Heijmans, 1999; Helder 
et al., 2002; Rutter & Rutter, 2002; Scharloo et al., 2000; Steed et al., 1999). 
Interestingly, in comparison to Study 2.1, after including benefit finding into the 
prediction model the contributions of reported mental health condition and the use 
of recreational drugs were no longer significant.  
In Study 2.3 the four criterion variables utilised in the cross–sectional 
studies reported in Study 1.1 and 1.2 were employed as predictors of HCV 
120 
 
treatment response after controlling for use of recreational drugs and reported 
mental health condition. As reported previously in Study 2.1, use of recreational 
drugs and reported mental health condition were the only clinical and behavioural 
variables to demonstrate significant associations with the treatment response 
criterion. A limitation of the results reported in Study 2 was that those who 
completed surveys at Time 2 were older than the mean age of participants who 
completed surveys at Time 1. Therefore, these results should be interpreted with 
some caution, as they may not be generalisable to younger individuals. 
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Study 2.3 - Depression, Physical Health, Life Satisfaction, Positive 
Affect and Treatment Response Outcomes in HCV 
7.9 Introduction 
Studies 2.1 and 2.2 identified a key role for the illness perception, treatment 
control in the prediction of HCV treatment response after controlling for the use of 
recreational drugs and reported mental health comorbidity, which were controlled 
after demonstrating significant associations with the HCV treatment response 
criterion variable. Further, benefit finding predicted HCV treatment response after 
controlling for the recreational drug use and mental health condition covariates, 
albeit in a counter-intuitive way. Lower benefit finding predicted HCV treatment 
response. The primary aim of Study 2.3 was to investigate whether the four 
criterion variables included in Studies 1.1 and 1.2 could predict HCV treatment 
response after controlling for the contributions of recreational drug use and 
reported mental health condition.  
A comparatively limited number of studies that have assessed whether 
depression predicted biomedical treatment outcomes in chronic disease have 
produced relatively mixed results (Chilcot et al., 2011; Lopes et al., 2002). For 
example, Chilcot et al. (2011) conducted a study to assess whether depression 
predicted survival rates among individuals with end stage renal disease. In this 
study, depression failed to predict survival rates (Chilcot et al., 2011). However, in 
a related study, Lopes et al. (2002) found that depression predicted mortality and 
hospitalization rates among patients with kidney disease who were undergoing 
haemodialysis treatment. To date, no identified published research that utilised a 
longitudinal research design has investigated the potential role for depression to 
122 
 
independently predict HCV treatment response. This gap in the literature provided 
an opportunity to extend the investigations related to whether an expanded SRM 
could explain variance in HCV treatment response as reported in Studies 2.1 and 
2.2, and assess the efficacy of depression to predict treatment response among a 
cohort of individuals undergoing HCV treatment. It should be noted, in the present 
study, mental health condition was removed from the predictive model due to its 
high correlation with depression.     
There is a wealth of research that has investigated the role of biomedical 
markers in predicting HCV treatment response outcomes (Shiffman et al., 2004). 
In assessing the efficacy of physical health to predict HCV treatment response, 
many studies have included various determinants of overall physical health, such 
as obesity and the presence of liver pathology (Lee & Abdo, 2003; Shiffman et al., 
2004). No published studies to date have assessed self-reported physical health 
(physical functioning, role functioning, general health perceptions, and the 
experience of bodily pain) as a predictor of HCV treatment response. Study 2.3 
provided an opportunity to assess the role of physical health to predict HCV 
treatment response. Similarly, no published research to date has investigated 
whether self-reported life satisfaction and positive affect could predict HCV 
treatment response. This gap in the literature provided an opportunity to assess the 
efficacy of life satisfaction and positive affect as broad measures of quality of life 
to predict HCV treatment response  
The following predictions were made based on previous work and theory: 
(1) After controlling for the use of recreational drugs, depression was 
expected to emerge as a strong predictor of HCV treatment response.  
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(2) Physical health was expected to predict HCV treatment response after 
accounting for the contributions of recreational drug use and reported mental 
health condition. 
 (3) Life satisfaction and positive affect were expected to predict HCV 
treatment response after controlling for recreational drug use and mental health 
condition.  
7.10 Method 
Details of the participants and procedure are described in Studies 2.1 and 
2.2. The measures are described in Chapter 5. 
7.10.1  Results  
Fisher’s exact tests were used to assess differences in the variables of 
interest as a function of treatment response. As reported in Study 2.1, results 
revealed significant differences between treatment responders and non-responders 
on recreational drug use (Fisher’s exact test p <.05) and the presence of a mental 
health condition (Fisher’s exact test p <.05) and so these variables were retained in 
the analyses.  
 To investigate differences in depression, physical health, life satisfaction, 
and positive affect as a function of treatment response, a multivariate analysis of 
variance (MANOVA) was performed. Table 7.6 presents descriptive statistics, 
univariate F-values and effect sizes for treatment non-responders versus treatment 
responders on each of the dependent variables included in the present analysis. 
Overall, only depression demonstrated a significant association with treatment 
response (p = .024). 
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Table 7.6 
Means and standard deviations for dependent variables as a function of treatment 
response 
 
 
 
Variable 
No Treatment 
Response 
(n = 17) 
Treatment Response 
(n = 15) 
Univariate 
 
M SD M SD F p   Eta 
Depression 18.24 11.88 10.13 6.07 5.66 .024 .159 
Physical health 48.90 26.32 58.13 18.32 1.29 .265 .041 
Life satisfaction 17.94 6.81 17.97 6.04 .001 .979 .000 
Positive affect 15.06 4.12 12.93 4.22 2.08 .160 .065 
 
 
 
 
Multivariate Prediction of Treatment Response 
 A logistic regression was performed to assess whether treatment response 
could be independently predicted by variables that had been found to differentiate 
responders from non-responders (refer to Table 7.7). Only depression 
demonstrated significance, and therefore was the only variable to be entered into 
the regression model along with use of recreational drugs.  
The full model containing the four predictor variables was statistically 
significant, χ² (2, N = 32) = 11.51, p = .003.The logistic model overall explained 
between 30% (Cox and Snell R square) and 40% (Nagelkerke R squared) of the 
variance in treatment response outcomes, and correctly classified 69% of the cases. 
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Table 7.7 indicates that depression was the only predictor of treatment response. 
Use of recreational drugs failed to add to the predictive model.  
 
Table 7.7 
Results of logistic regression for predicting treatment response in patients with 
HCV 
 
 
 
 
  
         95% CI 
           for Exp(B) 
 
B S.E. Wald P Exp(B) Lower   Upper 
Recreational Drugs 1.63 1.22 1.80 .18 5.11 .472 55.41 
Depression -.109 .053 4.13 .04 .897 .808 .996 
Constant 1.145 .890 1.65 .198 3.143   
 
7.11 Discussion  
In Study 2.3, depression emerged as a predictor of treatment response after 
controlling for the contributions of the use of recreational drugs. Further, these 
results are consistent with the findings in a related chronic disease study reported 
by Lopes et al. (2002) in which depression predicted mortality and hospitalization 
rates among patients who were undergoing haemodialysis treatment related to their 
kidney disease, and give support for including comprehensive assessment of mood 
among individuals preparing for HCV treatment.  
 Contrary to expectations, life satisfaction, positive affect and physical 
health were not associated with treatment response, and therefore these variables 
were not investigated further. Past research has identified a significant role for a 
number of HCV biomedical markers considered to be determinants of physical 
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health, including obesity and cirrhosis of the liver, in predicting HCV treatment 
response (Shiffman et al., 2004). This provided the primary rationale to assess the 
efficacy of physical health related to physical functioning, role functioning, 
reported bodily pain and general health perceptions to predict HCV treatment 
response. Further, life satisfaction and positive affect failed to meet the criteria for 
entry into logistic regression analysis following non-significant results of a 
MANOVA. However, life satisfaction and positive affect accounted for adjustment 
outcomes reported in Study 1.1 and 1.2. This provided support for their inclusion 
in the present longitudinal analysis. 
 
7.12 General Comments 
 In Study 2.3 pre-treatment depression was identified as a significant 
predictor of HCV treatment response. This result has important implications for 
individuals undergoing assessment and treatment for HCV from a wider 
psychosocial level. Depression should thus be included in future related HCV 
treatment response studies to follow up the results reported in the present study.  
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Chapter 8 
General Discussion 
8.1 Overview 
 In summary, the investigations presented in the present thesis have 
established several novel and important findings: 
1. Features of the SRM, illness perceptions and coping strategies, predicted 
physical and psychosocial adjustment among individuals with HCV. 
2. As part of an expanded SRM, benefit finding predicted psychosocial 
adjustment after first controlling for the contributions of illness perception 
components and coping strategies. 
3. Coping strategies and benefit finding in some, but not all cases mediated 
the relationships between illness perceptions and physical and psychosocial 
adjustment. 
4. Stronger treatment control perceptions, greater mental health comorbidity 
and recreational drug use predicted HCV treatment response. Lower 
reporting of benefit finding predicted HCV treatment response. Coping 
strategies failed to contribute to the prediction model among this same 
HCV treatment cohort.  
5. Lower pre-treatment depression predicted HCV treatment response after 
first controlling for the contributions of recreational drug use. 
8.2 Relations Between Illness Perceptions, Coping, Benefit Finding, and 
Physical and Psychosocial Adjustment – Review of Cross-Sectional Studies. 
 Studies 1.1 and 1.2 confirmed illness perceptions, coping strategies and 
benefit finding were linked to psychosocial adjustment indices of depression, life 
satisfaction and positive affect. Similarly, illness perceptions and coping strategies 
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predicted physical health adjustment. However, benefit finding did not predict 
physical health. These results are somewhat consistent with a number of other 
chronic disease studies that have demonstrated; (1) the efficacy of benefit finding 
to predict psychosocial adjustment, and (2) the efficacy of various combinations of 
traditional SRM features to predict both physical and psychosocial adjustment 
(Broadbent et al., 2015; de Ridder et al., 2008; Hagger & Orbell, 2003; Helgeson et 
al., 2006). Interestingly, other chronic disease studies have not reliably 
demonstrated coping as a predictor of physical and psychosocial adjustment 
(Hagger & Orbell, 2003; Heijmans, 1999; Rutter & Rutter, 2002; Steed et al., 
1999), and there has been mixed reports of benefit finding predicting physical 
adjustment (de Ridder et al., 2008).  The inconsistent results between HCV and 
other chronic disease conditions may be explained by the following; (1) a lack of 
consistency regarding versions of illness perception questionnaires used across 
studies reported in Studies 1.1 and 1.2. For example, earlier versions did not 
include specific illness perception components that have subsequently been 
included in more recent versions, such as the BIPQ (Broadbent et al., 2006; 
Weinman et al., 1996). Similarly, there has been a general lack of consistency 
regarding versions of coping and benefit finding measures used across a number of 
chronic disease studies, and therefore lack of consistency regarding individual 
coping and benefit finding items included in these measures, and (2) differences in 
the manifestation of disease characteristics across the various chronic health 
conditions reported in Studies 1.1 and 1.2. may have further contributed to 
variance in the reporting of results between those reported for HCV and other 
chronic health conditions.  
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A number of illness perception components and coping strategies made 
unique and significant contributions to the prediction of physical and psychosocial 
adjustment in Studies 1.1 and 1.2. Consistent with a number of other chronic 
disease studies (Broadbent et al., 2015; Rutter & Rutter et al., 2002; Vaughan et 
al., 2003), personal control made unique and significant contributions to the 
prediction of depression, physical health, life satisfaction and positive affect, 
independently and after controlling for the contributions of coping. Important to 
clinicians providing psychological assessment and interventions to individuals 
presenting with HCV, these results highlight the important role that increased 
perceptions related to an individual’s perceived personal control over their HCV 
can have in predicting lower levels of reported depression, higher satisfaction with 
physical health and better quality of life. However, as reported in Study 1.1, these 
findings were not consistently reported across other chronic disease studies 
(Heijmans, 1998; Heijmans, 1999; Scharloo et al., 1998; Helder et al., 2002). It 
may be that the use of cure/control combining both treatment control and personal 
control features in a single item in earlier versions of illness perception measures 
may have contributed to variance in results reported across chronic disease studies 
regarding the potential effectiveness of personal control to predict physical and 
psychosocial adjustment.  
 Similarly, illness identity made unique and significant contributions to 
depression and physical health adjustment in Studies 1.1 and 1.2. These results are 
consistent with a number of other chronic disease studies (Broadbent et al., 2015; 
Daleboudt et al., 2013; Heijmans, 1999; Helder et al., 2002), and indicate that for 
individuals living chronic disease, including HCV, higher reporting of illness 
symptoms was associated with lower mood levels, physical functioning and 
130 
 
perceptions related to physical health wellbeing. However, in one chronic disease 
study, illness identity did not predict either depression or physical health 
adjustment among a cohort of individuals living with irritable bowel syndrome 
(Rutter & Rutter, 2002). This result may highlight the role that differences in 
disease characteristics such as severity, duration and frequency of symptom 
reporting across different chronic health conditions, such as HCV and irritable 
bowel syndrome can have in contributing to variance in both physical and 
psychosocial adjustment outcomes.  
Illness coherence and emotional response predicted depression which is 
consistent with other chronic diseases (Broadbent et al., 2015; Hagger & Orbell, 
2003; Joshi et al., 2015). For example, Joshi et al. (2015) identified links between 
illness coherence, emotional response and depression in sufferers of type 2 
diabetes. Higher negative emotional responses predicted higher reporting of 
depression. Conversely, greater illness understanding predicted lower depression 
(Joshi et al., 2015). Similarly, as reported here, individuals with a greater 
understanding of their HCV reported lower depression, whereas individuals 
reporting a higher negative emotional response to their HCV reported higher 
depression. In Study 1.2 illness perceptions related to illness coherence and 
emotional response did not predict depression after controlling for the 
contributions of coping strategies. It may be that illness coherence and emotional 
response are relatively weaker predictors of depression among individuals with 
HCV. Illness identity and personal control both predicted depression independently 
and after controlling for the contributions of coping strategies. Interestingly, after 
controlling for coping strategies, emotional response accounted for significant 
variance in positive affect. Less negative illness related emotional responses to 
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HCV predicted increased positive affect. Similar findings that identified the 
important role of emotional response to illness in accounting for variance in quality 
of life adjustment were reported in a study conducted by Paddison et al. (2008). A 
lower negative emotional response to the experience of living with chronic type 2 
diabetes predicted improved quality of life. Further, in related chronic disease 
studies important links were identified between emotional response and medication 
adherence among individuals living with coronary heart disease (Platt, Green, 
Jayasinghe, & Morrissey, 2014), and in emotional response accounting for 
variance in physical functioning related to intimacy among a cohort of individuals 
living with the experience of lupus erythematosus (Daleboudt et al., 2013). These 
results identify important associations between emotional self-regulation and the 
subjective experiences of positive mood states among individuals living with HCV 
and Type 2 diabetes, and medication adherence and physical functioning among 
individuals living with coronary heart disease and lupus erythematosus, 
respectively (Daleboudt et al., 2013; Paddison et al., 2008; Platt et al., 2014). 
However, it should be noted that similar to previous findings reported in Studies 
1.1 and 1.2, variability in the inclusion of illness perception components across a 
number of chronic disease studies, emotional response was not included in an 
earlier version of the illness perception questionnaire (Weinman, Petrie, Moss-
Morris, & Horne, 1996), which may have contributed to the under-reporting of the 
potential importance of the role of emotional response in predicting physical and 
psychosocial adjustment in other chronic disease conditions (Fortune et al., 2002; 
Helder et al., 2002; Rutter & Rutter, 2002; Steed et al., 1999; Vaughan et al., 
2003). 
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Illness timeline predicted life satisfaction independently and after 
controlling for coping strategies. Perceptions related to a shorter illness timeline 
predicted higher life satisfaction. In a number of chronic disease studies 
perceptions related to illness timeline reported in Addison’s disease (Heijmans, 
199), multiple sclerosis (Vaughan et al., 2003), rheumatoid arthritis, psoriasis, and 
chronic pulmonary disease (Scharloo et al., 1998), have identified predictive links 
between longer illness duration and higher reporting of depression.  It may be that 
the link between shorter illness duration perceptions and greater life satisfaction 
may be related to the treatment cure that is potentially available for HCV which 
sets HCV apart from the majority of other chronic disease conditions where the 
focus is more on longer term symptom management and quality of life issues. This 
explanation may provide a partial explanation for the links between illness timeline 
and depression reported in other chronic disease conditions were a medical cure is 
not available. For example, it may be that in conditions where a treatment cure is 
not available such as multiple sclerosis a sense of hopelessness or resignation may 
arise regarding the progressive nature of their condition, which may then increase 
the risk of symptoms associated with depression (Vaughan et al., 2003). 
As reported in Studies 1.1 and 1.2, illness consequence, treatment control, 
and illness concern did not make significant contributions to the prediction of any 
of the four criterion variables, depression, physical health, life satisfaction or 
positive affect. Firstly, higher reported illness related seriousness or consequence 
and illness concern have accounted for variance in depression and physical health 
adjustment outcomes in a number of chronic disease studies (Broadbent et al., 
2015; Fortune et al., 2002; Hagger & Orbell, 2003; Heijmans, 1998; Heijmans, 
1999; Petriček et al., 2009; Rutter & Rutter, 2002; Vaughan et al., 2003; 
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Westbrook, Maddocks, & Andersen, 2016). Chronic health conditions by their 
nature are often associated with significant negative consequences and greater 
illness related concern which may contribute to lower physical functioning and 
mood disturbance (Broadbent et al., 2015; Fortune et al., 2002; Hagger & Orbell, 
2003; Heijmans, 1998; Heijmans, 1999; Petriček et al., 2009; Rutter & Rutter, 
2002; Vaughan et al., 2003; Westbrook et al., 2016). In comparing these findings 
with those reported for HCV in Studies 1.1 and 1.2, it may be that the idiosyncratic 
disease characteristics associated with HCV, including a potential treatment cure, 
result in generally lower perceived negative illness related consequences, and 
lower levels of illness related concern for individuals living with HCV in 
comparison to other chronic conditions. Additionally, illness concern was not 
included in earlier versions of illness perception  measures, therefore relatively 
fewer studies have been conducted that have included the measurement of illness 
concern in comparison to illness consequence (Broadbent et al., 2015; Hagger & 
Orbell, 2003; Moss-Morris et al., 2002; Weinman et al., 1996).  
Treatment control, did not make significant contributions to any of the 
criterion measures reported in Studies 1.1 and 1.2. A number of earlier chronic 
disease studies that utilised illness perception measures identified a role for a 
combined cure/control variable to account for variance in physical and 
psychosocial adjustment (Heijmans, 1999; Rutter & Rutter, 2002; Vaughan et al., 
2003). Other chronic disease studies did not identify these same predictive links 
(Heijmans, 1998; Helder et al., 2002) A number of more recent studies that have 
measured treatment control separately from personal control, and consistent with 
results reported in Studies 1.1 and 1.2 did not identify a role for treatment control 
in accounting for variance in physical and psychosocial adjustment (Broadbent et 
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al., 2015; Rahimi, Baljani, & Zadgasem, 2012; Westbrook et al., 2016). For 
example, in a study conducted by Rahimi et al. (2012) treatment control did not 
account for variance in physical and psychosocial adjustment outcomes among 
individuals with end stage renal disease. Similarly, Westbrook et al. (2016) did not 
identify a role for treatment control to predict depression among a group of 
individuals with chronic lymphocytic leukaemia. Further, significant links were 
identified between treatment control and HCV treatment response reported in 
Studies 2.1 and 2.2. It may be that treatment cure is less relevant to physical and 
psychosocial adjustment among a number of chronic diseases including HCV, but 
more relevant to the prediction of treatment outcomes, such as is found in HCV, 
were a treatment cure is possible. 
 Maladaptive coping strategies (i.e., denial, substance use, venting, self-
blame, and behavioural disengagement) (Carver, 1997), were associated with 
physical and psychosocial adjustment among individuals with HCV. Consistent 
with previous work (Fortune et al, 2002; Helder et al., 2002; Heijmans, 1999; 
Rutter & Rutter, 2002), greater adoption of maladaptive coping strategies predicted 
higher depression and poorer physical health. For example, in a study conducted 
by Helder et al. (2002) among a group of individuals with psoriasis, coping 
strategies associated with emotional venting accounting for variance in depression, 
whilst increased adoption of coping strategies associated with behavioural 
disengagement predicted poorer physical health outcomes. Similarly, greater 
adoption of coping strategies associated with behavioural disengagement predicted 
higher depression in individuals with irritable bowel syndrome (Rutter & Rutter, 
2002). Further, similar to results in a number of other chronic disease studies 
(Hagger & Orbell, 2003; Rutter & Rutter, 2002), greater use of adaptive coping 
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strategies (referring to strategies related to mental disengagement, active coping, 
use of instrumental and emotional support, positive re-framing, planning, use of 
humour, acceptance, and use of religion) (Carver, 1997) predicted lower 
depression, and higher quality of life, as reflected in greater life satisfaction and 
positive affect ratings. For example, in a study conducted by Rutter & Rutter 
(2002) greater seeking of emotional support predicted lower depression among 
individuals living with irritable bowel syndrome. In this same study, greater 
adoption of coping strategies associated with illness acceptance predicted higher 
quality of life (Rutter & Rutter, 2002).  
Counterintuitively, the data reported in Studies 1.1 and 1.2 revealed 
maladaptive and active coping strategies were associated with higher life 
satisfaction and positive affect ratings. As noted, these results may reflect an 
idiosyncratic picture of living with chronic HCV in comparison to other chronic 
health conditions, and are worthy of consideration when assessing coping 
strategies in HCV sufferers. For example, in the face of high levels of HCV 
symptom reporting individuals may engage with both maladaptive (e.g., substance 
use) and adaptive coping strategies (e.g., active planning) simultaneously in an 
attempt to ameliorate their negative experience of HCV related symptoms, and at 
the same time improve overall quality of life as reflected in higher life satisfaction 
and positive affect.  
Other chronic disease studies that have utilised the SRM have not 
consistently included coping strategies in their modelling (Broadbent et al., 2015; 
Hagger & Orbell, 2003). Further, there has been a greater variety of coping 
measures used in comparison to the relatively more homogenous use of illness 
perception measures across chronic disease studies that have investigated whether 
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the SRM could account for physical and psychosocial adjustment (Hagger & 
Orbell, 2003). These factors may have contributed to greater variability in the 
reporting of coping strategies in comparison to those that have been reported for 
illness perceptions (Hagger & Orbell, 2003). Despite the counter-intuitive results 
reported for maladaptive coping reported in Studies 1.1 and 1.2 in relation to 
quality of life, maladaptive strategies accounted for significant variance in physical 
and psychosocial adjustment outcomes independently, and after controlling for 
illness perceptions. Similarly, adaptive coping strategies predicted life satisfaction 
and positive affect adjustment. Taken together, these results demonstrate the 
relative importance of coping strategies in accounting for HCV adjustment in 
comparison to results reported in a number of other chronic disease studies where 
coping made less consistent contributions to the prediction of adjustment 
(Broadbent et al., 2015; Hagger & Orbell, 2003; Heijmans, 1999; Scharloo et al., 
1998; Vaughan et al., 2003).    
Similar to results reported in a number of other chronic disease studies 
(Bower et al., 2005; Helgeson et al., 2006; Park et al., 2009; Tennen at al., 1992), 
greater benefit finding predicted increased quality of life outcomes in Study 1.1. 
For example, Bower et al. (2005) reported that among women who had been first 
diagnosed with breast cancer between one to five years previously, greater benefit 
finding was associated with positive affect. However, in a related study conducted 
by Tomich and Helgeson (2004) among women who had first been diagnosed with 
breast cancer four months previously, benefit finding did not predict positive affect 
adjustment outcomes.  Further, as reported in Study 1.1 and consistent with 
findings reported in Helgeson et al. (2006) benefit finding did not predict physical 
health adjustment. In contrast, in a study conducted by Luszczynska et al. (2007) 
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among individuals with human immunodeficiency virus, greater benefit finding 
predicted better physical health among this cohort of individuals. In accounting for 
the relative discrepant findings reported in other chronic disease studies reported 
here in relation to positive affect and physical health, de Ridder et al. (2008) 
following a review of a number of studies that investigated links between benefit 
finding and adjustment, found associations between longer time periods of time 
since initial diagnosis, the provision of benefit finding interventions and greater 
benefit finding. To assist in explaining any discrepant findings in future HCV 
studies that investigate links between benefit finding and adjustment, questions 
related to time since diagnosis and whether individuals had received benefit 
finding interventions should be included in assessment protocols.  
In Study 1.1, greater benefit finding predicted higher depression scores. 
Similar results were reported by McMillen and Fisher (1998) who suggested that 
the discovery of meaning and depression may reasonably occur simultaneously 
among individuals with chronic health conditions such as HCV. Further, in a study 
measuring benefit finding among a group of women with breast cancer, increased 
benefit finding predicted higher negative effect (Tomich & Helgeson, 2004). In 
contrast, greater benefit finding predicted lower depression among a group of 
individuals living with human immunodeficiency virus (Littlewood et al., 2008). 
Further, Helgeson et al. (2006) conducted a meta-analytic review to investigate 
whether benefit finding accounted for physical and psychosocial adjustment among 
individuals who had experienced adverse events including chronic disease. Overall 
findings found associations between greater benefit finding and lower depression 
(Helgeson et al., 2006). Taken together, it may be that for a number of chronic 
conditions, including HCV, the level of significance reported for associations 
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between benefit finding and depression may be of greater value then the direction 
of these predictive links.  
 As reported in Study 1.1, maladaptive coping mediated the relationships 
between illness identity and depression and between emotional response and 
depression, and partially mediated the relationship between illness identity and 
physical health. These results are partially consistent with mediation tests between 
illness perceptions, coping strategies and physical and psychosocial adjustment 
reported by Rutter and Rutter (2002), in which coping mediated some, but not all 
of the relationships between illness perceptions and adjustment among individuals 
living with irritable bowel syndrome. Specifically, greater adoption of maladaptive 
coping strategies associated with behavioural disengagement predicted higher 
depression (Rutter & Rutter, 2002). Other studies have not found the same efficacy 
for coping strategies to mediate relations between illness perceptions and 
adjustment (Hagger & Orbell, 2003; Heijmans, 1998). For example, Heijmans 
(1998) assessed whether coping mediated relations between illness perceptions and 
physical and psychosocial adjustment among a cohort of individuals with chronic 
fatigue syndrome. Results did not establish a role for coping in mediating relations 
between illness perceptions and adjustment (Heijmans, 1998). Further, relatively 
few chronic disease studies have included tests that have assessed the efficacy of 
coping to mediate relations between illness perceptions and adjustment (Broadbent 
et al., 2015; Hagger & Orbell, 2003). This has been due in part to the more mixed 
results reported overall for coping in comparison to illness perceptions which has 
consistently accounted for variance in physical and psychosocial adjustment 
reported across a number of chronic disease studies (Broadbent et al., 2015; 
Hagger & Orbell, 2003). 
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 Maladaptive coping strategies predicted depression and physical health 
adjustment independently, and after controlling for the contributions of illness 
perceptions reported in Studies 1.1 and 1.2. In comparison, adaptive coping 
strategies did not make significant contributions to the prediction of depression or 
physical health in either of these studies and therefore were not entered into tests 
for mediation. Further, maladaptive coping strategies mediated relationships 
between illness identity and depression, emotional response and depression, and 
partially mediated the relations between illness identity and physical health. In 
contrast to these results, active coping mediated the relationship between 
cure/control and physical health adjustment reported in Rutter and Rutter (2002). 
The results reported for HCV in Studies 1.1 and 1.2 may indicate a relatively 
greater importance regarding the role of maladaptive coping in the prediction and 
mediation of relations between illness perceptions and adjustment in comparison to 
adaptive coping strategies, and therefore support providing psychological strategies 
that seek to modify illness identity and emotional response perceptions, at the same 
time assisting individuals to adopt more adaptive coping strategies with the aim of 
improving depression and physical health adjustment.        
As reported in Study 1.1, no previous published research as assessed for 
links between benefit finding and physical and psychosocial adjustment within the 
context of HCV. Further, relatively few studies have assessed the efficacy of 
benefit finding to mediate the relationship between illness perceptions and physical 
and psychosocial in other chronic disease studies (Helgeson et al., 2006; de Ridder 
et al., 2008). In one study that did conduct tests for mediation, Luszczynska et al. 
(2007) identified a role for benefit finding to mediate relations between self-
efficacy (closely related to personal control) and physical adjustment among a 
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cohort of individuals living with the human immunodeficiency virus. Importantly, 
as reported in Study 1.1, benefit finding mediated the relationships between 
personal control and life satisfaction, and between personal control and positive 
affect. These results support the inclusion of psychological interventions that seek 
to strengthen personal control perceptions or more internally focussed locus of 
control beliefs along with benefit finding ability or assisting individuals to 
discovery positive meaning in relation to their HCV, with the aim of improving 
quality of life outcomes.  
Including benefit finding within the SRM reported in Study 1.1 is an 
extension to the original SRM model which describes ongoing dynamic casual 
relationships between illness perceptions and health related outcomes, mediated by 
coping (Leventhal et al., 1980). A recommendation for future HCV research that 
utilises an expanded SRM would be to adopt longitudinal designs that would allow 
greater testing of the direction of causality in the relationships between illness 
perceptions, coping, benefit finding, and physical and psychosocial adjustment 
(Hagger & Orbell, 2003). Importantly, utilising longitudinal designs would also 
enhance the potential for the identification of roles for coping and benefit finding 
to mediate relations between illness perceptions and adjustment within the context 
of HCV in comparison to non-dynamic cross-sectional designs (Hagger & Orbell, 
2003).     
8.3 Relations Between Illness Perceptions, Coping, Benefit Finding, and HCV 
Treatment Response – Review of Longitudinal Studies. 
 Study 2.1 investigated whether baseline illness perceptions and coping 
strategies predicted HCV recovery after controlling for pre-treatment biomedical, 
clinical, behavioural and demographic variables. As reported in Study 2.1, only 
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treatment control, mental health comorbidity and use of recreational drugs 
demonstrated significant associations with HCV treatment response, and were 
therefore entered into subsequent logistic regression analysis. The results indicated 
that mental health comorbidity and increased use of recreational drugs predicted 
treatment response.  It may be that the relatively counter-intuitive direction of the 
relationships of mental health comorbidity and the use of recreational drugs to 
treatment response, was due in part to the use of a dichotomous yes or no response 
format used to elicit information on these complex variables, that may not have 
provided a broad enough context to differentiate between specific mental health 
conditions, types of substance use and their potential contributions to the 
prediction of HCV treatment response. Future research in this area would do well 
to consider including specific mental health conditions and types of recreational 
drugs that have been identified as having high prevalence among individuals living 
with HCV (i.e., depression and intravenous drug use) (Chen & Morgan, 2006; 
Golden et al., 2006; Lee & Abdo, 2003; Shiffman et al., 2004). However, other 
research has identified a role for the use of recreational drugs to improve HCV 
treatment response rates (Costiniuk et al., 2008; Sylvestre et al., 2006). In contrast, 
another study did not find the same results (Liu et al., 2014). Interestingly, in 
relation to links between reported mental health comorbidity and HCV treatment 
response Sockalingham & Abbey (2009) reported early identification and 
treatment of depression in individuals presenting for HCV treatment predicted 
improved HCV treatment response outcomes.      
 Consistent with a related chronic disease study (Chilcot et al., 2011), after 
controlling for mental health comorbidity and recreational drug use, perceptions 
related to treatment control predicted HCV treatment response. The results 
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reported in the present thesis provide support for the inclusion of cognitive 
variables, such as illness perceptions, in future HCV treatment studies. Clinically, 
the identification of treatment control as a predictor of HCV treatment response 
opens the potential to improve biomedical treatment outcomes for individuals 
undertaking HCV treatment by altering maladaptive illness perceptions. In 
comparison to illness perception components, very few studies have investigated 
the ability of coping strategies to predict biomedical treatment outcomes (Hagger 
& Orbell, 2003). Therefore, the results for coping have a significantly lower 
existing evidence base across chronic disease studies in comparison to illness 
perceptions. This in turn limits the ability to conduct benchmarking analysis which 
may have helped to explain or account for the failure of coping strategies to predict 
HCV treatment response as reported in Study 2.1.  
 Study 2.2 investigated whether benefit finding could predict HCV 
treatment response after controlling for the clinical and behavioural variables over 
and above the contributions of treatment control. In Study 2.2 treatment control 
predicted HCV treatment response outcomes. Interestingly, after including benefit 
finding in the predictive model both the reporting of mental health comorbidity and 
the use of recreational drug use no longer made significant contributions to the 
model. In Study 2.2, lower benefit finding predicted HCV treatment response after 
accounting for the contributions of treatment control, mental health comorbidity 
and the use of recreational drugs. This relatively counter-intuitive result is 
consistent with the findings reported in Study 1.1, and with a number of other 
chronic disease studies that identified both intuitive and counter-intuitive results 
whilst investigating links between benefit finding, physical and psychosocial 
adjustment and biomedical treatment outcomes (de Ridder et al., 2008; Helgeson et 
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al., 2006; McMillen & Fisher, 1998). For example, as reported in Study 1.1, 
Tomich and Helgeson (2004) conducted a study among women who had recently 
been diagnosed with breast cancer. At 3-9 months follow up, benefit finding 
predicted higher depression. In a more expected direction, Bower et al., (1998) 
found that benefit finding predicted a more favourable immune status among 
individuals with human immunodeficiency virus at 2-3 year follow up and 
decreased mortality rates after 4-9 years.  
Overall, results reported in the present thesis and across a number of other 
chronic health conditions have demonstrated a role for benefit finding in predicting 
biomedical outcomes, and accounting for variance in physical and psychosocial 
adjustment (de Ridder et al., 2008; Helgeson et al., 2006; McMillen & Fisher, 
1998). Importantly, the present thesis is the first to demonstrate that benefit finding 
can predict HCV psychosocial adjustment and biomedical treatment outcomes 
within the context of an expanded SRM.  
8.4 Review of Supplementary Longitudinal Study  
 Results of the longitudinal analysis reported in Study 2.3 identified the role 
of depression in predicting HCV treatment response after controlling for the use of 
recreational drugs. Lower reported depression predicted HCV treatment response. 
As outlined in Study 2.3, this result has important implications for clinical settings 
related to HCV, and provides support for the inclusion of comprehensive mood 
assessments for individuals presenting for HCV treatment. Contrary to 
expectations, physical health failed to predict HCV treatment response. As 
recommended in Study 2.3, future HCV studies may benefit from assessing 
individual physical health areas and their respective relations with HCV treatment 
response, rather than utilising the total scores of a number of physical health 
144 
 
related variables as used in the present thesis. Similarly, both life satisfaction and 
positive affect failed to predict HCV treatment response outcomes. Future HCV 
focussed research may benefit from utilising quality of life related variables that 
have demonstrated the efficacy to predict biomedical treatment outcomes in other 
areas of chronic disease.    
8.5 Empirical Limitations 
Firstly, future studies utilising the SRM within the context of HCV may 
benefit from adopting longitudinal designs to enable a more effective assessment 
of some of the dynamic aspects of the SRM (e.g., ongoing feed-back loop between 
features of the model) and help to limit the potential that cross-sectional designs 
have to generalise results of studies over time (Leventhal et al., 1997). Secondly, 
the sample size at Time 2 was relatively small compared to the baseline sample 
size at Time 1. One potential recommendation is to consider moving away from an 
anonymous online data collection design as used in the present study, and rather 
focus on clinic based, face to face approach that may potentially increase response 
rates, particularly at follow up data collection periods. Further, some of the 
methodological limitations (e.g., potential response bias) associated with the use of 
self-report yes/no response questions for measuring clinical, behavioural and 
demographic information may have contributed to the counter-intuitive findings 
regarding adherence, drug use and comorbidity. Future related studies could 
consider using standardised clinical measures for assessing medication adherence 
and other clinical markers such as substance use and mental health as a way of 
potentially avoiding some of the more counter-intuitive results reported in the 
present thesis.  
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A relatively large number of regression analyses were performed in the 
present thesis. Future related studies that conduct a similar number of regression 
tests may consider setting a more stringent p value to control for potential Type 1 
errors, then the p < .05 value that was utilised in regression tests reported in the 
present thesis. However, due in part to the relatively challenging process of 
recruiting study participants among HCV sufferers, it was intentionally decided not 
to control for potential Type 1 errors in regression analyses reported in the present 
thesis. This strategy which has support from a theoretical perspective (Tabachnik 
& Fidell, 2001), particularly when as in the present thesis ranges of scores were 
regressed against each other, allowed all potentially meaningful relationships 
between variables to be revealed.  Finally, Sobel tests for mediation were utilised 
in the present thesis (Baron & Kenny, 1986). This traditional method for testing for 
mediation between variables has strong theoretical support in the literature 
providing the primary rationale for including this approach in the present thesis 
(Barron & Kenny, 1986). However, future studies may benefit from considering 
more recent mediation approaches, such as bootstrapping to compliment the use of 
Sobel tests when conducting mediation analyses, particularly if investigators are 
seeking to increase the power of the study which can at the same time reduce the 
potential for Type II errors (Barron & Kenny, 1986; Preacher & Hayes, 2004). 
Further, bootstrapping also does not rely as heavily as the Sobel method for 
assumptions of normality to be met (Preacher & Hayes, 2004). However, the 
bootstrapping method can be more vulnerable in comparison to the Sobel method 
to the presence of outliers in the data which can increase the potential for Type 1 
errors to occur particularly when there is a relatively small participant sample as 
was reported in the present thesis (Preacher & Hayes, 2004).  
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8.6 Conclusion and Future Directions 
 A number of studies have demonstrated the efficacy of illness perceptions, 
coping and benefit finding to account for variance in physical and psychosocial 
adjustment and bio-medical treatment outcomes across a range of diverse chronic 
health conditions (Broadbent et al., 2015; de Ridder et al., 2008; Hagger & Orbell, 
2003; Helgeson et al., 2006; McMillen & Fisher, 1998). The present thesis 
produced results consistent with previous work within the novel area of HCV. The 
data reported here demonstrated that key individual and combined features of an 
expanded SRM (refer Appendix A), including illness perceptions, coping and 
benefit finding, could predict physical and psychosocial adjustment and treatment 
response among individuals with HCV. Additionally, both coping and benefit 
finding demonstrated efficacy in mediating some of the relationships between 
illness perceptions and physical and psychosocial adjustment, and lower 
depression predicted HCV treatment response. Finally, important to clinical 
practice, and consistent with other areas of chronic disease (Chilcot & Moss-
Morris, 2013; de Ridder et al., 2008; McMillen & Fisher, 1998), results reported in 
the present thesis support providing psychological interventions that target 
maladaptive illness perceptions and coping strategies along with providing 
opportunities for individuals to discover illness related benefits or positive 
meaning, and for conducting comprehensive mood assessments for individuals 
presenting for HCV treatment.  
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Pre-Treatment Survey (Survey 1) 
 
Welcome to the Hepatitis C treatment outcome prediction study. We would invite 
you to complete the following survey. Your valued contribution will help us to 
better predict Hepatitis C treatment outcomes. A second survey will be sent out to 
you following either your 8 week milestone blood test (if you are on the ‘triple 
therapy programme’), or your 12 week milestone blood test (if you are on the 
ribavirin and interferon combination therapy programme). The second survey will 
measure both treatment progress and levels of medication adherence.  
 
This survey will take approximately 45 minutes to complete. Thank you again for 
assisting us with our research, it is greatly appreciated. 
 
Section A: Questions about you and your Hepatitis C  
 
(1) What is your email address? 
 
_____________________________________ 
 
 
(2) What sex are you? 
 
□ Male 
□ Female 
□ Other (Please specify_______________________________________) 
 
(3) What is your date of birth? (DD/MM/YY) 
 
□ □ □ □ □ □ 
 
 
(4) What was your highest level of education completed? 
 
□ Primary School 
□ High School – Year 10 
□ High School – Year 12 
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□ Diploma or Certificate 
□ Undergraduate degree 
□ Post-Graduate degree 
□ Other (Please specify________________________________________) 
 
(5) Which of the following best describes your present employment/study 
situation? (Please mark with an X as many boxes that apply to you) 
 
□ Full-time Employment 
□ Part-time Employment 
□ Full-time study 
□ Part-time study 
□ Home duties 
□ Volunteer work 
□ Retired 
□ Looking for work 
□ Unable to work due to illness 
□ Not presently looking for work 
 
(6) Which of the following best describes your present support/living 
situation? 
 
□ Live with partner/spouse 
□ Live alone 
□ Live with dependent children 
□ Live with other family members 
□ Live with others (ex; flatmates/friends) 
□ Other (Please specify_______________________________________) 
 
(7) What is your present relationship status? 
 
□ Married 
 
□ Single 
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□ Divorced 
 
□ Separated from your partner 
 
□ Other (Please specify _______________________________________) 
 
(8) Do you hold any religious/spiritual beliefs? 
 
□  Yes 
 
□ No 
 
(9) If Yes, How would you define your religious/spiritual beliefs?  
 
□ Christian 
 
□ Jewish 
 
□ Muslim 
 
□ Buddhist 
 
□ New Age 
 
□ Other (Please specify ______________________________________) 
 
 
(10) How would you describe your ethnic background?  
 
□ Australian Aboriginal 
 
□ Torres Strait Islander 
 
□ Maori 
 
□ Pacific Islander (e.g., Fijian, Samoan) 
 
□ North-West European (e.g., English, German, Irish) 
 
186 
 
□ Southern and Eastern European (e.g., Spanish, Russian, Italian)  
 
□ North African (e.g., Egyptian, Libyan) 
 
□ Middle Eastern (e.g., Iranian, Saudi Arabian) 
 
□ Asian (e.g., Chinese, Indian) 
 
□ Other  (Please specify __________________________________) 
 
  
 
 
(11)   How much do you weigh? If uncertain, please give your best estimate 
 
________ KG 
 
Or 
 
________       Pounds 
 
Or  
 
________      Stone 
 
(12)   How tall are you? If uncertain, please give your best estimate 
 
 
____  .  ____ Meters 
 
Or 
 
___________  Centimetres 
 
 
(13)  Most likely route of Hepatitis C infection? 
 
□ IV drug use 
 
□ Blood Transfusion 
 
□ Other 
 
□ Unknown 
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(14) Most likely length of Hepatitis C infection? 
 
 Months _____________________ 
 
Years    ______________________ 
 
□ Not known 
 
(15)  Have you ever had a liver biopsy or scan? 
 
□ Yes 
 
□ No 
 
(16) If yes to Question 10, did the liver Biopsy or scan results indicate the        
presence of Cirrhosis of the liver? 
 
□ Yes 
 
□ No 
 
(17)  Have you ever been diagnosed with liver cancer? (also know as 
Hepatocellular Carcinoma) 
 
□ Yes 
 
□ No 
 
(18) Have you ever had a test to find out the particular type of HCV Genotype you 
have?  
 
□ Yes 
 
□ No 
 
(19) If yes, what was the result of this test? (eg, Genotype 1, 2, 3, 4, 5 or 6?) 
 
□ Genotype 1 
 
□ Genotype 2 
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□ Genotype 3 
 
□ Genotype 4 
 
□ Genotype 5 
 
□ Genotype 6 
 
(20) Have you ever had previous treatment for Hepatitis C?  
 
□ Yes 
 
□ No 
 
(21)  If yes, was the prescribed treatment 
 
□ Combined therapy using Ribavirin and Peginteferon (injection self-
administered once a week) 
 
□ Combined therapy using Ribavirin and Interferon (injection self-
administered more than once a week) 
 
□ Interferon monotherapy 
 
(22)  Have you ever been diagnosed with any other type of liver disease?  
 
□ Yes 
 
(23)  If yes, what type of liver disease? 
 
□ Steatohepatitis (a condition associated with fatty inflammation of the liver) 
 
□ Hepatitis B 
 
□ Other (If known, what type?) 
 
 ________________________________________ 
 
□ No 
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(24)  Do you have any other medical conditions that you are currently receiving 
treatment for?  
 
□ Yes 
 
(25) If yes, what medical condition/s are you receiving treatment for? 
 
(1) ___________________________________________ 
 
(2) ___________________________________________ 
 
(3) ___________________________________________ 
 
□ No 
 
(26)  In the past week, have you used illegal recreational drugs? 
 
□ Yes (injectable drugs) 
 
□ Yes (non-injectable drugs)  
 
□ Yes (both injectable and non-injectable drugs) 
 
□ No 
 
 
 
 
(27)  In the past week, have you consumed any alcohol? 
 
□ Yes 
 
(28) If yes, please insert in the box below how many standard drinks you 
consumed in the past week? (One standard drink is equal to a glass or pot of beer, 
or a glass of wine, or a single shot of spirits) 
 
________________________________________
_  
 
□ No 
 
(29)  In the past week, have you smoked any cigarettes? 
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□ Yes 
 
(30) If yes, please insert in the box below how many cigarettes you usually smoke 
per day 
 
________________________________________ 
 
□ No 
 
(31) Do you have any mental health condition/s that you are currently receiving 
medication based treatment for? (e.g. depression/anxiety/psychosis) 
 
□ Yes 
 
(32)   If yes, what are the name/s of these mental health condition/s? 
 
(1) ______________________________________________ 
 
(2) ______________________________________________ 
 
(3) ______________________________________________ 
 
□ No 
 
(33) Do you know what date you are starting treatment for your Hepatitis C? 
 
□ Yes 
 
(34)     If yes, please enter the date you are starting treatment 
 
Day _______________________________ 
 
Month ________________________________ 
 
Year ________________________________ 
 
□ No 
 
(35) Do you know what type of Hepatitis C treatment you will be receiving? 
 
□ 12 month combined Interferon and Ribavirin treatment 
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□ 6 month combined Interferon and Ribavirin treatment 
 
□ ‘Triple therapy’ (Interferon, Ribavirin and Boceprevir) 
 
□ ‘Triple therapy’ (Interferon, Ribavirin and Telaprevir) 
 
(36) Have you had the pre-treatment IL28B genotype test used to predict Hepatitis 
C treatment response? 
 
□ Yes 
□ No 
 
(37)  If yes, what was the result of this test? 
 
______________ % 
 
Section B: Coping with stress 
 
 
We are interested in how people respond when they confront difficult or stressful 
events in their lives. There are lots of ways to try to deal with stress. The following 
questions ask you to indicate what you generally do and feel, when you experience 
stressful events. Obviously, different events bring out somewhat different 
responses, but think about what you usually do when you are under a lot of stress. 
Please respond to each of the following items by inserting a number in the 
corresponding box for each item from the following four choices below, which 
best describes what you do when you experience a stressful and/or difficult event 
in your life.   
 
1 = I usually don’t do this at all. 
2 = I usually do this a little bit. 
3 = I usually do this a medium amount. 
4 = I usually do this a lot. 
 
(38) I turn to work or other activities to take my mind off things.  
 □ 
(39) I concentrate my efforts on doing something about the situation I am                                   
in.           
 □ 
(40) I say to myself “this is not real.”      
 □ 
(41) I use alcohol or other drugs to make myself feel better.   
 □ 
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(42) I try to get emotional support from others.    
 □ 
(43) I give up trying to deal with it.      
 □ 
(44) I take action to try to make the situation better.    
 □ 
(45) I refuse to believe that it has happened.     
 □ 
(46) I say things to let my unpleasant feelings escape.   
 □ 
(47) I try to get advice and help from other people.    
 □ 
(48) I use alcohol or other drugs to help me get through it.   
 □ 
(49) I try to see it in a different light, to make it seem more positive. 
 □ 
(50) I criticize myself.       
 □ 
(51) I try to come up with a strategy about what to do.   
 □ 
(52) I try to get comfort and understanding from someone.   
 □ 
(53) I give up the attempt to cope.      
 □ 
(54) I look for something good in what is happening.   
 □ 
(55) I make jokes about it.       
 □ 
(56) I do something to think about it less, such as going to the movies, watching 
TV, reading, daydreaming, sleeping or shopping.     
 □ 
(57) I accept the reality of the fact that it has happened.   
 □ 
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(58) I express my negative feelings.      
 □ 
(59) I try to find comfort in my religion or spiritual beliefs.   
 □ 
(60) I try to get advice or help from other people about what to do.  
 □ 
(61) I learn to live with it.       
 □ 
(62) I think hard about what steps to take.     
 □ 
(63) I blame myself for things that happened.    
 □ 
(64) I pray or meditate.       
 □ 
(65) I make fun of the situation.      
 □ 
 
Section C: Hepatitis C and illness perceptions 
 
Research has shown that individuals tend to cluster their ideas about an illness 
such as Hepatitis C around coherent themes or components. Collectively these 
themes or components make up an individual’s perception of their illness. 
Importantly, illness perceptions provide a framework for individuals to make sense 
of their illness experience, which will in turn influence action and coping 
strategies. For the following questions, please insert the number from the scale 
under each question that best corresponds to your views regarding your Hepatitis C 
(HCV): 
 
 
(66) How much does your HCV affect your life?                                     
□                                         0 1 2 3
 4 5 6 7 8 9 10 
No affect at all     Severely affects my life 
 
 
(67) How long do you think your HCV will continue?   
 □ 
0 1 2 3 4 5 6 7 8 9 10 
A very short time       Forever 
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(68) How much control do you feel you have over your HCV?  
 □ 
0 1 2 3 4 5 6 7 8 9 10 
Absolutely no control     Extreme amount of control 
 
 
(69) How much do you think your treatment can help your HCV?                            
□                       0 1 2 3 4 5 6 7
 8 9 10 
Not at all       Extremely helpful 
 
(70) How much do you experience symptoms from your HCV?                            
 □                       0 1 2 3 4 5 6
 7 8 9 10 
No symptoms at all     Many severe symptoms 
 
(71) How concerned are you about your HCV?                              
 □                       0 1 2 3 4 5 6
 7 8 9 10 
Not at all concerned      Extremely concerned  
 
(72) How well do you feel you understand your HCV?                           
□                       0 1 2 3 4 5 6 7
 8 9 10 
Don’t understand at all     Understand very 
clearly 
 
(73) How much does your HCV affect you emotionally (e.g. does it make you 
angry, scared , upset or depressed?)                              
 □                       0 1 2 3 4 5 6
 7 8 9 10 
Not at all affected emotionally   Extremely affected 
emotionally 
 
 
(74) Please list in rank-order the three most important factors that you believe 
caused your HCV. The most important causes for me:- 
 
1. ___________________________________________________ 
 
2. ___________________________________________________ 
 
3. ____________________________________________________ 
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Section D: Hepatitis C and physical health 
 
Hepatitis C can potentially contribute to illness related symptoms that can be 
associated with changes in physical health and activity levels. The following 
questions are taken from the RAND 36-item Medical Outcomes Study and relate to 
your physical health. For each question please respond by marking the box that 
best applies to you with an X. 
 
(75) In general, would you say your health is: 
 
Excellent  □ 
Very good  □ 
Good   □ 
Fair   □ 
Poor   □ 
 
(76) Compared to one year ago, how would you rate your health in general now? 
 
Much better now than one year ago  □ 
Somewhat better now than one year ago □ 
About the same    □ 
Somewhat worse now than one year ago □ 
Much worse than one year ago  □ 
 
The following items are about activities you might do during a typical day. Does 
your health now limit you in these activities? If so, how much? 
 
     Yes, limited Yes, limited No, not  
     a lot  a little  limited at all 
 
 
(77) Vigorous activities, such as running, □   □   □  
       Or Lifting heavy objects. 
(78) Moderate activities, such as bowling, □   □    □ 
   Or pushing a vacuum cleaner 
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(79) Lifting or carrying groceries  □  □  □ 
(80) Climbing several flights of stairs □  □  □ 
(81) Climbing one flight of stairs  □  □  □ 
(82) Bending, kneeling, or stooping  □  □  □ 
(83) Walking more then a mile  □  □  □ 
(84) Walking several blocks   □   □   □  
(85) Walking one block    □  □  □ 
(86) Bathing or dressing yourself  □  □  □ 
 
During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of your physical health? 
 
  
          Yes
 No 
(87) Cut down the amount of time you spent on work or other activities □
 □ 
(88) Accomplished less than you would like     □
 □ 
(89) Were limited in the kind of work or other activities   □
 □ 
(90) Had difficulty performing the work or other activities   □
 □ 
        (for example, it took extra effort) 
 
 
 
 
(91) How much bodily pain have you had during the past 4 weeks? 
 
None    □ 
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Very mild   □ 
Mild    □ 
Moderate   □ 
Severe    □ 
Very severe   □ 
 
(92) During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
 
Not at all   □ 
A little bit   □ 
Moderately   □ 
Quite a bit   □ 
Extremely   □ 
 
 
How TRUE or FALSE is each of the following statements for you. 
 
     Definitely   Mostly   Don’t   Mostly   
Definitely     true         true        know    false      
false  
 
(93) I seem to get sick a lot easier  
       then other people.  □  □ □ □ □ 
(94) I am as healthy as anybody □  □ □ □ □ 
        I know. 
(95) I expect my health to get 
        Worse    □  □ □ □ □ 
(96) My health is excellent   □  □ □ □ □ 
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Section E: Hepatitis C, mood, anxiety and stress levels 
 
Please read each statement and insert in the corresponding box for each statement a 
number from the rating scale below which indicates how much the statement 
applied to you over the past week. Please note that there are no right or wrong 
answers. 
 
The rating scale is as follows: 
 
 
0 Did not apply to me at all 
1 Applied to me to some degree, or some of the time 
2 Applied to me to a considerable degree, or a good part of time 
3 Applied to me very much, or most of the time 
 
(97) I found it hard to wind down      
 □ 
(98) I was aware of dryness of my mouth     
 □ 
(99)  I couldn’t seem to experience any positive feeling at all  
 □ 
(100) I experienced breathing difficulty (eg, excessively rapid breathing, 
breathlessness in the absence of physical exertion)    □ 
(101) I found it difficult to work up the initiative to do things  
 □ 
(102) I tended to over-react to situations     
 □ 
(103) I experienced trembling (eg, in the hands)    
 □ 
(104) I felt that I was using a lot of nervous energy    □ 
(105) I was worried about situations in which I might panic and make a  
fool of myself         □ 
     (106) I felt that I had nothing to look forward to    
 □ 
     (107) I found myself getting agitated     
 □ 
     (108) I found it difficult to relax      
 □ 
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     (109) I felt down-hearted and blue     
 □ 
     (110) I was intolerant of anything that kept me from getting on with what  
             I was doing        
 □ 
     (111) I felt I was close to panic      
 □ 
     (112) I was unable to become enthusiastic about anything  
 □ 
     (113) I felt I wasn’t worth much as a person    
 □ 
     (114) I felt that I was rather touchy     
 □ 
     (115) I was aware of the action of my heart in the absence of physical exertion 
             (eg, sense of heart rate increase, heart missing a beat)  
 □ 
     (116) I felt scared without any good reason    
 □ 
     (117) I felt that life was meaningless     
 □ 
 
Section F: Hepatitis C, effects on emotions, and levels of life satisfaction  
 
For the following questions, please think about how you have felt over the past few 
weeks and indicate on the following scale how relevant each of the statements have 
been to you. For each question please insert the relevant number from the rating 
scale below in the box alongside each question 
 
The rating scale is as follows: 
 
Not at all 1 
Rarely  2 
Sometimes 3 
Often  4 
Very Often 5 
 
 
(118)  Particularly excited or  □ 
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 Interested in something 
 
(119) Proud because someone □ 
 Complimented you on 
 Something you had done 
 
(120) Pleased about having  □ 
 Accomplished something 
  
(121) On top of the world  □ 
 
(122) That things were going □  
 your way 
 
This next set of questions measures life satisfaction levels. For each of the five 
statements below, please insert in the box provided the number that best describes 
how you feel, using the scale below as a guide. 
 
Strongly disagree  1 
Disagree   2 
Slightly disagree  3 
Neither agree or disagree 4 
Slightly agree   5 
Agree    6 
Strongly Agree  7 
 
(123) In most ways my life is close to my ideal □ 
 
(124) The conditions of my life are excellent  □ 
 
(125) I am satisfied with my life   □ 
 
(126) So far I have gotten the important things □ 
      I want in my life. 
 
(127) If I could live my life over, I would change □  
      almost nothing 
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Section G: Hepatitis C and personal growth 
 
 
It is possible for individuals living with Hepatitis C to experience positive personal 
growth. The following section will ask you to indicate how well each of the 
following statements describes your experience of living with Hepatitis C using the 
scale provided below. For each statement, please insert a number from this scale in 
the box provided for each statement that best describes your experience of living 
with this illness. 
 
 
0   1   2   3      
4 
Not at all like         Very 
much  
My experience        like my  
         
 Experience 
 
 
 
 
(128) This illness has taught me that I can handle anything   
 □ 
 
 
(129) As a result of this illness, I am more afraid that bad things will happen to 
me□ 
 
 
(130) As a result of this illness, I am more sensitive to the needs of others 
 □ 
 
 
(131) I have gained financially as a result of this illness   
 □ 
 
 
(132) Because of this illness, I have learnt how good people can be  
 □ 
 
 
(133) Because of this illness, I have a greater faith in God   
 □ 
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(134) As a result of this illness, I feel worse about myself   
 □ 
 
 
(135) Because of this illness, I live my life more simply   
 □ 
 
 
(136) Because of my experiences with this illness, I have learnt how to cope more 
effectively         
 □ 
 
 
(137) Because of this illness, I am more compassionate to those in similar 
situations          
 □ 
 
 
(138) Because of this illness, I feel more a part of my community  
 □ 
 
 
(139) As a result of this illness, I have learnt that my family loves me 
 □ 
 
 
(140) Because of this illness, I am a more assertive person   
 □ 
 
 
(141) Because of this illness, I am more understanding of those in need 
 □ 
 
 
(142) Because of this illness, I am more spiritual    
 □ 
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(143) As a result of this illness, I trust people less    
 □ 
 
 
(144) Because of this illness, I am more aware of how much my family means to 
me          
 □ 
 
  
(145) Because of this illness, I am more aware of how much people care for one 
another         
 □ 
 
 
(146) As a result of this illness, I am more withdrawn from people  
 □ 
 
 
(147) I am a more effective person because what I have gone through with this 
illness          
 □ 
 
 
(148) Because of this illness, I have a greater faith in other people  
 □ 
      
 
(149) Because of this illness, I know my neighbours better   
 □ 
 
 
(150) Because of this illness, I find myself placing less emphasis on material 
things□ 
  
 
(151) Because of this illness, I show more caring to others   
 □ 
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(152) As a result of this illness, I have been harmed financially  
 □ 
 
 
(153) Because of this illness, I feel more positive about my community 
 □ 
 
 
(154) Because of this illness, I am more religious    
 □ 
 
 
(155) As a result of this illness, I have lost all faith in other people  
 □ 
 
 
(156) This illness has made me a stronger person    
 □ 
 
 
(157) This illness has taught me that people will always be there for you 
 □ 
 
 
(158) As a result of this event, I live more for the moment   
 □ 
 
 
(159) As a result of this illness, it is harder for me to get close to people 
 □ 
 
 
(160) Because of this illness, I am closer to my neighbours   
 □ 
 
 
(161) Because of this illness, my priorities in life are different  
 □ 
 
 
205 
 
(162) As a result of this illness, I have gained material possessions  
 □ 
 
 
(163) As a result of this illness, my life is more complicated  
 □ 
 
 
(164) Because of this illness, I am a more capable person   
 □ 
 
 
(165) Because of this illness, I am closer to people I care about  
 □ 
 
Section H. Just three more closing questions! 
 
(166) How did you hear about the survey? 
 
Public or government hospital    □ 
 
Private Hospital or clinic     □ 
 
General practitioner      □ 
 
Hepatitis C community support agency   □ 
 
Other (please specify)      □ 
 
_______________________________________________ 
 
 
(167) On what date  did you complete the on-line survey? (DD/MM/YY) 
 
 
______________________________________________ 
 
 
(168) Where will you be receiving your HCV treatment? 
 
206 
 
Public or government hospital    □ 
 
Private Hospital or clinic     □ 
 
General practitioner      □ 
 
 
Other (please specify)      □ 
 
_______________________________________________ 
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Thank you! 
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Post-commencement of treatment questions (survey 2). 
 
In reference to Hepatitis C treatment outcomes. Can you please indicate below 
what blood tests (known as ‘PCR’ tests) you have had since commencing your 
Hepatitis C treatment programme and indicate what the results of each of these 
tests were? 
 
 
 
 (1) Week 4 PCR test result 
□ Hepatitis C virus was detected in my blood 
□ Hepatitis C virus was not detected in my blood 
□ PCR test was not conducted at this milestone treatment period 
 
(2) Week 8 PCR test result 
□ Hepatitis C virus was detected in my blood 
□ Hepatitis C virus was not detected in my blood 
□ PCR test was not conducted at this milestone treatment period 
 
(3) Week 12 PCR test result 
□ Hepatitis C virus was detected in my blood 
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□ Hepatitis C virus was not detected in my blood 
□ PCR test was not conducted at this milestone treatment period 
In reference to taking your Hepatitis C medication since commencing treatment 
(4) During the first 12 weeks of treatment, did you take your medication as 
prescribed?   
 
□ Yes 
□ No 
 
(5) On what date did you complete this on-line survey? (DD/MM/YY) 
 
 
_______________________________________________ 
 
 
(6) What is your email address? 
 
 
______________________________________________ 
 
Thank You! 
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Participant Information Sheet 
 
 
 
 
 
Principal Investigators 
 
 
Dr Mark Edwards 
Associate Professor and Research Project Supervisor 
Head and Chair of Psychology 
Faculty of Humanities and Social Sciences 
Bond University 
Gold Coast, Qld, 4229 
Australia 
(07) 55 95 2673 
 
Dr Mike Lyvers 
Associate Professor 
 
Dr Peta Stapleton 
Associate Professor 
 
Mr Simon A. Langston 
PhD Student Researcher 
Faculty of Humanities and Social Sciences 
Bond University 
Gold Coast, Qld 4229 
Australia 
(07) 55 95 1111 
 
 
 
 
 
Project Title: The Hepatitis C Treatment Outcome Study 
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Project Summary 
 
You are invited to take part in a study designed to determine some of the physical, 
psychological, and social factors associated with Hepatitis C treatment outcomes. 
Previous research has indicated that certain physical and psychological profiles 
predict better treatment outcomes across a range of medical conditions. However, 
little is known of how these factors predict treatment outcomes in Hepatitis C. The 
primary objective of this research is to increase understanding of 
individual profiles that are associated with better Hepatitis C treatment outcomes. 
 
What’s Involved? 
 
We are inviting individuals who are over the age of 18 years, who have a current 
diagnosis of Hepatitis C, who have access to the internet and a current email 
address, and who are planning to commence Hepatitis C treatment, to complete 
two confidential online surveys. Specifically, we require your email address so that 
we can send you a link to the second survey at the appropriate time. The first 
survey must be completed prior to the commencement of treatment. A link to the 
second survey will be sent out to participants 14 weeks after commencing 
treatment. The first survey should take 35-40 minutes to complete, whilst the 
second survey can be completed in 5-10 minutes. 
 
Participation in this research is voluntary and any information you provide is 
completely confidential. Your email address and responses to the survey are not 
linked to any information that could personally identify you. Only the principal 
investigators will have access to your email address. You have the right to 
withdraw from the research at any time, and without penalty. 
 
Prior to commencing the survey you will be asked to read the ‘participant consent 
acknowledgment’ section below. If you then agree to participate, you will be asked 
to check an acknowledgement box confirming your consent to voluntarily 
participate in the study. Clicking on a link directly below this acknowledgement 
box will lead you into the first survey. 
Questions included in the online surveys will cover some of the following areas: 
 Demographic information (For example, your gender, age and employment 
status) 
 Medical information (For example, your Hepatitis C genotype, the general 
condition of your liver, and questions related to your general overall health) 
 Psychological (For example, questions assessing how much Hepatitis C has 
impacted individuals lives, and further questions related to individual 
coping styles and general mental health) 
 
 
 
 
 
Benefits to Participants 
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At regular intervals, result summaries and other relevant Hepatitis C based 
education and information will be posted on our website blog page. This 
information may be useful for individuals preparing for and undergoing treatment 
for Hepatitis C. Further, in recognition for the time and effort involved in 
participating in this research, participants who meet the eligibility criteria for 
participating in this study (decision at the discretion of the PhD student researcher), 
will be sent a AUS $20 Amazon gift voucher after completing both the online 
surveys. 
 
 
 
Storage of Collected Information 
 
We value your privacy and right to have your information treated in the strictest 
confidence. All collected information will be stored electronically in a password 
secured file at the Bond University and only the principal investigators will have 
access to this information. 
 
Potential Risks to Participants 
 
If participating in this study results in any level of distress beyond the normal 
experience of everyday life, we would recommend that you consider contacting 
either or both of the following services: 
 
- Lifeline 24 hour counselling on 13 11 14.  
- A general medical practitioner (GP). 
 
Ethics Approval 
 
This research project has been granted ethics approval by the following Human 
Research Ethics Committees: 
 
- Bond University Human Research Ethics Committee (HREC Reference 
Number: RO1359). 
- Gold Coast Health Service District Human Research Ethics Committee 
(HREC Reference Number: HREC/11/QGC/39). 
 
 
If You Have Any Questions or Concerns About This Research…….. 
 
Any Questions regarding this study can be directed to the principal investigator 
and PhD student researcher, Mr Simon Langston at: slangsto@bond.edu.au  
 
If you have any concerns related to the manner in which this research is conducted, 
please contact either of the Human Research Ethics Committees listed below 
quoting the relevant research ethics approval reference details listed above: 
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If you have any concerns related to the manner in which this research is conducted, 
please contact either of the Human Research Ethics Committees listed below 
quoting the relevant research ethics approval reference details listed above: 
 
Bond University Human Research Ethics Committee 
Bond University 
Gold Coast  QLD 4229 
Phone: (07) 7 55 95 4194 
 
Or 
 
Chair of the Ethics Committee, 
Gold Coast Hospital and Health Service 
Southport, Qld, 4215 
Or 
 
Patient Liaison Services 
Gold Coast Hospital and Health Service 
Phone: 1300 744 284 
  
 
Thank you in advance for your contribution to this important study. 
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Participant Consent Acknowledgement 
 
 
 
By ticking the box below I confirm that I have read and understood the information 
contained in both the “Participant Information Sheet” and “Participant Consent 
Acknowledgement” forms and in particular that: 
 
 
 
1. I agree to participate in the study, and I am aware that I can withdraw from 
the study at any time. Further, I reserve the right not to provide any piece of 
information that I do not wish to provide. 
2. Whilst understanding that I may withdraw from this study at any time, I 
also understand that if I do decide to withdraw that I will not be able to 
remove information that I may have provided earlier. 
3. I understand that my involvement in the research project will involve 
completing online surveys both prior to and after commencing treatment 
for Hepatitis C.  
4. I understand that my participation in this study will contribute to an 
increased understanding of why individuals experience differences in 
Hepatitis C treatment outcomes, and that the findings from this study will 
primarily benefit individuals undergoing Hepatitis C treatment in the 
future.  
5. I understand the potential risks involved in participating in this study and I 
am also aware of the contact options should I experience any distress or 
discomfort related to participating in this study. 
6. I understand that if I have any additional questions related to this study I 
can contact a member of the research team. 
7. I understand that if I have any concerns related to the ethical conduct of this 
study I can contact either The Ethics Complaints officer at Bond University 
on (07) 55 95 4194 (quoting the following research project details: 
RO1359) or either the Chair of the Human Research Ethics Committee or 
the Patient Liaison Service at the Gold Coast Hospital on (07) 55 19 8211 
(quoting the following research project details: HREC/11/QGC/39).  
8. I agree that de-identified research information collected from me can be 
included in future research related activities, including the publishing of 
findings in thesis papers, presentation of results in relevant conferences and 
other public forums and may also be published in peer reviewed journals. 
 
 
□      I acknowledge that I have read and understood this information and that 
I freely give my consent to participate (Please tick box if you agree) 
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The Hepatitis C Treatment Outcome Study 
You are invited to take part in a study designed to determine some of the physical, 
psychological, and social factors associated with Hepatitis C treatment outcomes. 
The primary objective of this research is to increase understanding of 
individual profiles that are associated with better Hepatitis C treatment outcomes. 
We are inviting individuals who are over the age of 18 years, who have a current 
diagnosis of Hepatitis C, who have access to the internet and a current email 
address, and who are preparing for and planning to commence Hepatitis C 
treatment, to complete two confidential online surveys. The first survey (completed 
prior to treatment), should take 35 – 40 minutes to complete, whilst the second 
survey (completed 14 weeks post-commencement of treatment), can be completed 
in 5-10 minutes. 
Participation in this research is voluntary and any information you provide is 
completely confidential. Your email address and responses to the survey are not 
linked to any information that could personally identify you. Only the principal 
investigators will have access to your email address. You have the right to 
withdraw from the research at any time, and without penalty. 
At regular intervals, result summaries and other relevant Hepatitis C based 
education and information will be posted on our website blog page. This 
information may be useful for individuals preparing for and undergoing treatment 
for Hepatitis C. Further, in recognition for the time and effort involved in 
participating in this research, participants who meet the eligibility criteria for 
participating in this study (decision at the discretion of the PhD student researcher), 
will be sent a AUS $20 Amazon gift voucher after completing both the online 
surveys. 
If you have any questions regarding this research, please contact Mr Simon 
Langston at slangsto@bond.edu.au  
If you are interested in participating in our research, you can access the online 
survey at: 
http://hcvstudy.bond.edu.au 
Thank you in advance for your contribution to this important study. 
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